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Mospd3, a gene located on mouse chromosome 5, was identified in a gene 
trap screen in ES cells. The gene trap vector integration in multiple copies into the 
putative promoter of the gene, resulted in a loss of expression of Mospd3 at the 
trapped allele.  In mice generated from ES cells carrying the vector integration it was 
found that the lack of Mospd3 expression resulted in the death of a proportion of the 
homozygote mutants within the first day after birth. Homozygote neonates exhibited 
a thinning of the right ventricular free heart wall which resembles other mouse 
mutant phenotypes as well as human congenital heart defects caused by a loss of 
desmosome and adherens junction mediated cell adhesion between cardiomyocytes. 
The protein encoded by Mospd3, contains an N-terminal Major Sperm Protein (MSP) 
domain implicated as a mediator of protein- protein interactions, as well as a two C-
terminal transmembrane domains. 
Both, protein structure and phenotypic similarities with defects in 
desmosomal and adherens junction proteins suggests that Mospd proteins might play 
a role in cell adhesion and maintaining the structural integrity of the heart.  
The phenotype of Mospd3 mutants was highly dependent on genetic 
background, which led us to speculate that there might be genetic redundancy 
between Mospd3 and its closest family member the X-linked Mospd1. 
The aims of this thesis were to generate tools to better understand the 
function of the Mospd gene family in cardiac development as well as assessing 
genetic redundancy between Mospd1 and Mospd3. A conditional gene targeting 
strategy was designed for both Mospd genes. Large genomic regions of the Mospd1 
and Mospd3 loci were subcloned from bacterial artificial chromosomes (BACs) and 
using a recombineering approach, loxP sites and a drug selection cassette (neomycin) 
were placed in precise locations surrounding the MSP domain of both genes. The 
conditional targeting vectors were electroporated into both CGR8 and E14 ES cells 
and homologous recombinant clones were identified at a frequency of 2% and 1.3% 
for Mospd1 and Mospd3 respectively. Five euploid targeted clones for both Mospd1 
and Mospd3 have been generated.  
ii 
 
Transient expression of Cre recombinase in ES cells carrying the conditional 
Mospd1 allele was used to delete the one copy of this X-linked gene.  Phenotypic 
characterisation of this null ES cell line revealed that Mospd1 is neither essential for 
ES cell viability and self-renewal, nor for the early differentiation of these cells 
towards a cardiac fate.  
In order to investigate the mechanism of action of Mospd proteins, specific 
polyclonal antibodies were generated to detect either Mospd1 or Mospd3.  These 
antibodies were purified and tested by western blotting using COS7 cells 
overexpressing either Mospd protein as well as mouse tissue lysates. Whilst the 
antibodies were found to detect the proteins and differentiate between Mospd1 and 
Mospd3, they showed insufficient purification to be used in co-localisation and co-
immunoprecipitation experiments to identify interacting proteins and determine 
whether Mospd proteins are involved in cell adhesion complexes.  
Monoclonal antibodies were subsequently generated and initial western 
blotting experiments showed promising results, indicating that these antibodies may 
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1 CHAPTER 1:  INTRODUCTION 
2 
 
1.1 WHY STUDY MOSPD GENES? 
Motile sperm domain-protein (Mospd) 3 a member of the Mospd gene family 
was identified in a gene trap screen designed to identify genes which are involved in 
embryonic development (Forrester et al., 1996; McClive et al., 1998). Transgenic 
mice carrying the gene trap integration showed neonatal death in a proportion of 
homozygote animals as well as cardiac dilation in surviving litter mates of that 
genotype. The phenotype suggested that Mospd3 might be involved in the 
development or function of the heart (Pall et al., 2004).  
In studying the role of Mospd3 during development we hope to gain not only 
information regarding the function of this largely uncharacterized family of genes but 
also new insights into cardiac development and function. 
 
1.1.1 The Motile Sperm Domain-protein Family  
Mospd3 encodes a 235 amino acid protein, which belongs to a family of 4 
proteins in the mouse. Mospd1 to 4 are all defined by the presence of a major sperm 
protein (MSP) domain. In addition, all four proteins also contain one or two C-
terminal transmembrane domains (Figure 1.1 and 1.2). 
Protein sequence alignments (using ClustalW
1
) as well as analysis of the 
structural domains between Mospd proteins in the mouse revealed that Mospd1 
shared the greatest amount of protein sequence and structural identity with Mospd3, 
whilst both Mospd2 and 4 are evolutionary more diverged (Figure 1.1). Even though 
the protein conservation between Mospd1 and Mospd3 may be as low as 38%, most 
of the sequence identity is found in the MSP and transmembrane domains (Figure 
1.2).     
Mospd3 appears to be mammalian specific and is 88% similar to its human 
orthologue encoded on Chromosome 7q22, a region syntenic to chromosome 5 in 
mouse (Pall et al., 2004). In contrast to Mospd3, Mospd1 is conserved in a wide 
range of vertebrate organisms: from zebrafish, Fugu and Xenopus; to chicken, rat and 
human. Mospd1 is encoded on the X-chromosome in mouse and human. 





Interestingly, rats possess two Mospd1 genes: one located on the X-chromosome, 
whilst its paralogue maps to rat chromosome 14 (Pall et al., 2004). 
Expression analysis and data obtained from the Gene Expression Omnibus 
(GEO) database
2
 show that both Mospd1 and Mospd3 are expressed in a wide range 
of embryonic and adult tissues; indicating that their expression may be ubiquitous. 
The widespread expression of both genes was confirmed in RT-PCR and in situ 
studies. In situ analysis of Mospd3 detected expression of the gene throughout the 
late gestation embryo (Pall et al., 2004). Similarly, RT-PCR analysis on a range of 
available test cDNA samples including those of hematopoietic tissues in the embryo 
(fetal liver, yolk sac and aorta-gonad-mesonephros tissue) showed expression in all 
these tissues as well as in in vitro generated embryoid bodies at day 3 and day 5 
(explanation of in vitro differentiation of ES cell in section 1.4.2). Mospd1 also 
showed expression in the hematopoietic tissues and embryoid bodies (Forrester, 
unpublished). This overlapping expression pattern of both Mospd1 and Mospd3 
could indicate a functional redundancy between these two genes. In addition to these 
embryonic tissues Mospd3 was found to be expressed in neonatal brain, kidney, liver, 
spleen and heart (Pall et al., 2004). Lastly, both Mospd3 and Mospd1 were also 
shown to be expressed in adult heart (Forrester, unpublished). In order to gain insight 
into the function of these Mospd genes more detailed expression analysis throughout 
mouse development may be required, and perhaps more importantly information 
about the expression and localisation of the protein products encoded by both genes 
is needed. 
 
1.1.2 Function of the Major Sperm Protein domain 
A study looking at MSP-domain proteins identified 199 members in the Pfam 
database (Tarr and Scott, 2005). The majority (about 60%) of this group of proteins 
was made up of nematode sperm-specific major sperm protein. The first of these to 
be identified was the major sperm protein in C. elegans (Burke and Ward, 1983; 
Scott et al., 1989).  
  
                                                          
2
 http://www.ncbi.nlm.nih.gov/geo/ 
Figure 1.1: Mospd protein family in Mus musculus. In mouse this family
contains four members, which all contain a Major Sperm Protein domain (MSP).
Mospd1 and Mospd3 proteins show the highest degree of protein structure
conservation with both containing two C-terminal transmembrane (TM) domains,
whilst Mospd2 and Mospd4 only contain only one transmembrane domain. Mospd2
also includes a nuclear localisation (NLS) domain and a Cellular retinaldehyde-










Figure 1.2: Protein sequence alignment of Mospd3 and Mospd1 using
(ClustalW). Although the global alignment score between the to proteins is only 38%
most of the sequence similarity is contained within the major sperm domain marked
with an orange box and the two C-terminal transmembrane domains marked with
green boxes. The colouring of the amino acid residues identifies their
physiochemical properties. Red indicates small hydrophobic amino acids which
include aromatic residues; blue marks acidic residues; magenta marks basic
residues; green indicates residues containing hydroxy-,sulfhydryl or amine groups.
Asterisk (*), colon (:) and single dot (.) refer to the level of conservation between the
amino acid residues in Mospd1 and Mospd3. The asterisk (*) indicates identical
amino acid residues between the two protein sequences. The colon (:) marks amino
acid substitution with the same physiochemical properties, whilst the single dot (.)




One of the functions of MSP (major sperm protein) in nematodes is as a 
signalling molecule to promote oocyte maturation and sheat cell contraction in 
female animals (Miller et al., 2001). More importantly, MSP acts as a nematode-
specific cytoskeletal protein; required to allow crawling motility in nematode sperm 
(Italiano et al., 2001; King et al., 1994b). Blocking of major sperm protein function 
in nematodes leads to male infertility.  
Analysis of the crystal structure of nematode major sperm protein revealed 
that the protein assumes an immunoglobulin (Ig)-like fold structure (Bullock et al., 
1996). This fold is also found in a variety of other proteins such as fibronectin, 
laminin and human growth factor. The Ig-like domain interacts with other Ig-like 
domains via the -sheet region of its structure. This interaction forms the basis of the 
assembly of MSP monomers into dimers; and further into helical filaments and 
higher order structures called macrofibres (King et al., 1994b). MSP filaments 
assemble at the leading edge of a pseudopod formed by nematode sperm. This 
assembly mechanism drives motility in these cells (King et al., 1994b; Roberts and 
King, 1991).  
 It has been noted that the motility function, which major sperm protein 
provides in nematode sperm, is almost indistinguishable from the actin-based 
motility observed in other cells (Roberts and Stewart, 2000). 
1.1.2.1 Comparison of MSP and actin based motility 
Actin facilitates motility in a variety of cells such as amoeba and white blood 
cells. Movement of these cells is achieved through the formation of an actin-rich 
pseudopod structure at the front of these cells. The pseudopod attaches to the 
substrate and pulls the cells along the surface. Sperm movement in nematodes 
utilises a similar pseudopod structure. However, as nematode sperm do not contain 
significant amounts of actin (Nelson et al., 1982); the locomotion of these cells is 
based on the MSP protein in the pseudopod.  
Akin to actin-based motility; sperm locomotion functions by MSP filament 
assembly at the leading edge of the pseudopod and disassembly of the filaments near 
the cell body at the base of the pseudopod structure (King et al., 1994b; Roberts and 
King, 1991). As a result of this treadmilling process the cell is pulled along.  
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The assembly and disassembly of the actin cytoskeleton in the pseudopod 
requires ATP hydrolysis as well as a whole host of accessory factors; to orchestrate 
this process (Borisy and Svitkina, 2000; Pollard and Borisy, 2003). In contrast, MSP 
filaments appear to be able to polymerise spontaneously without the need for ATP 
binding and hydrolysis (Italiano et al., 1996). Instead, MSP filament assembly and 
disassembly in the pseudopod is partly due to a pH gradient of 0.2 units higher at the 
leading edge compared to the cell body end (King et al., 1994a). 
More recently, it was found that similar to the actin cytoskeleton; the MSP 
cytoskeleton also employs a number of accessory factors to modulate MSP filament 
assembly. These factors include MFP1, MFP2 (MSP fibre protein) and MPOP (MSP 
polymerization organizing protein). Whilst MPOP is instrumental in directing the 
assembly of MSP filaments at the membrane of the pseudopod‟s leading edge 
(LeClaire et al., 2003); MFP1 and MFP2 have been found to modulate the growth of 
MSP filaments (Buttery et al., 2003; Grant et al., 2005).   
MSP and actin-based motility appear to be morphologically and dynamically 
analogous despite being based on entirely different sets of proteins (Roberts and 
Stewart, 2000). Although the proteins involved in either of these two cytoskeletal 
systems seem to be mutually exclusive; a study looking at nematode sperm-specific 
clusters of gene transcripts has identified increased levels of expression of 3 clusters 
of ESTs encoding proteins, containing either a LIM or a PDZ domain (Tarr and 
Scott, 2004). Both of these protein-protein interaction domains have been associated 
with the actin cytoskeleton and its organization (Khurana et al., 2002; Pomies et al., 
1999; Xia et al., 1997). LIM domains are found in a variety of different proteins. 
Whilst LIM-domain proteins found in the nucleus function in tissue-specific gene 
regulation and cell fate determination; cytoplasmic LIM-domain proteins have been 
shown to facilitate actin filament organization (Zheng and Zhao, 2007). A number of 
these cytoplasmic LIM-domain proteins also contain a PDZ domain. This group of 
proteins includes Alp and Mlp; two proteins which are further discussed in section 
1.3.2.  
The PDZ protein-protein interaction domain functions by facilitating the 
formation of branched networks of target proteins via specific C-terminal binding 
sequences (Harris and Lim, 2001). PDZ proteins, like Alp and Mlp, mediate actin 
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bundling by binding through the PDZ domain to the spectrin-like motifs of α-actinin; 
thereby enhancing α-actinin-associated actin cytoskeleton organization (Pomies et 
al., 1999; Xia et al., 1997). As many of the MSP domain encoding genes also code 
for potential PDZ domain binding sites, it has been speculated that PDZ-domain 
proteins may also modulate MSP cytoskeleton assembly (Tarr and Scott, 2004). The 
possibility of an interaction of PDZ-domain proteins with both actin and MSP 
filaments could indicate a link between these two different and distinct cytoskeletal 
systems.   
  
1.1.3 Major Sperm Protein domain proteins in other eukaryotic 
organisms 
 Apart from the major sperm protein in nematode, very little is known about 
the function of MSP-domain proteins. The only functional information for this type 
of protein in other model systems comes from the study of vesicle associated 
membrane protein (VAMP)-associated proteins (VAP) proteins. 
 Similar to Mospd proteins, VAP proteins encode an N-terminal MSP domain 
as well as a C-terminal transmembrane domain. Both these domains are separated by 
a coiled-coil domain not found in Mospd. VAP proteins have been described in 
vertebrates (Nishimura et al., 2004; Skehel et al., 2000); and lower organisms such as 
Drosophila (Pennetta et al., 2002), Aplysia (Skehel et al., 1995), yeast (Kagiwada et 
al., 1998) and plants (Laurent et al., 2000).  
The first of these proteins to be identified was the VAP33 protein of Aplysia, 
which was found to be involved in synaptic transmission in the central nervous 
system (Skehel et al., 1995). The next VAP to be described was in Drosophila. 
Interestingly, two VAP genes are expressed in this system. Whilst one of the protein 
products is required for male fertility; the protein of the other is found to localise at 
the neuromuscular junction; where it appears to be involved in the transport of 
vesicles towards the synaptic membrane (Pennetta et al., 2002). The mouse 
orthologue, VAP33, was shown to serve a similar vesicle trafficking function; a 
finding supported by the localisation of mouse VAP33 protein to: not only the 
endoplasmic reticulum but also the microtubules and intracellular vesicles (Skehel et 
al., 2000). A mutation in the VAP-B gene in humans was recently described 
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(Nishimura et al., 2004). Affected individuals suffered from amyotrophic lateral 
sclerosis - a motor neuron disease.  Disease in these individuals is the result of a 
point mutation in the sequence encoding the MSP domain of VAP-B, which causes a 
conformational change in the Ig-like domain. The mutant VAP-B protein fails to 
localise to endoplasmic reticulum (ER), vesicles or microtubules (Mitne-Neto et al., 
2007). Evidence gained from these VAP protein studies indicates that MSP-domain 
proteins may be functioning as mediators of protein-protein interaction within or 
between cells. 
 
1.1.4 Phenotype of Mospd3Gt1lmf/Gt1lmf mice 
Besides the comparative analysis with other MSP-domain proteins, the only 
other clue to the function of Mospd proteins has come from a mouse mutant 
generated by gene trapping (called R124 gene trap integration) that appeared to result 
in a null allele of Mospd3 (McClive et al., 1998; Pall et al., 2004).  
When mice carrying the Mospd3
Gt1lmf
 allele were generated on a C57BL/6 
inbred genetic background, a reduction in the number of expected homozygous 
mutant mice was observed (Pall et al., 2004). It was subsequently discovered, by 
close monitoring of the homozygotes obtained by caesarean section at embryonic day 
19.5 (E19.5) compared to those taken after natural birth, that about half of the 
homozygous pups died within the first 24 hours of their neonatal life. This was not 
the case when the gene trap integration was crossed onto an outbred MF1 
background. On this mixed genetic background, even after three weeks, the normal 
Mendelian ratio of homozygote pups was observed; and homozygous mice did not 
display any obvious phenotypic defect. As the phenotype appears dependent on 
genetic background, and even in the inbred strain only half the homozygote offspring 
die, this would indicate the presence of a genetic modifier.  
On the C57BL/6 inbred background, the gene trap integration leads to a 
defect in the morphology of the cardiac right ventricle in homozygous pups delivered 
just before birth by caesarean section. Heterozygote animals carrying only one 
trapped allele did not display this defect. When the hearts of homozygous pups were 
examined, they were found to display dilation of the right ventricle with a 
pronounced thinning of the right ventricular parietal (free) wall as well as an 
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attenuation of the growth of the papillary muscle and supraventricular crest (Figure 
1.3). The ventricular region near the apex of the heart was most affected by this 
thinning of the heart wall. Measurements of this region in homozygotes, compared to 
unaffected heterozygous and wild type littermates, showed a reduction of 37% in the 
thickness. In addition, the volume of the right ventricular chamber was found to be 
increased by 56%. The observed thinning of the right ventricular wall appears to be 
the result of a narrowing of the compact myocardium and a reduction in the number 
and size of the trabeculae carnae. 
The hearts of Mospd3
Gt1lmf/Gt1lmf 
embryos were also analysed at E16.5 
(Forrester, unpublished data). The heart, at this stage, does not differ from that of 
heterozygote and wild type littermates, indicating that the right ventricular defect is 
associated with the growth, maturation or structural integrity of the ventricle between 
E16.5 and birth. 
The phenotype observed in Mospd3
Gt1lmf/Gt1lmf 
animals shows that Mospd3 
may be required for the proper development of the heart, in particular the right 
ventricle. The observation that right ventricular thinning does not arise until very late 
in gestation suggests that the defect may be caused by problems in the maturation of 
the right ventricular compartment. An alternative explanation may be that Mospd3 is 
involved in providing structural integrity to the ventricle; and in its absence the 
developing heart fails to cope with the ever-increasing hemodynamic forces, it is 
subjected to, during later embryonic development; and after birth when the 
hemodynamic load increases exponentially.  
In addition to the neonatal death phenotype observed in Mospd3
Gt1lfm/Gt1lfm  
mice, an adult phenotype of hypertrophy of the heart, kidney and testis has been 
described in these homozygote mutant animals (Pall, 1998). However, this phenotype 
was only observed during early backcrosses (N2-4) of the gene trap integration into a 
pure C57BL/6 genetic background, and had been lost by generation N10. This adult 
phenotype may have been associated with the particular mixed genetic mouse 
background of 129/Ola and C57BL/6 strains, or with an unrelated genetic mutation 
which had occurred during the gene trap integration. In both cases, further crossing 
onto a C57BL/6 background would have led to the loss of this phenotype.  
  
Figure 1.3: Transverse heart sections from heterozygous Mospd3Gt1lmf/+
(A and C) and homozygous Mospd3Gt1lfm/Gt1lfm (B and D) embryos at
E19.5. Haematoxylin and eosin stained cardiac tissue sections revealed that
compared to the heterozygous heart (A) the compact myocardium of the right
ventricular free heart wall in the homozygote heart (B) shows pronounced
thinning. The layer of compact myocardium is thinnest in the anterior region
of the right ventricle of the homozygous heart marked by the arrow in (B)
and shown at greater magnification in (D). (C) Magnified view of the anterior
right ventricle of the section shown in (A) through the heart of a heterozygote
embryo. The homozygote heart (A and C) also shows a reduction in the
number of trabeculae carnae compared to the heterozygote heart (B and D).
Abbreviations: LV, left ventricle: RV, right ventricle. Bar (A and B) = 100µm




 Interestingly, hypertrophy of the heart - specifically the right ventricular wall- 
was also observed in later generations (beyond N10), when a litter of 
Mospd3
Gt1lfm/Gt1lfm 
neonates along with their heterozygous littermates was retrieved 
within the first 24 hours after natural birth, and analysed for heart morphology 
(Forrester, unpublished). One of the homozygote neonates had died before being 
taken for analysis. Morphological analysis of the hearts of these animals performed 
by Dave Brownstein
3
 showed that all the homozygote animals, including the one 
which had died, displayed a hypertrophy of the septum transversum and the right 
ventricular free heart wall. The tissue thickening was primarily observed in the 
compact cell layer of the affected heart wall. It is possible that lack of Mospd3 in the 
heart could result in a loss of structural integrity of the heart muscle or reduced 
contractile force transmission in the ventricle (described in more detail in section 
1.3). The observed postnatal right ventricular wall hypertrophy may be an adaptation 
mechanism of the cardiac muscle, in order to cope with the high hemodynamic 
pressures and to compensate for decreased structural integrity. This observation was 
not analysed in further litters, as at this time the neonatal death phenotype in the 
Mospd3
Gt1lmf/Gt1lmf
 animals began to be lost. Nearly all the homozygote neonates 
carrying the gene trap integration, at this stage, survived into adulthood. This fact 
along with the complexities of the gene trap integration (described in detail in section 
1.4.5.4) have left us to consider the generation of an alternative in vivo mouse model 
for the study of Mospd3 (described in detail in Chapter 3). 
      
                                                          
3
 Mouse Pathologist at the Queen‟s Medical Research Institute, Edinburgh  
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1.2 HEART DEVELOPMENT  
The contractile heart is the first fully functioning organ present in the embryo. 
Its morphogenesis, including alignment of the cardiac chambers and formation of 
vascular connections, is complete by late mid-gestation. The subsequent period of 
cardiac development involves the maturation and further growth of the structure. 
Development of the heart starts during gastrulation, when cells from the 
anterior region of lateral mesoderm become committed to the cardiogenic fate. 
Although little understood, this commitment is thought to be achieved in part by 
signals from the adjacent endoderm along with morphogens such as bone 
morphogenic proteins (BMP) (Schultheiss et al., 1997),  fibroblast growth factors 
(FGF) and Wnts (Marvin et al., 2001; Schneider and Mercola, 2001). Cardiac 
progenitor cells subsequently form a bilateral symmetric heart field (Figure 1.4 A), 
also called the cardiac crescent, which fuses at the ventral midline to form a beating 
linear heart tube (Figure 1.4 B). Factors such as Nkx2.5 (Nk2 transcription factor 
related 5), Gata (GATA binding protein) and Mef2c (myocyte enhancer factor 2C) 
have been implicated in this process (Srivastava and Olson, 2000). The linear heart 
tube, formed by E8, comprises an outer layer of myocardium and an inner layer of 
endocardium separated by extracellular matrix (ECM). Even as this tubular structure 
develops, it becomes patterned along its anterior-posterior (AP) axis, specifying the 
future structures of the four chambered heart – namely atria, left and right ventricle, 
conotruncus and the aortic sac (Redkar et al., 2001). 
Initiated by the asymmetric axial expression of factors such as 
TGF transforming growth factor , Nodal and Pitx2 (paired-like homeodomain 
transcription factor 2) in the embryo, the vertebrate heart undergoes rightward 
looping (Capdevila et al., 2000). This process is essential to establish the correct 
orientation of the right (pulmonary) and left (systemic) ventricle as well as aligning 
the heart chambers with their respective vascular connections. The morphogenesis of 
the heart culminates in the septation of the four cardiac chambers by dividing both 
atria, and the right and left ventricles, through septa and the formation of the two 
atrioventricular valves, which arise from the cardiac cushion. As a consequence of 
septation, the flow of blood in the embryo becomes partitioned into pulmonary and 
systemic circulation.  
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Finally, the connections from the heart to the vascular system are fashioned 
by neural crest cells from the pharyngeal arches invading the developing heart to 
help pattern the outflow tract and the great arteries (Farrell et al., 1999). 
 
1.2.1 Specification of the heart – Two heart fields 
 As early as the cardiac crescent, cells are fated to contribute to specific 
cardiac compartments (Figure 1.4). Upon looping of the heart, the developing 
chambers become morphologically distinct and establish specific chamber identities, 
identifiable by the expression of different combinations of transcription factors as 
well as structural proteins such as myosin light chains (Small and Krieg, 2004). 
These physiological and gene expression pattern differences distinguish not only 
atrium from ventricle, but also between right and left ventricle.    
 Recent lineage tracing studies in both the chick (Mjaatvedt et al., 2001; 
Waldo et al., 2001) and the mouse (Cai et al., 2003; Kelly et al., 2001) have revealed 
that these differences, particularly between the two ventricles, are due to their origin 
from two distinct populations of cardiac precursor cells (Figure 1.4). These studies 
have shown that a second population of progenitor cells, named the second or 
anterior heart field, contributes to the developing heart.  
 In the mouse, this second heart field arises from cells located anterior and 
dorsal to the linear heart tube, which itself is derived from the first heart field (Figure 
1.4) (Cai et al., 2003). As the heart tube is formed, cells from the second heart field 
migrate into the anterior and posterior ends of this structure (Figure 1.4 B), where 
upon looping they contribute to the outflow tract and the right ventricle (Figure 1.4 
C). The left ventricle and both atria are formed by cells of the first heart field; and 
the left ventricle, in particular, is only sparsely populated by progenitors from the 
second heart field (Figure 1.4 D) (Cai et al., 2003). 
 
1.2.2 Morphogenesis of the right ventricle 
 In correspondence with their origin from two distinct progenitor populations, 
the right and left ventricles have also been shown, through mouse mutagenesis 
studies, to require different transcription factors for their proper morphogenesis.  
Figure 1.4. Contribution of the first and second heart fields to the developing mouse heart. Oblique views of whole embryos
(in upper panels) and frontal views of the cardiac structure and precursors (in lower panel) are shown. (A) First heart field (FHF)
cells form a crescent shape in the anterior embryo at E7.5 with second heart field (SHF) cells medial and anterior to the first heart
field. (B) Once the primitive heart tube has formed at the ventral midline of the embryo (B, upper panel) SHF cells positioned dorsal
to the heart tube start to migrate (arrows) into the anterior and posterior ends of the tube (B, lower panel) to form the right ventricle
(RV), the conotruncus (CT) and part of the atria (A). (C) Following the rightward looping of the heart tube, the right and left
ventricular (RV and LV) chambers of the heart are formed and start to mature (C, lower panel). Also at this stage cardiac neural
crest (CNC) cells migrate (arrow, C, upper panel) from the dorsal neural tube into the outflow tract (indicated by bracket; OFT) to
form the vascular connections of the heart (marked in blue, the aortic arch arteries III, IV and VI). (D) The septation of the atria and
ventricles results in the formation of the four chambered heart. Both atria and left ventricle of the heart are mainly derived from
precursors of the first heart field (pink and red), whilst the right ventricle and outflow tract are almost exclusively formed from
precursors of the second heart field (yellow). Abbreviations: A, atria; Ao, aorta AS, aortic sac; AVV, atrioventricular valve; CNC,
cardiac neural crest; CT, conotruncus; DA, ductus arteriosus; FHF, first heart field; LA, left atrium; LCA, left carotid artery; LSA, left
subclavian artery; LV, left ventricle; OFT, outflow tract; PA, pulmonary artery; RA, right atrium; ; RCA, right carotid artery; RSA,
right subclavian artery; RV, right ventricle; SHF, second heart field; V, ventricle; aortic arch arteries numbered III, IV and VI. Figure
adapted from Srivastava et al. (2006).
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 One of the first markers to be expressed in the second heart field is Islet1 
(Isl1) (Cai et al., 2003). Its absence in mutant embryos appears to cause a defect in 
the expansion of the second heart field along with an inability of this cell population 
to migrate into the linear heart tube, resulting in the specification of only two cardiac 
chambers in these mice. Genetic marker analysis of the two cardiac chambers 
revealed that they correspond to the left ventricle and the atria, whilst the right 
ventricle failed to form. In addition, the absence of the outflow tract confirms the 
lack of contribution of the second heart field derivatives to the cardiac structure of 
Isl1
-/- 
embryos (Cai et al., 2003).  
 Another transcription factor found to be required for the development of the 
right ventricle is Hand2 (heart and neural crest derivatives expressed transcript 2, 
formerly dHand) (Srivastava et al., 1995; Srivastava et al., 1997). Mice lacking 
Hand2 show right ventricular hypoplasia, indicating that cells from the second heart 
field fail to expand to form the right ventricle (Srivastava et al., 1997; Yamagishi et 
al., 2001). In contrast, Hand1 (heart and neural crest derivatives expressed transcript 
1; formerly termed eHand) appears to be important for the development of the left 
ventricle. While Hand2 is predominantly expressed in the right ventricle, Hand1 
expression is enriched in the outer curvature myocardium of the left ventricle 
(Yamagishi et al., 2001). Hand1 is down-regulated in Nkx2.5 deficient embryos that 
fail to properly specify the ventricular compartments of the linear heart tube and die 
around the time of cardiac looping (Biben and Harvey, 1997). Conditional deletion 
of Hand1, specifically in the heart, results in left ventricular hypoplasia (McFadden 
et al., 2005), indicating that Hand1 may be required for the proliferation of 
progenitors of the first (primary) heart field. Loss of both Nkx2.5 and Hand2 in a 
double knockout (Yamagishi et al., 2001), or compound loss of both Hand genes 
(McFadden et al., 2005), results in the complete absence or expansion failure of both 
ventricles, respectively. 
 Consistent with these findings in the mouse mutant model; studies in fish, 
which only develop one ventricle, show that lack of the single fish Hand orthologue, 
hand2, results in a failure to develop a ventricular chamber (Yelon et al., 2000). 
 Additional factors shown to be required for the development of second heart 
field derivatives - such as the right ventricle and outflow tract - are the transcription 
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factors Mef2c (myocyte enhancer factor 2C) (Lin et al., 1997) and Foxh1 (forkhead 
box H1) (von Both et al., 2004) as well as the chromatin remodelling protein Smyd 
(or Bop) (Gottlieb et al., 2002). All three of these genes have been implicated as 
upstream regulators of Hand2 expression (Phan et al., 2005; Srivastava, 2006), and 
deletion of any of these genes was found to result in a phenotype resembling that of 
Hand2 mutation in mice, leading to hypoplasia of the right ventricle and incomplete 
development of the outflow tract.   
 
1.2.3 Heart Chamber Maturation 
 Initial specification and morphogenesis of the cardiac chambers of the looped 
heart tube is followed by the maturation of the respective heart chambers. This 
process is particularly important in the ventricles, as ventricles need to adapt to the 
increasing hemodynamic load of the developing embryo.  
 In ventricles this maturation process involves the expansion (or ballooning) 
of the chambers along with cardiomyocyte expansion and the formation of 
trabeculae. Only some of the factors involved in this process are known. Amongst 
these are the endocardial growth factor neuregulin and its receptors Erbb2 and 4 (v-
erb-b2 erythroblastic leukaemia viral oncogene homolog 2, neuro/glioblastoma 
derived oncogene homolog). Mutant mice deficient in any of these three genes 
displayed absence of trabeculae, a slight reduction in the compact myocardium of the 
ventricles and endocardial cushion defects, leading to the death of embryos in mid-
gestation (Garratt et al., 2003; Gassmann et al., 1995; Meyer and Birchmeier, 1995). 
 In addition to these endocardial factors, BMP10 and the polycomb protein 
gene BAF180 have recently been implicated in the proliferation of the ventricular 
myocardium (Chen et al., 2004; Wang et al., 2004). Mice lacking either gene display 
hypoplastic ventricular development. Ablation of BMP10, which is required for the 
maintenance of Nkx2.5 and Mef2C expression levels, also leads to absence of 





1.3 STRUCTURAL INTEGRITY OF THE HEART AND CARDIOMYOPATHY 
 In addition to the expansion of the compact myocardium during heart 
chamber maturation, the establishment of structural integrity in the heart tissue, 
especially in the ventricular myocardium, represents another mechanism to cope with 
the increased hemodynamic load in the developing embryo and after birth. Structural 
integrity in cardiac muscle involves stable connections of neighbouring 
cardiomyocytes and the integration of the contractile muscle cytoskeleton at the 
centre of the cardiomyocytes with the cell membrane. As the hearts primary function 
consists of continuously pumping blood, in order to supply the whole body with 
oxygen and nutrients, an efficient system of force transmission from the contractile 
structure of the cardiomyocyte to the rest of the cell as well as amongst all the 
cardiac muscle cells in the heart is essential.   
The contractile force in cardiac muscle is generated by myofibril structures, 
which fill nearly the entire mature rod-shaped cardiomyocyte cell. These myofibrils 
span the whole length of the cardiomyocyte and are attached at both ends to the 
intercalated disc, a structure at the polar membranes of cardiomyocytes (Figure 1.5). 
Each myofibril is made up of sarcomere subfilaments connecting to each other via 
their Z-disc structures, at which the actin filaments of each sarcomere are anchored. 
The muscle contraction in cardiomyocytes is a result of the interaction of actin (also 
thin filaments) with myosin filaments (thick filaments) in the sarcomere.  
The contractile force generated by the sarcomeres in cardiac, and all other 
kinds of striated muscle, is transmitted to other organelles of the muscle cell and to 
the cell membrane though non-sarcomeric cytoskeletal components, which tether and 
maintain the contractile apparatus. Long filamentous actin fibres at the cell periphery 
tether the myofibrils via their Z-discs to adherens junctions of the cardiomyocyte 
intercalated disc. Another cytoskeletal component helping to integrate the contractile 
apparatus with the rest of the muscle cells is desmin. This desmosomal protein 
(described in more detail the next section 1.3.1) provides a network which 
interconnects the Z-discs of neighbouring myofibrils as well as connecting the 
myofibrils to the intercalated discs, the extracellular matrix and to the organelles and 
nucleus of cardiomyocytes (Small et al., 1992).   
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Structural and functional connection between adjoining cardiomyocytes in 
the heart is primarily maintained by the intercalated disc. In addition to gap 
junctions, which allow electrophysiological coupling of cardiomyocytes, the 
intercalated disc also contains a network of cell adhesion complexes such as 
desmosomes and adherens junctions (Figure 1.5). These two structures function by 
interconnecting neighbouring cardiac muscle cells as well as acting as membrane 
anchorage sites for myofibrils via the cytoplasmic actin and desmin cytoskeleton.    
 Mutations in genes encoding protein components of either of these two 
complexes have been linked to cardiac defects in humans such as Arrhythmogenic 
Right Ventricular Cardiomyopathy (ARVC) (Awad et al., 2008) and Dilated 
Cardiomyopathy (DCM) (Perriard et al., 2003). Both these conditions involve a 
weakening of the ventricles of the heart caused by varying degrees of ventricular 
wall thinning and dysmorphogenesis, as well as dilation of one or both ventricular 
chambers (particularly in dilated cardiomyopathy). These morphological changes 
result in a decrease in pumping efficiency and wall stress resistance in the heart.  
 In ARVC, the thinning of the right ventricular wall is also linked with fibro-
fatty replacement of the myocardium in this heart chamber in addition to arrhythmia. 
Whilst ARVC has been predominantly linked with a defect in desmosome assembly, 
DCM is generally regarded as a condition caused by deregulation in the contractile 
actin cytoskeleton tethering to the intercalated disc and defects in adherens junction 
proteins (Awad et al., 2008; Perriard et al., 2003). 
 
1.3.1 Desmosomes 
 Desmosomes are abundant in tissues which experience mechanical stress, 
such as heart and skin, where they predominantly function to provide structural 
stability by forming adhesive complexes which tether cells together. This function is 
facilitated by multiple proteins interacting to form a macromolecular complex, also 
called plaque, which links the intermediate filaments of one cell to the intermediate 
filaments of another through transmembrane proteins (Figure 1.6 A). 
  
Figure 1.5: Structure of the intercalated disc in cardiomyocytes.
(A) Immuno-electronmicrograph of a cross-section through the intercalated
discs of rat heart muscle showing labeling of the intercalated disc structure
with desmoplakin antibodies. Desmosome complex regions (denoted by
arrows) show a higher density of labeling antibody. (B) Schematic of the
intercalated disc in cardiac muscle. The intercalated disc contains three types
of membrane junction: gap junctions, desmosomes and adherens junctions.
Bar in (A) = 500µm. Figure (A) was adapted from Franke et al. (2005) and






The transmembrane part of the desmosome is made up of two distinct 
cadherin proteins - desmocollin and desmoglein. These proteins interact with the 
intracellular linker protein plakoglobin (also known as -catenin), which in turn is 
bound by the N-terminal region of desmoplakin. The desmosome plaque is 
connected to the intracellular intermediate filaments (desmin in cardiac cells) via the 
carboxy-terminal end of desmoplakin. The stability of this interaction is enhanced by 
the simultaneous binding of plakophilin to plakoglobin (Green and Gaudry, 2000). 
 As previously highlighted, the loss of structural integrity caused by mutations 
in desmosomal proteins is linked to human disease. Mutations in both plakoglobin 
and desmoplakin have been shown in Naxos disease, which causes woolly hair, skin 
blistering (keratoderma) and ARVC (McKoy et al., 2000; Norgett et al., 2000; 
Protonotarios et al., 2001). Less severe defects, such as isolated ARVC without hair 
and skin involvement, have been observed in human mutations of both desmoglein-2 
(Awad et al., 2006; Pilichou et al., 2006), plakophilin-2 (Gerull et al., 2004) and 
desmocollin (Heuser et al., 2006). Currently only 50% of all cases of ARVC in 
humans have been linked to mutations in known desmosomal proteins, whilst among 
the identified desmosome components, mutations in Plakophilin-2 appear to be the 
most prevalent cause of ARVC (van Tintelen et al., 2006). 
 The generation of loss-of-function alleles for desmosome components in the 
mouse model (Figure 1.6 B (Table)), and gene silencing in zebrafish have facilitated 
a better understanding of the functional requirement of desmosomes in the heart and 
the subcellular structural defects caused by the loss of plaque stability.  
 Deletion of plakoglobin (Bierkamp et al., 1996; Ruiz et al., 1996) and 
plakophillin-2 (Grossmann et al., 2004) in mouse has revealed that both protein 
products are essential for the maintenance of structural integrity in the heart.  
Absence of either gene leads to a thinning of the compact myocardium and a lack of 
trabeculation in homozygote mutant animals, which can result in rupturing of the 
right ventricular heart wall and embryonic death.  
Similar results have been observed in cardiac-specific deletion of 
desmoplakin (Garcia-Gras et al., 2006). Desmoplakin has been shown to be required 
for the structural integrity of the early blastocyst stage embryo (Gallicano et al., 
1998), as well as the heart and epithelia of the skin and neural system in later stages 
22 
 
of development (Gallicano et al., 2001). Desmoplakin deficiency in the hearts of 
mutant animals resulted in death within two months from birth, caused by right 
ventricular dilation and contractile dysfunction due to fibro-fatty replacement 
(Garcia-Gras et al., 2006).  
Mice heterozygous for a mutation in either plakoglobin or desmoplakin, 
although normal at birth, were also found to develop right ventricular dilation and 
dysfunction, leading to death at six months of age due to arrhythmia. This condition 
was exacerbated by exercise (Garcia-Gras et al., 2006; Kirchhof et al., 2006). 
Mouse models of mutations in desmoglein or desmocollin have not been 
reported in the literature. However, silencing of desmocollin-2 by morpholino 
knockdown in the zebrafish model (Heuser et al., 2006) indicates that this protein 
may also be important for desmosome function, as zebrafish mutants display 
ventricular chamber dilation and contractile defects. 
Detailed ultrastructural analysis of the intercalated disc in the mutant animal 
models has revealed that the loss of desmosome complex proteins, such as 
plakophilin-2 and plakoglobin, results in an uncoupling of the remaining plaque 
structure from the plasma membrane (Bornslaeger et al., 1996; Ruiz et al., 1996). 
Most strikingly, in plakophillin-2
-/-
 animals, desmoplakin was found to dissociate 
from the intercalated disc and accumulate in the cytoplasm (Grossmann et al., 2004). 
Loss of the desmosome plaque in the heart results in a decrease of cell-cell adhesion 
at the intercalated disc, leading to impaired myocardial tissue integrity under 
conditions of mechanical stress. 
In addition to the loss of heart tissue integrity, plakoglobin, which dissociates 
from the desmosome plaque in mutant animals, has been proposed to cause ARVC 
by competing with -catenin in the Wnt pathway to alter the fate of cardiomyocytes 
to that of adipocytes (Garcia-Gras et al., 2006; MacRae et al., 2006).   
As described in this section, mutations in desmosomal proteins are generally 
associated with ARVC in both humans and mice. However, this is not the case with 
mutations in the desmosome-associated intermediate filament: desmin. The loss of 
desmin in homozygote knockout mice results in dilated cardiomyopathy (Li et al., 
1996; Milner et al., 1996) comparable to DCM observed in humans (Milner et al., 
1999; Thornell et al., 1997). Although desmin
-/-
 mice appeared to be normal at birth, 
Gene Type of 
mutation
Heart defect Other defects Reference
Plakoglobin t, null - death at E10.5
- RVW thinning & rupture
- impaired contractility
- absence of 
desmosomes




Desmoplakin t, null ES +
Extraembryonic
rescue
t, null, cardiac 
muscle specific
- death at E10
- heart malformation and 
collapse
- death at E10-12 some  











Plakophilin-2 t, null - death at E11






Desmin t, null - late onset dilated 
cardiomyopathy
- myocyte cell death
- exercise induced heart 










Mutations in Desmosome complex components in the mouse model  
t – targeted mutation       RVW – right ventricular wall
A
B
Figure 1.6: Protein components of the desmosome complex. (A)Schematic
of the desmosome complex and its protein components tethering two adjacent
cells. (B) Table of mouse phenotypes resulting from mutations in desmosome





defects in highly exercised muscle, such as the heart and diaphragm, start developing 
as early as 2 weeks of age (Li et al., 1997).  Exercise in these animals can result in 
increased muscle fatigue. The hearts of these animals develop cardiac chamber 
dilation and myocyte cell death, leading to cardiac failure and in extreme cases 
exercise-induced ventricle wall rupture (Li et al., 1997). 
All three muscle types - smooth, cardiac and skeletal - are affected by the loss 
of desmin (Li et al., 1996; Thornell et al., 1997). Structural analysis of desmin null 
myocytes showed that the alignment of the myofibrils in these cells was perturbed 
and neighbouring muscle cells had lost adhesion as seen by increased intercellular 
spaces.  The reason for the development of DCM instead of ARVC in desmin null 
mice most likely lies in the fact that desmin is not only involved in the desmosome-
dependent tethering myocyte cells, but also in stabilizing the sarcomeric cytoskeleton 
by tethering it via its Z-disc structures to the organelles and cell membrane of the 
muscle cell (Li et al., 1997). Thus the desmin network is important for contractile 
force transmission within cardiomyocytes and throughout the heart. Loss of 
maintenance of the contractile apparatus and inadequate force transmission, within 
and amongst cardiomyocytes, is generally linked to dilated cardiomyopathy 
(Capetanaki, 2000). 
 
1.3.2 Adherens Junctions 
 In addition to desmosomes, a second membrane spanning protein complex, 
namely the adherens junction, has been shown to be required for providing adequate 
cell-cell adhesion between cardiomyocytes at the intercalated disc.  
 Adherens junctions function by tethering actin microfilaments to the plasma 
membrane (Figure 1.7 A). This function is achieved by a complex containing N-
cadherin, which spans the intercellular space and is coupled via its cytoplasmic tail to 
both plakoglobin and -catenin. These two proteins in turn interact with -catenin, 
which binds to actin filaments anchoring them at the plasma membrane (Perriard et 
al., 2003). The anchoring of actin filaments via -catenin is thought to be facilitated 
by a number of mediator proteins such as -actinin (Blanchard et al., 1989; Djinovic-
Carugo et al., 1999) and two members of the LIM-domain protein family: -actinin 
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associated LIM-domain protein (Alp) (Pashmforoush et al., 2001) and muscle 
specific LIM-domain protein (Mlp) (Arber et al., 1994). 
Adherens junctions are the first cell-cell adhesion complexes established 
during development and have been shown to be required to initiate the assembly of 
desmosomes (Huen et al., 2002; Linask, 1992). In fact, recent structural analysis of 
the intercalated disc indicates that both cell adhesion complexes interact closely and 
may even form mixed complexes at the intercalated disc (Borrmann et al., 2006; 
Franke et al., 2006). That plakoglobin has been found to be a major component in 
both structures (Ruiz et al., 1996) appears to support these findings as does the co-
localisation of plakophillin-2 and desmoplakin with adherens junctions in the rat 
myocardium shown by these authors. Gene mutagenesis studies of adherens junction 
proteins in the mouse model have confirmed the importance of this complex for the 
structural integrity of the developing heart. 
N-cadherin is the only cadherin expressed in cardiac muscle. Deletion of this 
protein specifically in the mouse heart at six to ten weeks after birth was shown to 
lead to the disassembly of the intercalated disc, including desmosome and adherens 
junction structures resulting in the subsequent death of the homozygote animals after 
the second month (Kostetskii et al., 2005).  
Similar to N-cadherin, deletion of the actin cross-linking mediators Mlp and 
Alp have been found to affect the structure and function of the cardiac muscle in the 
ventricles (Ehler et al., 2001; Knoll et al., 2002; Pashmforoush et al., 2001). In 
particular, the phenotype in Alp deficient mice appears to be reminiscent of that seen 
in Mospd3 gene trap animals (described in section 1.1.3).  
Both Alp and Mlp are members of the PDZ-LIM-domain proteins, a group of 
proteins involved in the organization of the actin cytoskeleton (Zheng and Zhao, 
2007). Alp and Mlp were both found to localize to the Z-discs of sarcomere 
structures in myocytes as well as being highly concentrated at the intercalated disc in 
cardiac muscle (Arber et al., 1997; Pomies et al., 1999; Xia et al., 1997). This 
localisation coincides with that of α-actinin. Biochemical studies particularly with 
Alp demonstrate that Alp and Mlp act by enhancing α-actinin mediated cross-linking 
of actin filaments and actin anchorage to the adherens junctions of the intercalated 
disc (Pashmforoush et al., 2001). 
Gene Type of 
mutation 
Heart defect Other defects Reference
Alp t, null - neonatal death  in  15%
of animals
- RVW thinning 
- RV dilation




Mlp t, null - some death at 2 weeks 
- in surviving adults:
- dilated cardiomyopathy
- LV dilation
- impaired contractile   
function





t, null, induced 
cadiac -specific 
deletion at  6-
10 weeks 
- death at E10
- severe cardiac 
malformation
- death after 2 month
- dilated cardiomyopathy
- disarrayed cytoskeleton









Mutations in Adherens Junction components in the mouse model  
t – targeted mutation    LV- left ventricle        RV – right ventricle      RVW – right ventricular wall
Figure 1.7: Protein components of the adherens junction complex.
(A)Schematic of the adherens junction complex and its protein components
tethering two adjacent cells. (B) Table of mouse phenotypes resulting from
mutations in adherens junction complex components. Abbreviations: Alp, α-
actinin associated LIM-domain protein; muscle specific LIM-domain protein.







Mlp is expressed during differentiation of all striated muscle types, but 
expression is only maintained in cardiac and a subset of skeletal muscle in adult mice 
(Arber et al., 1994; Schneider et al., 1999). Loss of Mlp in the knockout mouse heart 
results in the loss of ordered sarcomeric arrangement along with morphological 
defects in cell-cell and cell-matrix connections (Arber et al., 1997). In order to 
compensate for the lack of Mlp at the ICD, the expression of other adherens junction 
proteins was found to be upregulated, presumably in an attempt to compensate for 
the loss of actin anchorage and the resulting decrease in force transmission in 
cardiomyocytes (Ehler et al., 2001). 
The dilated cardiomyopathy observed in Alp
-/-
 mice is less severe than that seen 
with the loss of Mlp. Instead of affecting both ventricles, the cardiomyopathy in    
Alp
-/-
 mice appeared to be exclusive to the right ventricle. This chamber specificity 
correlates with the expression pattern of Alp. Whilst the protein is expressed 
throughout the heart at the early stages of cardiac development, it becomes restricted 
predominantly to the right ventricle wall and outflow tract after heart looping 
(Pashmforoush et al., 2001). 
     Lack of Alp in the mouse model leads to right ventricle wall thinning, RV 










 mutants, only a percentage of homozygote 
neonates die, 15% and 50%, respectively (Pall et al., 2004; Pashmforoush et al., 
2001). This neonatal mortality is in both cases dependent on the genetic background 
of the mouse strain carrying the genetic alteration. The presence of either mutation 
on a pure C57BL/6 background results in neonatal death whilst homozygous mutants 
on a mixed genetic background, such as MF1, are unaffected. 
Alp has been shown to be important for α-actinin-associated actin cytoskeleton 
organization in cardiomyocytes (Pashmforoush et al., 2001). By facilitating actin 
fibre bundling through α-actinin, Alp helps to enhance the stability and mechanical 
resistance to high hemodynamic forces specifically in the embryonic right ventricular 
heart chamber (Lorenzen-Schmidt et al., 2005). Overexpression of Alp in cultured 
cardiomyocytes was found to improve sarcomeric structure and Z-disc arrangement 
(Pashmforoush et al., 2001). 
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Recent reports also show that, in addition to stabilizing the sarcomeric complex 
and thus providing efficient structural integrity and contractile force transmission in 
the heart, Alp is also required for myocyte differentiation in vitro. The α-actinin-
associated actin filament stabilization through Alp was found to provide an important 
structural signal for MyoD (myogenic differentiation) and myogenin-dependent 
differentiation of myocytes in culture (Pomies et al., 2007). 
With the exception of -actinin and Mlp (Mohapatra et al., 2003), mutant 
forms of other adherens junction proteins have not currently been linked to 




1.4 FUNCTIONAL ANALYSIS OF GENES  
1.4.1 Using animal model systems 
 Animal models have played an important role in the study of genes and 
diverse biological aspects. Model organisms including worms, flies, fish, frogs and 
rodents have proved to be invaluable tools for understanding how genes work, and 
for elucidating fundamental principles of development. Among these organisms, the 
mouse has become a favourite model for researching mammalian biology such as 
embryonic development, disease, behaviour and cancer. Several features have helped 
its popularity as the preferred mammalian model organism. Short generation cycles, 
relatively large litter sizes and a small body make it a very cost effective model. 
More importantly however, mice show a high degree of physiological similarity to 
humans which is reflected in the similarity between the mouse and human genome. 
Analysis of these two fully sequenced genomes indicates that almost all genes in the 
human have mouse counterparts and vice versa.  
A similar level of genomic conservation to human is also seen in rats, which 
have long been the preferred organism for modelling human physiology. But there 
are two unique feature of the mouse model setting it apart from other mammalian 
model systems. These are the availability of sophisticated genetic manipulation 
technologies, and well established and characterized embryonic stem (ES) cell lines.  
 
1.4.2 ES cells   
 The establishment of mouse embryonic stem cells has opened many exciting 
experimental approaches in the field of mammalian developmental biology. 
ES cells are pluripotent cells derived from the inner cell mass (ICM) of the 
blastocyst-stage mouse embryo (Evans and Kaufman, 1981; Martin, 1981). These 
cells can be maintained in feeder-free culture indefinitely due to their ability to self 
renew when grown in the presence of serum and leukaemia inhibitory factor (LIF) 
(Smith et al., 1988). When re-introduced into a host blastocyst, ES cells also have the 
ability to differentiate into all cells of the embryo proper (Keller, 1995), allowing 
mutations introduced into ES cells to be carried through to the germ line, in order to 
facilitate the generation of mice with specific genetic modifications. 
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In addition to their differentiation capabilities in vivo, ES cells can be induced 
to differentiate into a wide range of cell types in vitro. The differentiation of ES cells 
in culture can facilitate the isolation and study of early differentiation precursor cells, 
as well as help to assess the differentiation potential of ES cells carrying mutations in 
genes essential for embryonic development. 
The differentiation of ES cells in vitro can be achieved by generation of 
embryoid bodies (EBs) (Doetschman et al., 1985; Keller, 1995). These structures are 
formed by aggregation of ES cells in a „Hanging Drop‟ culture. Removal of LIF from 
EBs in culture results in spontaneous differentiation of these structures, promoting 
the formation of a range of differentiated cell types such as hematopoietic cell 
lineages (Doetschman et al., 1985; Nakano et al., 1994; Nishikawa et al., 1998), 
endothelial cells (Risau et al., 1988; Yamashita et al., 2000), neuronal cells 
(Fraichard et al., 1995; Strubing et al., 1995) and bone derivatives (Buttery et al., 
2001; Kramer et al., 2000). 
 
1.4.3 In vitro Cardiomyocyte Differentiation Model 
 When differentiating EBs are allowed to attach to gelatine they can often be 
observed to form foci of cells that begin rhythmic contraction, indicating cardiac 
muscle development. 
 The development of these cardiomyocyte lineages has been shown to 
progress through distinct stages, recapitulating the in vivo process of differentiation. 
Akin to in vivo development, beating cardiomyocytes in culture express cardiac gene 
products in a developmentally controlled manner, initially expressing lineage 
induction markers such as Gata4 and Nkx2.5 followed by distinct cardiomyocyte 
maturation genes such as Nppa (natriuretic peptide precursor type A), Mlc2v (myosin 
light chain 2v), myosin heavy chains and connexin 43 (Boheler et al., 2002; 
Hescheler et al., 1997). As in the in vivo system, the differentiation process in 
cardiomyocytes is associated with morphological cell shape changes from round 
cells towards elongated cells with well developed myofibrils and sarcomere 
structures (Robbins et al., 1990; Westfall et al., 1997). Furthermore, the shift from 
early pacemaker cells to more terminally differentiated atrial- and ventricle-like cell 
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types indicates that differentiating cardiomyocytes in culture can correctly mirror the 
electrophysiological changes observed in vivo (Hescheler et al., 1997; Maltsev et al., 
1993). 
 The ability to induce multiple cell lineages during in vitro differentiation of 
ES cells provides exciting opportunities to, not only model embryonic development 
in culture, but also study the developmental potential of deliberate mutation in genes 
implicated in lineage specific development.  
 Accordingly, the in vitro cardiomyocyte model has been successfully used to 
elucidate the role of transcription factors and ECM components in cardiac 
development. Loss-of-function studies of Gata4 and Hand1 transcription factors by 
in vitro differentiation of ES cells into cardiomyocytes have revealed that, although 





 embryos in utero from myocardial defects (Firulli et al., 1998; 
Kuo et al., 1997; Molkentin et al., 1997), neither of these genes is required in order to 
generate beating cardiomyocytes in culture (Narita et al., 1997; Riley et al., 2000). 




 ES cells can 
contribute to the developing heart in chimaeric embryos (Narita et al., 1997; Riley et 
al., 2000).  
Proper myocardial development does not only depend on transcription factors 
but also on the interaction of ECM components with the cytoskeleton of the 
developing cardiomyocytes. Whilst the loss of the cardiac-specific intermediate 
filament - desmin - has barely any effect on the in vitro cardiomyocyte commitment 
and differentiation potential (Weitzer et al., 1995), loss of 1-integrin (providing 
cardiomyocyte and ECM contact) leads to delayed cardiomyocyte differentiation in 
conjunction with disarrayed sarcomere structures and reduced survival of terminally 
differentiated myocardial cells (Fassler et al., 1996). Hence, 1-integrin appears to be 
required for terminal differentiation and maintenance of cardiac muscle cells (Fassler 





1.4.4 Gene Mutagenesis in ES cells 
 The generation of mutations in the mouse genome is arguably one of the most 
powerful tools for studying gene function. The scope of such genetic manipulations 
has been greatly expanded since the isolation of ES cells. For instance, the 
availability of ES cells has been instrumental to the development of mouse genome 
mutagenesis approaches such as gene trapping (Gossler et al., 1989) and gene 
targeting (Thomas and Capecchi, 1987).    
 The mutagenesis of genes in ES cells has several advantages. Firstly, ES cells 
can be screened in vitro for the desired genetic alteration before being reintroduced 
into the embryo. Secondly, it is possible to study the effect of genetic manipulation 
on the differentiation potential of ES cells using the previously described in vitro 
differentiation models (described in section 1.4.2 and 1.4.3).  
 
1.4.5 Gene trapping 
 Gene trapping in ES cells is one of the most widely used mutagenesis 
approaches. This phenotype-driven method enables large-scale mutagenesis in mice 
combined with relatively easy cloning and identification of the mutated gene. In its 
most basic form the vector used for gene trapping contains a splice acceptor site 
immediately upstream of a promoterless reporter gene such as -galactosidase ( -
gal), which is followed by a selectable marker gene as well as a polyA tail for 
transcriptional termination (Figure 1.8) (Gossler et al., 1989). 
 The integration of this vector into an active gene can lead to the expression of 
an in-frame fusion transcript between the upstream sequences of the gene and the -
gal reporter gene (Figure 1.8) (Friedrich and Soriano, 1991; von Melchner et al., 
1992). The presence of a transcription termination site in the trapping vector prevents 
the downstream sequences of the gene from being expressed, thus generating a 
truncated mutant transcript. In addition, the presence of the -gal reporter under the 
control of the trapped genes promoter allows analysis of the genes endogenous 
expression pattern whilst providing a convenient DNA tag for the identification of 
the trapped locus (Stanford et al., 2001). 
   
Figure 1.8: Gene trapping. The gene trap vector containing a splice acceptor
(SA), βgeo (β-galactosidase reporter gene fused to a neomycin resistance gene)
and a polyadenylation signal (pA). Random integration of this vector into the
intron of a gene results into the generation of a fusion transcript between the
vector and the trapped endogenous gene. The splice donor of the upstream exon
(exon1) is spliced to the splice acceptor sequence present in the vector
transcript. Transcription of the vector sequences is regulated by enhancer and
promoter elements of the trapped endogenous gene. Translation of this fusion
transcript results in a fusion protein. Abbreviations: E, enhancer; P, promoter;




A number of centres world-wide have performed high-throughput gene 
trapping screens. ES cell clones generated in these screens have been made publicly 
available through the International Gene Trap Consortium (IGTC)
4
. This repository 
currently comprises nearly 135,500 ES cell clones, representing more than 32% 
coverage of the mouse genome. The International Gene Trap Consortium database 
allows researchers to search for suitable gene trap integrations into their gene of 
interest before generating a gene mutation of their own. 
 A search of the database for gene trap integrations into Mospd gene found 5 
different vector integrations into Mospd3, and none in Mospd1, Mospd2 or Mospd4. 
One of these gene trap integrations appears to correspond to the vector integration 
into the 5‟-untranslated gene sequence, also observed in the Mospd3
Gt1lmf
 allele.  This 
integration led to the identification of Mospd3 (described in section 1.1.3). In the 
remaining four ES cell lines the vector appears to have integrated into the last or 
penultimate exon of the gene, leading to a likely loss of one, or both, of the 
transmembrane domains of Mospd3.        
 The most effective gene trap integrations usually involve vector insertions 
near the 5‟ end of a gene, resulting in early termination of the endogenous gene 
transcription.  On the other hand, integrations into 3‟ introns can sometimes result in 
incomplete inactivation of the protein, since upstream sequences are still expressed; 
thus, leading to reduced (hypomorphic) function (Herrick and Cooper, 2002; 
McClive et al., 1998; Skarnes et al., 1992). As gene trap integrations occur randomly 
in the genome, a large number of mutations can be generated. To date, it is estimated 
that about two-thirds of all known protein coding genes in the mouse have been 
trapped using this approach (Skarnes et al., 2004). 
1.4.5.1 Gene trap screens for developmentally regulated genes 
 The use of gene trap mutagenesis in the mouse facilitates the identification of 
developmental genes expressed in a specific cell lineage. However, this in vivo 
approach requires the generation of large numbers of mice from trapped ES cell 
clones, to identify only a limited number of developmentally regulated genes.  
                                                          
4
 www.genetrap.org  
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 Fortunately, the ability to differentiate ES cell in vitro into a wide range of 
different cell lineages (as previously described in Section 1.4.2) has helped to 
overcome this problem, and has enabled high-throughput screening of ES cell clones 
for tissue-restricted gene trap expression. Using this in vitro screening approach, 
genes expressed specifically in neuronal, hematopoietic and endothelial lineages; as 
well as in myocytes and chondrocytes; have been successfully identified (Baker et 
al., 1997; Shirai et al., 1996; Stanford et al., 1998).    
1.4.5.2 Inductive gene trap screens  
 An alternative approach to identifying developmentally regulated genes, via 
gene trap reporter expression in in vitro differentiated ES cells, is to induce 
differentiation of ES cells into defined cell lineage in vitro, by provision of specific 
developmental cues in the form of growth and differentiation factors.  
 One such inductive gene trap screen was designed to isolate genes responsive 
to transforming growth factors such as BMP2, nodal and activin.  This enabled 
identification of Chondroitin-4-sulfotransferase. This gene, which was induced by 
BMP2, was subsequently shown to exhibit a distinct spatio-temporal expression 
pattern in embryonic development (Kluppel et al., 2002). Enrichment for 
developmentally regulated genes was also achieved in another induction screen, in 
which gene trapped ES cell clones were analysed for their response to follistatin, 
nerve growth factor and retinoic acid (Bonaldo et al., 1998). 
1.4.5.3 Induction trap used to identify Mospd3 
 The high-throughput induction gene trap screen which led to the 
identification of Mospd3 was designed to isolate genes which lie downstream of the 
retinoic acid (RA) receptor ligand-mediated signalling pathway (Forrester et al., 
1996).  Retinoic acid, the active metabolite of vitamin A, has been shown to affect 
the expression of developmental genes in embryos (Conlon and Rossant, 1992; 
Marshall et al., 1992), as well as ES cells differentiated in culture (Wobus et al., 
1997). 
In this screen, trapped ES cell clones were selected which exhibited an RA 
induced change in -gal expression upon differentiation in culture. In total 20 
trapped genes were identified in this study. Among these clones, nine showed an 
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induction of -gal activity whilst the remaining 11 exhibited repression in response 
to externally provided RA. Furthermore, ten of the repressed clones also showed a 
spatially restricted pattern of reporter gene expression in the developing embryo in 
vivo. The -gal expression pattern, observed in repressed clones, appeared to be 
distinct from that of induced clones. One of these ten repressed gene trap integrations 
was shown to have trapped a novel gene, called Mospd3. Like most of the repressed 
lines, the Mospd3 gene trap reporter showed a distinct expression in the embryonic 
heart (Forrester et al., 1996; McClive et al., 1998).  
1.4.5.4 Complex gene trap integrations 
 Gene trap mutagenesis is a very powerful tool for the identification of new 
genes, and their functional analysis. However, not all gene trap integrations are as 
straightforward as previously described. Some of these unsuspected complexities 
have been analysed and reviewed (Voss et al., 1998).  In one case, Niwa et.al. found 
that the gene trap vector, used in their screen, caused large deletions and 
rearrangement in the DNA sequences surrounding the vector integration site (Niwa et 
al., 1993). In another screen, the gene trap vector was found to trans-splice to splice 
donor sites unrelated to the trapped gene (Voss et al., 1998). 
 In the case of the gene trap screen which resulted in the identification of 
Mospd3, detailed analysis of the integration site revealed that the vector had 
integrated at the start of the first exon of Mospd3 (Pall et al., 2004). This exon 
contains the 5‟-untranslated region of the gene, including part of a highly conserved 
sequence (83% similarity between mouse and human). This conserved region, 
stretching from sequences upstream of Mospd3 into exon1 of the gene, corresponds 
to the putative promoter of Mospd3. It was shown that the expression of the -gal 
reporter did not recapitulate all of the expression domains of the endogenous gene 
(Forrester et al., 1996). Similar observations have been made in other gene trap 
mouse lines (Deng and Behringer, 1995; Skarnes et al., 1992; Voss et al., 1998). In 
addition to having trapped the promoter of Mospd3, the vector has integrated in 
multiple copies in reverse transcriptional direction to that of the gene itself. Similar 
tandem vector integrations have also been reported (Friedrich and Soriano, 1991). 
The presence of other genes in close proximity to the vector integration site gave rise 
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to the possibility that, in addition to disrupting Mospd3, the integration also alters the 
transcriptional regulation of adjacent genes.  Expression of neighbouring genes was 
examined, including that of pcolce, which was found to be unaffected by the 
integration. 
 
1.4.6 Gene targeting 
 This method for mutagenesis of the mouse genome is based on the site-
specific introduction of an exogenous DNA sequence into chromosomal DNA via 
homologous recombination. Gene targeting facilitates a wide range of precise target 
gene modifications including gene deletion, addition of new genes, and the 
introduction of subtle gene mutations such as base pair changes in the target 
sequence. If the gene targeting has been performed in ES cells, clones featuring the 
correctly targeted allele can be used to generate germ line transmitting transgenic 
mice to study the phenotype arising from this vector integration (Joyner, 1999; 
Thomas and Capecchi, 1987). 
 There are two types of vector, which can be used for target gene 
modification. Depending on the type of desired mutation to be generated, an 
insertion or a replacement vector can be used. 
 Insertion vectors have been predominantly used for target gene inactivation 
through integration of a mutagenic sequence. This type of vector can also be used to 
generate subtle target gene mutations in conjunction with a “hit and run” or “in and 
out” targeting approach detailed in section 1.4.6.2.  Linearization of the insertion 
vector within the region of homology to the target site results in the integration of the 
entire vector into the endogenous DNA sequence. The integration of the vector 
through a single homologous recombination cross-over event also leads to a partial 
duplication of the targeting homology. 
 The replacement targeting vector has found much wider application than the 
insertion vector, especially since the development of conditional targeting constructs, 
which are described in more detail in sections 1.4.6.3 -1.4.6.7.  Replacement vectors 
generally consist of a 5‟- and a 3‟- targeting homology sequence, flanking a mutant 
foreign sequence such as a selectable marker gene and other modifications.    
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1.4.6.1 Factors affecting gene targeting frequency 
The rate of targeting vector integration upon electroporation into ES cells is 
very low (10
-3
). It is therefore important to include a selectable marker in the 
targeting vector sequence, in order to enrich for ES cells carrying the vector 
integration.  The most commonly used positive selection cassette, for this purpose, is 
the neomycin (neo) phosphotransferase gene under the control of a constitutive pgk 
(phosphoglycerate kinase 1) promoter. Other positive selection cassettes include 
hygromycin B (hygro)-phosphotransferase and the puromycin (puro) gene. 
Most vector integration events into genomic DNA take place via non-
homologous recombination. Only about one in every 1000 vector integrations occurs 
by homologous recombination (Thomas et al., 1986). One of the ways to select 
against random vector integration events in ES cells lies in using a negative selection 
approach in conjunction with positive selection. This positive-negative selection 
approach is based on a replacement vector containing the positive selection marker 
within the flanking regions of homology and a negative selection cassette at one or 
both ends of the targeting homology (Mansour et al., 1988). The most commonly 
used negative selection cassettes are the diphtheria toxin A (DT or DT-A) gene (Yagi 
et al., 1990) and the herpes simplex virus thymidine kinase (HSV-tk) gene. Isolation 
of ES carrying a homologous targeted integration is achieved by initial positive 
selection through application of neomycin, puromycin or hygromycin; followed by 
selection against ES cell clones carrying the negative selection cassette. Homologous 
integration of the targeting vector into chromosomal DNA via cross-over events in 
the flanking homology sequences, between vector and target site, results in the loss 
of the negative selection cassette. In the case of random vector integration, on the 
other hand, the cassette generally integrates along with the rest of the vector. The 
presence of the negative selection cassette leads to ES cell death through the 
expression of the diphtheria toxin A gene; or in the case of the HSV-tk cassette, cell 
death through the conversion of the nucleoside analogues ganciclovir or FIAU 
(Fialuridine) in the selective media into toxic metabolites. Positive-negative selection 
was found to improve the retrieval of correctly targeted ES cell clones only by about 
5- to 10-fold (Jeannotte et al., 1991; McMahon and Bradley, 1990). Due to 
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occasional loss of the negative selection cassette during non-homologous 
recombination, the enrichment achieved by positive-negative selection is limited.  
A number of additional factors, besides the positive-negative selection 
strategy, are known to improve retrieval of correctly targeted ES cell clones. These 
parameters include the type of target locus, the length of the homology region used in 
the targeting construct, as well as the use of isogenic DNA (Frohman and Martin, 
1989). The length of the targeting homology sequences is known to have a 
particularly profound impact on the frequency of homologous vector integrations. 
Even small increases in the length of these sequences, up to a total length of about 
10kb, can dramatically increase the frequency of gene targeting (Deng and Capecchi, 
1992; Hasty et al., 1991b).  Likewise, the use of isogenic rather than non-isogenic 
DNA for the generation of the targeting vector has been shown to increase the 
potential targeting frequency of a vector by 10- to 20-fold (te Riele et al., 1992).  
1.4.6.2 Integration of subtle mutations 
The ability to generate subtle mutations, such as single base-pair changes, in 
a target sequence is very important for modelling human genetic defects, which are 
often caused by single base-pair mutations in a gene. 
 The nature of this type of genetic modification required the development of a 
targeting strategy which resulted in a subtle mutation without leaving a selectable 
marker in the modified gene. Two different types of approach have been developed 
for this kind of gene targeting.  
The first type of method called “hit and run” (Hasty et al., 1991a) or “in-out” 
(Valancius and Smithies, 1991) was based on the use of an insertion-type gene 
targeting vector. One of the characteristics of this type of vector is that it has the 
ability to self-excise from the locus it has been targeted to. This excision occurs via 
homologous recombination of the duplicated homology sequences which have been 
generated during the integration of the insertion vector into the target locus. 
Although it only occurs at very low frequency, this excision event can result in the 
removal of the endogenous gene sequences whilst leaving behind the modified gene 
targeting construct with the subtle mutation of choice. The alternative outcome in 
this case is that the targeted locus reverts to the endogenous allele, as the insertion 
vector containing the subtle mutation is excised instead.  
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The second type of approach, called “tag and exchange” (Askew et al., 1993) 
or “plug and socket” (Detloff et al., 1994) is suitable for generating subtle mutations 
using gene replacement-type vectors. These two-step gene targeting procedures 
involve the initial integration of a vector construct carrying both a positive and a 
negative selection cassette. In a second targeting step, the vector sequences carrying 
the selectable markers can be replaced by homologous recombination of a targeting 
construct containing the endogenous gene sequence with a single base-pair or other 
subtle mutation. In the “tag and exchange” approach, cells which have not been 
correctly targeted in the second vector integration step die if grown in negative 
selection medium. Negative selection thus enables the enrichment for correctly 
targeted clones. 
The “plug and socket” approach contains a modification on the “tag and 
exchange” approach. Instead of using HSV-tk as the negative selection cassette, a 
non-functional mutated HPRT (hypoxanthine-guanine phosphoribosyltransferase) 
minigene is used in the first targeting construct, along with a positive selection 
marker. The second targeting construct, containing the mutated target gene sequence, 
also features a mutant HPRT minigene - in one of the flanking homology arms. 
Correct integration of the second targeting construct into the target locus leads to 
homologous recombination between the sequences of the two mutant HPRT 
minigenes, thereby creating a functional HPRT positive selection marker. The 
presence of a functional HPRT gene facilitates HAT-medium mediated enrichment 
of all ES cell clones which have integrated the mutated gene sequence. The HPRT 
minigenes of the two replacement vectors are designed in the flanking homology 
regions away from the gene so as not to interfere with the expression of the targeted 
gene.    
Since the development of the Cre/loxP system (described in more detail in the 
following sections) it has become possible to generate subtle mutations in ES cells 







1.4.6.3 Conditional control of gene expression 
Constitutive inactivation of some genes may not be suitable for the functional 
analysis in the mouse model. If the deleted gene is crucial for embryonic 
development its loss can lead to embryonic lethality thus impeding the study of the 
genes function in later developmental stages (Mitchell et al., 2001) and adulthood.  
It is therefore important to have the ability to use conditional systems which 
provide control over the spatial and temporal expression of a gene. Two main 
strategies have been developed for this purpose: 1) conditional gene knockout 
through site-specific recombination and 2) inducible expression of a transgene. Both 
methods provide control over when and where a gene is activated or silenced.  
1.4.6.4 Site-specific DNA recombination  
 Site-specific recombination is currently the most widely used method for 
inactivation of a gene in a time and tissue-specific manner. 
 This system is based on two components: site-specific recombinase enzyme, 
and recombination recognition DNA sequences. Cre and Flpe are the most 
commonly used site-specific recombinases. Both enzymes belong to the integrase 
family of recombinases, and have been derived from bacteriophage P1 (Sauer and 
Henderson, 1989) and Saccharomyces cerevisiae (Buchholz et al., 1998; O'Gorman 
et al., 1991), respectively.  
The function of these recombinases lies in catalysing the DNA recombination 
between two 34bp recognition sites such as loxP (acted on by Cre) and FRT (Flpe) 
(Nagy, 2000). These recognition sites consist of two 13bp inverse (palindromic) 
sequence repeats surrounding an 8bp core which assigns direction to the sequence 
(Figure 1.9 A). Depending on the orientation of two recognition sites - placed into a 
DNA sequence - site specific recombination can lead to deletion, inversion or 
switching of the sequence linking these sites. Both the Cre/loxP and the Flpe/FRT 
system are widely used; but, in further descriptions of the conditional allele, I will 
focus mainly on the former.  
Figure 1.9: Site-specific recombination mediated by Cre or Flp recombinase.
(A) The 34-bp loxP and FRT sites each consist of two 13-bp inverse repeats
(black) that flank an 8-bp core sequence (red). This core sequence confers
directionality to these sites (red arrows). (B) Dimers of Cre or Flp (pink) catalyze
the recombination between two directly repeated loxP or FRT sites (red
arrowheads), resulting in a deletion of sequences (region B) flanked by loxP or
FRT. If region B is an essential region of a gene, then the recombination event
results in gene inactivation. (C) The use of three loxP sites can result in three
different alleles following Cre or Flp recombination. Either the neomycin (neo)
resistance cassette as well as the essential region of the gene are deleted (1, 3;
generating a null allele) or only one of these regions is removed resulting in either
a conditional floxed allele (1, 2) or a null allele of the gene leaving a neo cassette
(2,3). Abbreviations: pA, polyadenylation site; TSP, tissue-specific promoter.







As the site-specific recombination of DNA sequences flanked by loxP sites 
(floxed) is dependent on the presence and action of Cre recombinase, it is possible to 
control this process by adding the enzyme to drive the reaction only when and where 
desired (Figure 1.9 B). This control is particularly advantageous in the generation of 
knockout alleles. Using this conditional system, early lethal phenotypes can be 
prevented by addition of Cre recombinase only at later stages of embryogenesis.  
The design of a conditional knockout allele generally involves placement of 
the loxP sites upstream and downstream of an essential region of the gene of interest 
(Figure 1.9 C). Prior to Cre induced recombination, the gene should display wild 
type function. To avoid any effect of these loxP sites on the normal expression of the 
floxed gene, they are usually placed into the introns flanking the essential sequences 
of the gene.  
1.4.6.5 Tissue specific control of Cre expression 
 The tissue and time-dependent inactivation of essential gene sequences in a 
conditional allele can be achieved by controlling the expression of Cre recombinase. 
Tissue specific inactivation of a gene of interest can be achieved by crossing the 
mouse line harbouring a conditional KO allele of the gene to an effector mouse strain 
which expresses Cre from a tissue specific promoter. In the resulting progeny, the 
gene of interest will only be inactivated in the tissues where Cre is expressed (Gu et 
al., 1994; Lewandoski, 2001). This conditional approach allows complex questions 
about the expression of a particular gene of interest to be asked. 
 Cardiac specific deletion of Fgf8, for example, has revealed that this growth 
factor is required for second (anterior) heart field development (SHF) (Ilagan et al., 
2006). Fgf8 appears to be involved in four different processes of heart development. 
Firstly, Fgf8 is involved in the cardiac specification during gastrulation; secondly, in 
the establishment of right-left axis for cardiac looping; and thirdly, in promoting 
survival of neural crest cells migrating into the heart (Abu-Issa et al., 2002; 
Albertson and Yelick, 2005; Sun et al., 1999). Finally, Fgf8 has also been implicated 
in the specification and maintenance of the second heart field (Kelly et al., 2001). In 
order to show the requirement for Fgf8 in the SHF, the gene was inactivated in, both, 
the first and second heart field using Cre recombinase expressed from the cardiac 
specific Nkx2.5 promoter (Ilagan et al., 2006). Mice carrying this tissue specific 
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deletion of Fgf8 showed truncation of the right ventricle and the outflow tract. 
Deletion of Fgf8 specifically in the first heart field - and not the second heart field, 
using Cre expressed from the titin gene promoter, resulted in no apparent phenotype. 
The comparison of these two cardiac-specific knockouts has confirmed the role of 
Fgf8 in the SHF.      
1.4.6.6 Inducible transgene activation 
 Several binary models have been developed to provide control over the 
transcription of a transgene in mice. These transactivation approaches are based on a 
transgene being placed under the control of a promoter/enhancer element which can 
be specifically regulated by a ligand-inducible transcription factor.  The requirements 
for the transcriptional activation or silencing in such a system are; that the 
transactivation should be fast, robust; and should only occur if the effector molecule 
is present. The process should also be reversible by effector depletion.  The most 
commonly used transactivation systems are the Tet “on/off” (Gossen et al., 1995) 
and the GAL4-based GLVP system (Ornitz et al., 1991).    
 The tetracycline system consists of two versions of the tetracycline controlled 
transactivator, which can either block (tTA/ tet “off”) or activate (rtTA/ tet”on”) the 
expression of a transgene in the presence of a doxycycline inducer. The presence of 
doxycycline in the tet”off” system prevents the tetracycline-controlled transactivator 
(tTA) from binding to the tetracycline response element which controls the 
expression of the transgene. Transgene expression is thus blocked in this setting. 
Binding of the tetracycline response element to reverse tTA (tet “on”), on the other 
hand, is promoted by the presence of doxycycline, thus allowing transgene 
expression to be activated.  
 The second inducible system, the GLVP system, is based on the 
transactivation of a target transgene by the Gal4 transcriptional transactivator from 
Saccharomyces cerevisiae. The Gal4 transactivator, in this system, has been 
engineered to contain a mutated steroid ligand domain. Due to this mutated steroid 
receptor component, Gal4 can only activate its target transgene in the presence of a 
suitable synthetic hormone such as the antiprogesterone compound RU486. 
 Similar transactivation systems can also be used to provide temporal control 
of Cre expression.    
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1.4.6.7 Temporal control of Cre expression 
 Temporal control of Cre mediate recombination can be achieved by 
combining the Cre/lox system with a transcriptional transactivation system such as 
Tet “on”. Using this system, Cre expression can be activated in a defined manner by 
administration of doxycycline to mice (Kistner et al., 1996). 
 Another approach, providing temporal control over the activity of Cre 
recombinase, is the Cre-LBD (ligand-binding domain)
 
system (Metzger et al., 1995). 
This post-translational transactivation system is based on a fusion construct of the 
Cre transgene with a mutated steroid ligand-binding domain under the control of a 
ubiquitous or tissue specific promoter. Upon expression, the Cre fusion protein is 
sequestered in the cytoplasm of the cell by a heat-shock protein. Binding by the heat-
shock protein leaves the chimaeric Cre protein unable to localise to the nucleus, 
where Cre acts to mediate the recombination of the floxed target-gene allele. Nuclear 
localisation of Cre can only occur in the presence of a suitable synthetic steroid such 
as RU486 or tamoxifen (Kellendonk et al., 1996; Zhang et al., 1996). The ligand-
binding domain in this system has been mutated to prevent endogenous steroid 
hormones, such as estrogen or progesterone, from translocating Cre to the nucleus.  
One very popular version of this approach is the MerCreMer system (Sohal et 
al., 2001). The inducible Cre gene in this approach is flanked by two mutated murine 
estrogen-receptors. This system has been widely used in generating conditional gene 
deletions in adult mice. The inducible MerCreMer system has been successfully used 
in two different studies analysing the importance of adherens junction proteins in 
maintaining the structural integrity of the intercalated disc (Kostetskii et al., 2005; 
Zhou et al., 2007) (Adherens junctions have been described in detail in section 
1.3.2).  
 The first of these studies involved the inactivation of β-catenin specifically in 
adult cardiomyocytes. Β-catenin signalling controls a multitude of biological 
processes such as embryonic development, tumorigenesis as well as the 
establishment of cell shape and polarity (Klymkowsky, 2005). This wide range of 
activities can complicate the study of β-catenin function in a particular biological 
system. In order to circumvent the embryonic lethality caused by β-catenin 
inactivation and analyse the involvement of the protein in the adherens junction-
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mediated structural integrity of the fully matured adult heart, an inducible conditional 
knockout approach was employed. Mice carrying a loxP flanked β-catenin allele 
were crossed with mice carrying a tamoxifen inducible MerCreMer transgene driven 
by a cardiac specific α-myosin heavy chain promoter. Using this inducible system, β-
catenin was deleted only in the cardiac tissue of 3 to 4 month old mice after injection 
with tamoxifen. This study found that upregulation of γ-catenin can compensate for 
the absence of β-catenin from the adherens junctions in adult cardiomyocytes (Zhou 
et al., 2007). 
 Another study showed that cardiac-specific deletion of N-cadherin by MHC-
MerCreMer, after tamoxifen administration to 2-3 month old mice, caused extensive 
remodelling of the intercalated disc; resulting in reduced cell-cell adhesion and 
contraction abnormalities in the hearts of these animals (Kostetskii et al., 2005).   
The availability of tissue-specific promoters and inducible systems of Cre 
expression, to inactivate conditionally targeted genes, has made it possible to 
perform very intricate functional gene studies. The advent of these methods has also 
significantly widened the spectrum of possible modifications in the mouse genome. 
This flexibility was further facilitated by the discovery of novel recombinase 
enzymes (Diaz et al., 2001; Sauer and McDermott, 2004; Thyagarajan et al., 2001), 
and the development of mutant site-specific recognition sites which do not 
recombine with wild type ones (Araki et al., 2002).     
1.4.6.8 Neomycin resistance marker and hypomorphs 
 The conditional targeting vector, usually, contains a selectable marker to 
allow selection of ES cells which have integrated the vector construct into their 
genome. Although it is a necessary part of the conditional construct, the presence of 
the neo resistance marker - in introns or in the untranslated sequences of a gene - can 
interfere with the expression of the floxed allele, creating a hypomorphic allele which 
shows reduced gene activity (Meyers et al., 1998).  By flanking this resistance 
marker in the conditional construct with FRT sites, in addition to the loxP sites at 
either end of the gene essential sequence, it is possible to remove neomycin in ES 




1.5 RECOMBINEERING  
Traditional vector construction approaches, especially for the generation of 
conditional gene targeting vectors, have a number of drawbacks. As these methods 
rely on restriction and ligation of DNA fragments, the generation of a vector 
construct is often limited by the availability of appropriate and unique restriction 
sites. Additionally, some manipulations require constructs which are too large to be 
efficiently cloned by standard techniques, or their size cannot be tolerated by 
conventional cloning vectors. 
The development of a phage-based homologous recombination system in 
E.coli – called Recombineering – has helped to overcome these problems. This 
method significantly simplifies the generation of transgenic and knockout constructs, 
as well as permitting the manipulation of large genomic DNA fragments like those 
present on Bacterial Artificial Chromosomes (BAC). As this method relies on 
subcloning by homologous recombination, it negates the need for unique restriction 
sites (which may be more difficult to find as length of the construct, to be 
manipulated, increases). This independence from appropriate endonuclease cleavage 
sites allows modifications to be made in any sequence.  
Previously, cloning by homologous recombination was only done in yeast 
(Baudin et al., 1993), and was not possible in E.coli. However, being able to clone by 
homologous recombination in E.coli cells would have certain advantages over using 
the approach in yeast. Manipulating recombinant DNA in yeast is difficult and time 
consuming, and it often involves the transfer of the construct to E.coli cells for 
further processing (Bhargava et al., 1999). In contrast, recombinant DNA generated 
in E.coli can be used directly without the need not be transferred.  
 
1.5.1 Phage-encoded recombination systems 
 Linear double-stranded DNA is unstable in E.coli cells due to the activity of 
the endogenous RecBCD exonuclease, thus preventing homologous recombination in 
this system (Cosloy and Oishi, 1973; Wackernagel, 1973). By studying the effect of 
defined mutations in the E.coli rec genes (Cosloy and Oishi, 1973; Lloyd and 
Buckman, 1985; O'Connor et al., 1989; Yang et al., 1997), researchers managed to 
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develop a bacterial recombination system which allowed linear dsDNA sequences 
with 40-50bp flanking homology to be integrated into a target BAC or plasmid 
present in E.coli cells (Muyrers et al., 1999; Zhang et al., 1998). 
 
1.5.2 Rac-encoded RecET system 
 Francis Stewart and his colleagues were the first to show efficient integration 
of a PCR fragment flanked by 42bp homologies into the intended target site in a 
plasmid, by electroporation of the fragment into recBC sbcA E.coli strains (Zhang et 
al., 1998). sbcA is a mutation which activates the expression of recE and recT genes 
encoded in the cryptic Rac prophage, present in E.coli K12 strains (Clark et al., 
1984). The expression of both these rec genes facilitates the homologous 
recombination of linear dsDNA sequences with only short homology arms (Zhang et 
al., 1998).  
This discovery led to the generation of a pBAD-ETγ plasmid (Zhang et al., 
1998); which, if transfected into E.coli cells, permitted these cells to perform 
homologous recombination.  
The pBAD-ETγ plasmid contains the recE gene under the control of an 
arabinose-inducible promoter; as well as the recT and bacteriophage λ-gam gene, 
each expressed from a constitutive EM7 and Tn5 promoter, respectively. Upon 
induction with arabinose, recE is expressed. This protein, in turn, acts together with 
recT to allow homologous recombination in the E. coli cell, whilst expression of the 
gam protein gene inhibits the RecBCD-dependent degradation of the linear targeting 
cassette. 
 
1.5.3  - encoded red system 
In parallel to the RecET system, another set of recombination genes - 
encoded by bacteriophage λ - was utilised for recombineering in E.coli (Datsenko 
and Wanner, 2000; Yu et al., 2000). In the λ-phage, the recombination genes are 
called redα (or exo) and redβ (or bet). Both, exo and bet are analogous in their 
function to the recE and recT genes, respectively.  
49 
 
Exo is an exonuclease which progressively digests the 5‟-end strand of 
dsDNA, leaving 3‟-overhangs (Carter and Radding, 1971); whilst the beta protein 
binds to the single-stranded DNA ends and promotes annealing of the 
complementary sequences (Takahashi and Kobayashi, 1990). As in the RecET 
system, the gam protein, also present in the phage, inactivates the exonuclease 
function of RecBCD (Poteete, 2001; Stahl, 1998). 
 Similar to the ET cloning system, homologous recombination can be induced 
in E.coli cells carrying BACs or plasmids for modification, if these cells are 
transfected with a pBAD-αβγ vector (Datsenko and Wanner, 2000). In the pBAD-
αβγ vector, exo is under the control of the arabinose inducible promoter, whilst bet is 
expressed from the constitutive promoter EM7, and gam from the Tn5 promoter.  
E.coli strains expressing the red recombination system show very high levels 
of recombination activity, and BAC recombination efficiency in these cells was one- 
to three-fold better compared with E.coli cells containing the pBAD-ETγ plasmid.  
 Contrary to recombination in yeast cells, the presence of the arabinose-
inducible promoter in both these systems controls the amount of time during which 
the recombination function is active in E.coli cells; thereby, reducing the chance of 
any unwanted recombination events occurring. 
 Even more control over the expression of the Red recombination genes was 
made possible with the development of the defective λ-prophage (Yu et al., 2000). In 
this prophage based system; exo, bet and gam are expressed from a defective 
prophage which is integrated into the E.coli chromosome. All three recombination 
genes in this system are expressed from a strong promoter (λPL); which, in turn, has 
been placed under the control of a temperature sensitive λ-cI857 repressor. At 32ºC 
the repressor is active, and none of the red genes are expressed; however, a 
temperature shift to 42 ºC for 15 minutes leads to the inactivation of the repressor, 
resulting in very high levels of recombination activity.   
 The expression of the red recombination genes from the defective prophage, 
instead of the pBAD vector, has several advantages. For one, the presence of the 
repressor allows the expression of the red genes to be tightly controlled. This is 
particularly important as constitutive expression of gam can be toxic to E.coli cells, 
and cause plasmid instabilities (Sergueev et al., 2001). Furthermore, due to its 
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integration into the E.coli chromosome, the prophage is genetically stable in these 
cells and does not have to be maintained by drug selection.  
 The defective prophage has been integrated into DH10B E.coli cells, which 
are a commonly used host strain for BACs. The presence of the Red recombination 
system in the modified DH10B strain, called DY380, facilitates modification of BAC 





electroporated cell (Lee et al., 2001).   
The presence of the BAC, in such a recombinogenic cell line, facilitates a 
multitude of modification to be undertaken with relative ease. BAC modifications, 
possible in this system, range from precise base pair changes, to deletions and 
insertions of large stretches of DNA, up to 70kb or more (Copeland et al., 2001).  
 
1.5.4 Generation of conditional targeting vectors   
 BAC recombineering has also been used for the construction of 
conditional targeting vectors (Liu et al., 2003). As recombineering allows precise 
restriction enzyme-independent DNA manipulation, loxP or FRT sites can be 
efficiently placed in any location within the targeting construct.     
  In this vector construction approach, loxP sites are integrated into the 
conditional construct in the form of a neomycin resistance cassette flanked by loxP 
and FRT sites. Efficient targeting of these constructs is facilitated by flanking the 
FRT/loxP-neo cassette with sequences homologous to the DNA sequences to be 
targeted. The neomycin resistance marker present in the cassette is under the control 
of both; a PGK promoter, and an EM7 promoter; allowing the gene to be expressed 
in E.coli and ES cells, respectively. Consequently, E.coli and ES cells can be 
selected for the presence of the cassette by either kanamycin (E.coli), or G418 (ES 
cells). 
 The generation of conditional targeting vectors by recombineering has been 
assisted further by the generation of DY380 E.coli cells carrying, either a cre 
recombinase gene in EL350 cells, or a flp recombinase gene in EL250 cells (Lee et 
al., 2001; Liu et al., 2003). Both strains are able to mediate homologous 
recombination and site-specific recombination. The former of these functions is 
controlled by temperature, whilst the latter can be induced by arabinose. This dual 
51 
 
regulation facilitates both; the integration of the loxP/FRT flanked targeting cassette, 
and the subsequent removal of the neomycin resistance marker from the targeted 
locus. 
 The use of BACs for the creation of conditional targeting vectors has a 
number of advantages. Due to the size of the average BAC (~200kb), any modified 
sequence in this construct will be flanked by very long regions of homology to the 
target locus in the mouse genomic DNA. This means that homologous recombination  
in ES cells occurs at relatively high frequencies (on average 3.8% in one study 
(Valenzuela et al., 2003)) without the need for positive or negative selection. The 
same study also showed that, due to these long stretches of homologous sequence; 
BAC vectors did not require isogenicity to the mouse ES cell line they are integrated 
into. 
 
1.5.5 Cloning DNA by Gap repair 
 However, using BAC vectors to generate mutant conditional alleles in ES 
cells complicates the screening process for correctly targeted clones; as such long 
homology arms make Southern blot analysis, to determine the integration site, 
impossible.  
Instead, homologous recombination in E.coli cells can be used to subclone a 
smaller genomic region of the target gene into a plasmid backbone. This subcloning 
approach, called Gap repair (or Gap retrieval), involves the homologous 
recombination of the free ends of a linear plasmid with the homologous sequences 
carried on the BAC (Lee et al., 2001; Liu et al., 2003; Zhang et al., 2000).  
 
1.5.6 Generation and use of targeting vectors without a selectable 
marker 
With the mouse and human genome fully sequenced, the focus for 
researchers now lies in annotating a function to all of the approximately 28,000 
identified genes (Auwerx et al., 2004). Of particular interest is the replication of 
human diseases in the mouse model organism. As most human genetic defects 
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involve point mutations or deletions in a gene, efficient recreation of these mutations 
in the mouse gene orthologue is crucial. 
 BAC targeting vectors - containing point mutations or deletions in a gene of 
interest - can be rapidly generated using either a two-step SacB selection and 
counter-selection approach, or a single-step recombination of short double-stranded 
(dsDNA) or single–stranded DNA (ssDNA), into the sequence to be mutated 
(Muyrers et al., 2000). This two-step method relies on the integration of a selectable 
SacB-neo cassette, flanked by target specific homology arms, into the BAC vector. A 
subsequent targeted integration - with the mutated gene sequence of interest - leads 
to a replacement of the SacB cassette. The recombinant clones, carrying the designed 
gene deletion or point mutation, can easily be identified by counter-selection against 
the SacB gene from Bacillus subtilis, which renders E.coli cells sensitive to sucrose 
(Bramucci and Nagarajan, 1996). 
  The single-step method for introduction of sequence modifications into a 
gene of interest relies, predominantly, on the high level of homologous 
recombination in DY380 cells. Short dsDNA sequences, flanked by only 24bp of 
homology arms, have been shown to integrate into a target locus with an efficiency 
of 0.1 - 0.2% (Lee et al., 2001; Yu et al., 2000). This targeting efficiency can be 
improved by using ssDNA to generate the mutant vector construct, as ssDNA has 
been shown to integrate into the target sequence with an efficiency ranging from 1% 
to 6%, depending on the length of the flanking homology arms (Ellis et al., 2001; 
Swaminathan et al., 2001). As the final modified vector construct does not contain a 
selectable marker, and may only differ from the wild type target gene sequence by 1 
base pair, large numbers of recombinant clones need to be screened by PCR. Due to 
the high number of recombinants generated per electroporated cell, when using the 
red recombination system, PCR based screening is a feasible method.  
The relatively high targeting frequency of BAC vectors (Valenzuela et al., 
2003) means that sequences containing only subtle mutations, without selectable 
markers, can be efficiently integrated into the ES cell genome. If conventional sized 
targeting vectors are used to integrate a sequence containing a subtle mutation into 
ES cells, a “tag and exchange” or “plug and socket” approach (see section 1.4.6.2) 
may be necessary. 
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1.5.7 High-throughput recombineering   
 The development of the recombineering techniques in E.coli has greatly 
improved the scope of possible DNA sequence modifications, without some of the 
limitations posed by previous approaches for targeting vector construction. 
Recombineering also presents a less complicated and faster approach.  
Recent improvements of this method have mainly focused on adapting it for 
high-throughput construction of targeting vectors. Two research groups demonstrated 
the successful generation of more than 100 targeting vectors in a fast, efficient and 
almost fully automated 96-well format (Chan et al., 2007; Valenzuela et al., 2003). In 
both approaches, 96 different genes were chosen for simultaneous modification. For 
this purpose, DH10B cells harbouring BACs - which contained the genes of interest - 
were seeded into a 96-well plate. These cells were then made recombineering-
competent by introduction of the red recombination genes, present in either a 
plasmid construct or the defective λ prophage (Chan et al., 2007; Valenzuela et al., 
2003).    
The BAC construct, in these recombineering competent cells, can then be 
efficiently modified by homologous recombination of PCR-amplified targeting 
cassettes, in a similar manner to that previously described for the generation of a 
conditional targeting construct.  
Another bottleneck for the use of gene targeting as a high-throughput 
approach for mouse mutagenesis lies in the generation and identification of correctly 
targeted ES cell clones. The homologous recombination of traditional gene targeting 
vectors, harbouring the desired gene modification (such as deletions, floxed exons or 
reporter construct integrations) flanked by 2-6kb homology arms, into the ES cell 
genome has been shown to occur at a frequency of only 0.1 to 1%. This low level of 
homologous recombination coupled with the use of Southern blot screening methods 
to identify the correctly targeted ES cell clones make this stage of the gene targeting 
protocol very time consuming.  
In order to speed up this process, Valenzuela and his colleagues opted to use 
BAC targeting vector constructs, which in their hands can integrate into the mouse 
genome with an average targeting frequency of 3.8% (Valenzuela et al., 2003). 
Furthermore, these researchers have developed a qPCR-based ES cell screening 
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approach which can greatly minimise the time taken to identify correctly targeted ES 
clones. This approach can be used to screen for gene targeting events designed to 
delete part of the wild type allele sequence. The qPCR primers used in this screening 
method are designed to the wild-type sequences to be deleted by the BAC targeting 
vector integration. This screen is based on measuring the copy number of the 
sequence which would be deleted upon vector integration, and comparing it to a 
control autosomal gene sequence. Therefore, the amount of PCR product produced 
from the sequence of interest (if it is present in two copies in the genome) should in 
wild-type cells be comparable to the amount of PCR product from an autosomal 
control gene after the same number of amplification cycles. Deletion of the target 
sequence in one allele would, therefore, result in a reduction of the PCR product, 
which correlates with only half the PCR template being amplified. Loss-of-native 
allele screening represents a suitable approach for the isolation of BAC-based gene 
targeting events as these vectors rarely get incorporated into the mouse genome by 
non-homologous, random integration. A further advantage of this method is that it 




1.6 NEW TOOLS FOR LARGE SCALE MOUSE MUTAGENESIS 
 With the genomes of several animal models now fully sequenced, the new 
focus for researchers world-wide now lies in ascribing a function to all the identified 
protein-coding genes. Particularly in the mouse model, the most informative tool for 
the functional gene analysis is to deliberately engineer gene mutations. With a 
multitude of genes still needing to be analysed; new mouse mutagenesis methods are 
required, and existing ones need to be improved, to allow detailed gene functional 
analysis on a large scale.  In recent years, advances have involved adding some of the 
advantages of other mutagenesis approaches to improve an existing technique.  
 As previously explained, the advantage of gene trapping has been its 
amenability to large scale mutagenesis in mice, allowing large numbers of mutant 
animals to be generated using just one vector construct. However, one drawback of 
this technique is that, unlike in conditional gene targeting approaches, timing and 
place of expression of the trapped gene cannot be controlled. Gene targeting, on the 
other hand, has the advantage of generating a defined genetic modification in a 
particular gene; as well as allowing control over the activation or silencing of a 
targeted gene, with the use of a conditional construct. But, as every targeting vector 
has to be generated specifically to a gene of interest, this approach lacks the 
possibility of high-throughput mutagenesis. According to current estimates and 
statistics produced by the International Mouse Knockout Consortium, only 4,000 
targeted knockout alleles have been produced, to date. 
 The development of the recombineering approach, coupled with the 96-well 
method for targeting vector construction and ES cell screening (Chan et al., 2007; 
Valenzuela et al., 2003), has drastically improved the use of gene targeting on a large 
scale. In comparison, improvements to the gene trapping approach have involved the 
generation of a multi-purpose gene trapping allele (Schnutgen et al., 2005). Apart 
from the traditional features of a gene trapping vector, this multi-purpose construct 
also contains strategically placed site-specific recognition sites; such as loxP, FRT 
and their mutant derivatives. This system of directional site-specific recombination, 
called FlEX, facilitates the successive inversion of the trapping cassette - from the 
sense to the anti-sense orientation on the DNA strand (Figure 1.10). In the sense 
orientation, the cassette leads to silencing of the trapped gene; whilst inversion of the  
Figure 1.10: Conditional gene trap vector and mechanism of gene inactivation.
(A) Schematic representation of the retroviral gene trap vector. This vector consists of
two flanking long terminal repeats (LTR); two sets of heterotypic target sequences for
the FLPe recombinase: frt (yellow triangles) and F3 (green triangles) as well as
heterotypic target sequences for the Cre-recombinase: loxP (red triangles) and lox511
(purple triangles). The vector sequences at the core of this construct contain a splice
acceptor sequence (SA); a β-galactosidase-neomycin (βgeo) fusion gene and a
polyadenylation sequence (pA). (B) Conditional gene inactivation by the gene trap
vector. The SAβgeopA cassette flanked by recombinase target sites (RTs) in a FlEx
configuration is illustrated after integration into an intron of an expressed gene.
Transcripts (shown as gray arrows) initiated at the endogenous promoter are spliced
from the splice donor (SD) of an endogenous exon (here, exon1) to the SA of the
SAβgeopA cassette. This leads to the βgeo reporter gene being expressed. The
endogenous transcript, in this configuration, is captured and prematurely terminated at
the cassette's pA, causing a mutation. In step 1, FLPe inverts the SAβgeopA cassette
onto the antisense, non-coding strand at either frt (shown) or F3 (not shown) RTs and
positions frt and F3 sites between direct repeats of F3 and frt RTs, respectively. By
simultaneously excising the heterotypic RTs (step 2), the cassette is locked against
reinversion because the remaining frt and F3 RTs cannot recombine. This inversion
reactivates normal splicing between the endogenous splice sites, thereby repairing the
mutation. Cre-mediated inversion in steps 3 and 4 repositions the SAβgeopA cassette
back onto the sense, coding strand and reinduces the mutation. Abbreviations: βgeo, β-
galactosidase-neomycin fusion gene; pA, polyadenylation sites; RT, recombinase





cassette - to the anti-sense strand - allows reactivation of the trapped gene. These 
inversion events, controlling the expression of the gene, are driven by Cre and Flp 
recombinase.   
 The repertoire of current mouse mutagenesis approaches, for the large scale 
functional analysis of genes, is completed by: Cre/loxP-mediated conditional RNA 
interference (Ventura et al., 2004),  and transposon-mediated saturation mutagenesis 





The aim of this PhD project is to analyse the function of Mospd1 and Mospd3 
in order to gain insight into the function of the Mospd family of genes. From the gene 
trap model of Mospd3, we know that loss of gene expression in Mospd3
Gt1lmf/Gt1lmf
 
mice causes neonatal death, and cardiac defects (specifically in the right ventricle). It 
was noted that, this phenotype closely resembled the defect associated with loss of 
desmosomal and adherens junction proteins, which provide structural integrity and 
contractile force transmission in the heart. In addition, the severity of the 
Mospd3
Gt1lmf/Gt1lmf
 phenotype appeared to be highly dependent on genetic 
background, which indicated a possible genetic redundancy, maybe, involving 
another member of the Mospd family, such as Mospd1. 
Although the gene trap model has helped to shed some light on the role of 
Mospd3 in mammalian development; for a number of reasons, this mouse model has 
become unsuitable for further studies to elucidate the role of Mospd genes in heart 
development and function. These reasons include: the complexity of the gene trap 
integration; the incomplete correlation between expression of endogenous Mospd3 
and the β-gal marker gene; and, most importantly, the loss of severity of the neonatal 
death and cardiac malformation phenotype in Mospd3
Gt1lmf/Gt1lmf
animals. 
In order to gain further insight into the role of Mospd genes, particularly 
Mospd3 and its closest family member, the aim of this PhD project was to generate 
new tools for these functional studies.  These molecular tools include:  
 
 Conditional knockout alleles of Mospd3 and Mospd1 
With the aim of studying the effect of loss of function of Mospd3 and Mospd1 in a 
particular tissue, such as the heart, or at a specific time point of development; we 
decided to generate conditional knockout alleles of both genes. In addition to 
functional studies, the mice carrying the knockout alleles can also be used to 
generate double-knockout animals, in order to determine whether genetic redundancy 






 Mospd1 null ES cells  
In order to obtain evidence that Mospd1 may also have a role in cardiac 
development, underpinning our hypothesis that it might be the genetic modifier 
affecting the Mospd3
Gt1lmf/Gt1lmf
 phenotype, Mospd1-null ES cells were studied for 
their potential to differentiate into beating cardiac cells in vitro. 
 
 
 Custom antibodies specific to Mospd3 and Mospd1 
To study the hypothesis that Mospd proteins, in particular Mospd3, may be involved 
in the desmosome or adherens junction based structural integrity and force 
transmission in the heart; it is important to study the proteins localisation in the 
whole mouse model, as well as on a subcellular level. Antibodies are important 
analytical tools for such studies. As there were no commercial antibodies available to 
study the localisation and protein interaction of Mospd3 or Mospd1, we have 





















2.1 MOLECULAR BIOLOGY TECHNIQUES 
All standard molecular techniques described in this chapter were carried out 
in accordance to the Molecular Cloning Laboratory Manual (Sambrook et al., 1989), 
unless otherwise stated. The same applies to the preparation of commonly used 
solutions for molecular techniques.  
 
2.1.1 Transformation of Bacterial Cells 
Frozen aliquots of 50µl chemically-competent DH5α (TOP10, Invitrogen) 
cells were thawed on ice. Once thawed, 1µl of plasmid DNA, or 5-20µl of ligation 
product, was mixed with the cells and incubated on ice for a further 20 minutes. The 
cells were then heat -shocked at 42ºC for 45 seconds and then left to recover on ice 
for 2 minutes. The transformation reaction was added to a 15ml Falcon containing 
500µl SOC (Superoptimal culture broth) medium and incubated at 37ºC for 1 hour in 
an orbital shaker running at 200rpm. Finally, 50µl and 450µl, respectively, of this 
growth culture were spread on LB plates with the appropriate antibiotic and left to 
grow at 37ºC overnight. 
 
2.1.2 Plasmid preparation (Miniprep and Maxiprep) 
A single colony, picked from a LB or SOC agar plate or a 5ml starter culture, 
was grown in 5ml (Miniprep), or 200 to 400ml (Maxiprep), in LB or SOC medium 
and antibiotic overnight at 200rpm in an orbital shaker. The following day, the cells 
in culture were harvested by centrifugation at 6.000g for 5 minutes. The cells were 
then further processed to isolate plasmid DNA in accordance with the QIAgen kit 
and protocol for either Mini or Maxipreps.  
 
2.1.3 Polymerase chain reaction (PCR) 
This method was used for various purposes, such as: generating DNA 
fragments for subcloning, making Southern blot probes, or genotyping animals and 
cells. A representative PCR generally contained 10 to 100ng template DNA along 
with 10µM of 2 primers each in 1xPCR buffer supplemented with MgCl2 (1.5mM), 
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dNTPs (10µM) and 1unit of Taq DNA polymerase (Invitrogen) in a final volume of 
50µl. The template DNA was amplified in a HYBAID PCR-Express machine. A 
typical PCR proceeded as follows: 2 minutes denaturing at 94ºC, followed by 30-32 
cycles of 94ºC for 15 seconds, 55ºC for 30 seconds, 72ºC for 1 minute, and a final 
extension cycle of 72 ºC for 10 minutes.     
 
2.1.4 Restriction digest 
The DNA was cut using the appropriate restriction enzyme and buffer. The 
restriction reaction was incubated for 2 hours to overnight at the temperature 
required for the enzymes activity (usually 37ºC). If restriction with two different 
enzymes was performed, the restriction buffer allowing optimal activity of both 
enzymes was used. The restriction fragments were then visualised and separated by 
gel electrophoresis. 
 
2.1.5 Sequencing  
 Plasmid DNA samples were submitted for automated sequence analysis by 
the University of Edinburgh‟s School of Biological Sciences Sequencing Service. 
For this, 5µl of DNA obtained from Miniprep samples were combined with 1µl of 
10mM uni-direction primer. Sequencing reactions were carried out according to the 
manufacturer‟s specifications, using the ABI PRISM Big-dye terminator premix 
sequencing kit (Perkin-Elmer). Samples, subjected to thermocycle-sequencing, were 
run on an ABI sequencer (Applied Biosystems).   
 
2.1.6 DNA extraction from animal tissue and ES cells 
Genomic DNA was extracted from animal tissues by boiling a small amount 
of the tissue for 20-30 minutes in 200µl of 0.05M NaOH solution. The lysis reaction 
is then neutralised by 25µl of 1M Tris (pH7.7), vortexed, and the cell debris pelleted 
at the bottom of an 1.5ml Eppendorf. The lysis supernatant contained genomic tissue 
DNA of good enough quality to be used in PCRs. For higher quality genomic DNA, 
tissues were lysed and DNA extracted using a DNeasy® Tissue kit (Qiagen). 
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For genomic DNA extraction from ES cells grown in 6-well plates or 25cm
2
 flasks, 
cells were first harvested in a 15ml Falcon tube and then incubated overnight at 55ºC 
in 2 ml of lysis buffer (4M Urea, 10mM CDTA, 0.5% sarcosyl, 0.1M Tris pH8 and 
0.2M NaCl) with 1mg/ml Proteinase K. The following day, 2ml of isopropanol was 
added to the lysis reaction and the tube was gently vortexed until a precipitate of 
genomic DNA was visible. The DNA was then spooled onto a sterile glass rod and 
resuspended in 500µl TE.  
To extract genomic DNA from ES cells grown on a 96-well plate, the cells 
were first washed with 100µl of PBS, and then 50µl of ES cell lysis buffer (10mM 
Tris pH7.5, 10mM EDTA, 10mM NaOH, 0.5% sarcosyl) and 1mg/ml Proteinase K 
was added to each well. The plate was incubated in a moist chamber at 55ºC 
overnight. The following day, the DNA in the wells was precipitated by 200µl of 
7.5mM NaOH in 95% ethanol. After 4 to 12 hours incubation at room temperature, 
the supernatant from the precipitation was tipped out of the plate, and the wells were 
washed 3 times with 100µl of 70% ethanol and then air-dried for 30 minutes.  
 
2.1.7 DNA preparation for electroporation 
20µg of targeting vector used for electroporation into ES cells were linearized 
with the appropriate enzyme, overnight. The restriction reaction was subsequently 
purified using an equal volume of 50:50 phenol: chloroform solution. The mixture 
was vortexed, spun at full speed in an Eppendorf Centrifuge 5415D microfuge, and 
the aqueous phase removed. A further purification using an equal volume of 
chloroform, vortexing and spinning followed. The purified vector was then 
precipitated with ammonium acetate and isopropanol, washed with 70% ethanol, and 
resuspended in 20µl tissue grade PBS, ready for electroporation. 
 
2.1.8 Southern blot 
Genomic DNA (10µg) was digested with the appropriate enzyme overnight at 
a temperature specific to the enzyme. Afterward, the digested DNA was precipitated 
with ammonium acetate and isopropanol, and resuspended in 30µl of TE.  
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When using genomic DNA isolated in a 96-well format, a restriction cocktail 
containing 1x buffer, 1mM spermidine, 100µg/ml RNAse and 10units of restriction 
enzyme per sample was used to digest the DNA. Of this restriction cocktail 30µl 
were added to each well with a multi-channel pipette, and the 96-well plate was 
incubated in a moist chamber overnight at the appropriate temperature. 
The restriction fragments were resolved on a 0.7% agarose gel overnight. A 
picture of the gel was captured using a UVdoc system (Uvitec) with a ruler next to 
the DNA ladder, to allow future sizing of the DNA fragments. The gel was incubated 
for 5 minutes in depurination solution (10.25ml HCl in 500ml H2O), and denatured 
for 45 minutes in 0.5M NaOH and 1.5M NaCl. After a further 15 minutes incubation 
in 10xSSC neutralisation solution, the DNA from the gel was transferred to an 
Hybond N+ membrane (Amersham) by wet Southern blotting capillary transfer, as 
described in (Sambrook et al., 1989). Following overnight blotting, the location of 
the wells was marked on the membrane. The membrane was rinsed in 2xSSC and air-
dried. Using a UVdoc System (Uvitec), the DNA was cross-linked to the membrane. 
2.1.8.1 Radioactive labelling and purification of probes 
All radioactive work was performed under strict adherence to Working with 
Radioactivity guidelines for the university. Procedures involving radioactivity were 
performed in a designated room, and great care was taken to avoid radioactive 
spillage and contamination of work surfaces and materials. 
The probe DNA was generated by high-fidelity PCR of the DNA from the 
appropriate BAC. Sequences of primers used for Southern blot probe generation can 
be found in Appendix table 2. The neomycin probe was generated by NcoI digestion 
of plasmid PL451 (Appendix Figure 3). The resulting PCR or restriction fragments 
were gel purified, and 100ng of purified DNA was added to nuclease-free water to a 
final volume of 11µl, and incubated at 100ºC for 5 minutes. This denatured DNA 
solution was snap-cooled on ice; and 4µl of HighPrime mix (Roche) containing 1 
unit/µl Klenow polymerase, as well as 125µM dATP, dGTP and dTTP (each) in 50% 
glycerol was added. Also on ice, 5µl of radioactively labelled [α-
32
P] dCTP 
(10mCi/ml) was added to the labelling mix, and the reaction was incubated at 37ºC 
for 1 hour.  After this time the reaction mix was applied to a 1.5ml Sephadex G50 
(Sigma) column. The column was washed with 1ml dH2O and the labelled probe, 
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eluted in the 800µl of dH2O, subsequently added. Finally, the probe DNA was 
denature for 5 minutes at 100ºC and hybridised to the Southern blot membrane.  
2.1.8.2 Prehybidisation and hybridisation 
ExpressHyb solution (Clontech) was pre-warmed to 65ºC in a water bath. The 
membrane was pre-hybridised for 30 minutes at 65ºC, in an evenly rolling Techne 
hybridisation bottle, in a Techne Hybridiser HB-1D oven. The denatured 
radioactively labelled probe was added to the 10ml pre-hybridisation solution, and 
the blot was further incubated at 65ºC overnight. 
2.1.8.3 Washing 
The following day, the hybridisation solution was discarded, in accordance with 
radioactivity disposal guidelines, and the blot was washed 3 times with 100ml of pre-
warmed 2xSSC/ 1%SDS for 15 minutes at 65ºC. After a further 3x15 minute washes 
with 0.2xSSC/ 1%SDS at 65ºC, the blot was mounted in Saran-wrap in an X-ray 
cassette and exposed to X-ray film (Kodak) at -80ºC for 2 to 10 days. During the 
washing procedure, the level of background radioactivity was monitored with a 
Geiger counter; and when only a low localised radioactive signal was detected, the 





2.2 TARGETING VECTOR GENERATION AND RECOMBINEERING IN 
E.COLI 
2.2.1 Bacterial Strains and Plasmids 
The E.coli strains, used in this study, were derived by transferring a defective 
lambda prophage into DH10B cells, to create DY380 cells (see Table 2.1 adapted 
from (Liu et al., 2003)). Addition of an arabinose-inducible cre gene (pBAD–cre) 
into the lambda prophage in DY380, led to the creation of EL350 cells (Lee et al., 
2001). Chemically competent DH5  cells (Invitrogen) were used for the initial 
construction steps of the targeting vector.   
 The plasmids used in this study include: pNEB-DT, which carried a 
diphtheria toxin cassette for negative selection of targeting vector integrations into 
ES cells; as well as PL452 and PL451,  both carrying a neomycin resistance gene 
flanked by either two loxP sites (PL452) or two FRT sites followed by a downstream 
loxP site (PL451). A list of plasmid features can be found in Table 2.1, and plasmid 
maps can be found in the appendix (Appendix figures 1, 2 and 3).  
   
2.2.2 Subcloning of DNA targeting fragment from BAC into pNEB-
DT vector 
2.2.2.1 Preparation of BAC DNA 
The E.coli cells containing the bacterial artificial chromosomes (BAC), used 
for the recombineering strategy, were obtained from a C57BL/6-BAC library, held at 
the BACPAC Resources Facility at the Children‟s Hospital Oakland Research 
Institute (CHORI). The BACs, carrying the entire genomic sequences of either 
Mospd1 or Mospd3, correspond to the following NCBI accession numbers and 
CHORI-BAC clone number: Mospd1-BAC (AC100311 and RP23-123K17), 
Mospd3-BAC (BH063983 and RP24-129E14).  
E.coli cells containing BACs were grown overnight in 600ml LB broth 
supplemented with 20µg/ml chloramphenicol. The cells were collected, and DNA 
was extracted using a QIAGEN Maxiprep kit. In accordance with the instructions for 
Plasmid DNA purification from very low-copy plasmid/cosmid containing cells, 
20mls of buffers P1, P2 and P3 were used. The lysate, containing the cell‟s protein 
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Table 2.1: Recombineering reagents. 
 
Strains Genotype 
DY380 DH10B [λc1857 (cro-bioA < >tet] 
EL350 DH10B [λc1857 (cro-bioA < >araC-PBADcre] 
Selection cassettes  
PL451 FRT-PGK-EM7-NeobpA-FRT-lox 
PL452 loxP-PGK-EM7-NeobpA-loxP 







precipitate, was spun twice at 17,900xg for 30 minutes. The clear, protein 
precipitate-free supernatant was applied to 2x500 Qiagen MaxiPrep column, and 
after washing with buffer QC, the DNA was eluted with 55ºC elution buffer QF. The 
DNA was then precipitated with isopropanol, and washed with 70% ethanol, and 
subsequently the two samples of the same clone were resuspended and pooled in 
300µl of TE.  
2.2.2.2 Subcloning of Mospd1 by restriction-ligation methods 
The Mospd1-BAC (AC100311) was digested with SmaI and SacI enzyme, 
and the resulting restriction fragments were separated by gel electrophoresis on a 
0.7% gel. The bands, corresponding to a size of approximately 12kb, were cut from 
the gel and re-cast in a fresh 0.7% gel, to be further resolved at 20V, overnight. In 
parallel, the pNEB-DT vector (Appendix figure 1 and Table 2.1) was digested with 
SmaI and SacI restriction enzyme. The linearized pNEB-DT plasmid DNA was then 
precipitated with ammonium acetate, resuspended in 50µl 1xCIP (Calf Intestinal 
Alkaline Phosphatase) buffer, and heated to 65ºC for 5mins, and then placed on ice. 
After the addition of 1µl CIP (Calf Intestinal Alkaline Phosphatase, Roche), the 
reaction was incubated at 37ºC for 2hrs, and then stopped by heating to 65ºC. Like 
the SmaI/SacI digest of the BAC, the linearized pNEB-DT plasmid was purified 
twice on a 0.7% gel. The plasmid and the BAC fragments were purified using 
QIAexII kit (Qiagen). Finally, 1.5µg BAC fragment was mixed with 0.5µg of 
linearized pNEB-DT in 1x ligation buffer and 1µl T4 ligase (Invitrogen). The 
reaction was incubated in 37ºC for 2hrs, resulting in the directional ligation of the 
BAC (SmaI/SacI) fragment into the SmaI/SacI linearized pNEB-DT vector. This 
targeting vector was then transformed into DH5α cells (Section 2.1.1). 
2.2.2.3 Cloning of homology regions for Mospd3 gap retrieval into  pNEB-DT  
Two genomic regions of the Mospd3-BAC, flanking the 13kb Mospd3 DNA 
fragment, were PCR amplified using primer pairs: Mospd3A‟-HindIII and 
Mospd3B‟-BamHI, or Mospd3Y3-BamHI and Mospd3Z3AvaI. Primer sequences are 
listed in Appendix table 1. These primers amplify the following fragments: a 204bp 
(A,B) fragment with the primer pair one, and a 207bp (Y,Z) fragment with primer 
pair two.  
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PCR amplification (Invitrogen, Platinum Taq Polymerase High Fidelity kit) 
was performed with the following settings: 94 C for 5min, then 30 cycles of 94 C 
for 15sec, 55 C for 30sec, and 72 C for 1min, followed by 72 C for 10min. The PCR 
products were then digested with HindIII and BamHI for fragment A,B; and BamHI 
and AvaI for fragment Y,Z.  Subsequently, 10 l of each fragment were 
simultaneously ligated with 1 l AvaI/HindIII-linearized pNEBDT vector.  To 
facilitate gap retrieval of the 13kb Mospd3 fragment for the targeting vector, the 
pNEB-DT vector, containing the Mospd3 homology arms A,B and Y,Z; was 
electroporated into recombination efficient EL350 cells containing the Mospd3 BAC 
(BH063983) as described in section  2.2.2.5.  
2.2.2.4 Electroporation of BAC or Plasmid DNA into EL350 cells 
EL350 cells were grown in 5ml LB/ 2% sucrose broth overnight at 32 C. The 
cells were collected the next day by centrifugation for 10 minutes at 3,000xg at 4 C. 
The cells pellets were resuspended in 900 l of ice-cold water, transferred to a 1.5ml 
Eppendorf tube (on ice), and centrifuged at 16,000xg using a bench-top Heraeus 
Sepatech Biofuge13 for 25sec at 4 C. The supernatant was removed and cells 
resuspended in 900 l fresh ice-cold water. The process was repeated 5 more times. 
Finally, the cell pellet was resuspended in 50 l ice-cold water and transferred into to 
pre-cooled electroporation cuvette (0.1cm gap). Next, 4 l Mospd3-BAC (300ng) or 
2 l pNEB-DT-Mospd1 plasmid DNA (300ng) was added and mixed. Electroporation 
was performed using a BIO-RAD electroporator under the following conditions: 
1.75kV, 25 F with pulse controller set at 200 . After electroporation, 0.5ml SOC 
was added to each cuvette, and then transferred with the electroporated EL350 cells 
into a 1.5ml Eppendorf tube, and grown at 32 C for 1h. Cells were spread on plates 
with either chloramphenicol (Mospd3-BAC) or ampicillin (pNEB-DT-Mospd1). 
2.2.2.5 Gap retrieval 
EL350 cells containing Mospd3-BAC (BH063983) were inoculated into 5ml 
of LB broth with 20µg/ml chloramphenicol and grown overnight at 32 C with 
shaking. The next day, 1.0ml of overnight culture was transferred to 20ml of super 
optimal broth with glucose (SOC) and incubated for approximately 2.5h with 
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shaking, until the OD600 reached 0.7 to 0.8. Then 10ml of the cells were transferred 
to a new flask and shaken at 42 C for 15min, whilst the remaining 10ml of culture 
were put on ice to be used as un-induced control.  After their 15min incubation, the 
induced cells were also put on wet ice and shaken to cool them rapidly. After 5min 
on ice, the induced and un-induced cells were transferred to chilled Falcon tubes and 
spun at 5,000rpm (4 C) for 5min. Cells were resuspended in 900 l ice-cold water, 
then transferred to a 1.5ml Eppendorf tube, and washed 5 times with ice-cold water, 
as described above. Finally, the cell pellet was resuspended in 50 l ice-cold water. 
This cell suspension was mixed with 2 l BamHI linearized pNEB-DT vector, 
containing the Mospd3 homology regions AB and YZ, and the cells were 
electroporated as described above. The electroporated cells were plated on SOC agar 
containing ampicillin. 
 
2.2.3 Introduction of the neo cassettes  
The 2kb loxP-neo-loxP cassette was PCR amplified from the PL452 vector 
(Appendix Figure 2 and Table 2.1) using 80mer primers Mospd1-loxpneo-1_for and 
Mospd1-loxpneo-2_rev, along with the Invitrogen Platinum Taq Polymerase High 
Fidelity kit. The primers used in the case of Mospd-3 were: Mospd3-loxpneo-1_for 
and Mospd3-loxpneo-2_rev. Expand High Fidelity polymerase enzyme (0.5µl, 
Roche), 1µl of each primer and 1µl template in 21.5µl water were mixed with 25µl 
Failsafe PCR mix J for the amplification. All sequences of primers used for 
recombineering are listed in Appendix table 1.  
The approximately 2kb FRT-neo-FRT-loxP cassette was PCR amplified from 
PL451 vector (Appendix Figure 3 and Table 2.1) using 70mer primers Mospd1-
FRTneo_p1 and Mospd1-FRTneo_p2 for Mospd-1 targeting, and primers Mospd3-
FRTneo_p1  and Mospd3-FRTneo_p2 for Mospd-3. Failsafe mix H and I were used 
for this PCR. 
The PCR, in both cases, was performed using a two-stage program with the 
following settings: pre-warm at 94 C for 2min, after which the PCR was added to the 
machine; this was followed by 94 C for 2min; then 10 cycles of 94 C for 15sec, 
45 C for 30sec, and 68 C for 4min; followed by 20 cycles of 94 C for 15sec, 60 C 
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for 30sec, and 68 C for 4min - with an additional 5sec extension time after each 
cycle. The reaction was concluded by 68 C for 7min.  
The PCR product was re-precipitated and digested for 1 hour with DpnI to 
eliminate plasmid template contamination. The Dpn1 restriction enzyme only acts on 
methylated DNA, like that of the E.coli plasmid; but does not cut the unmethylated 
DNA of the newly synthesised PCR product. The PCR fragment DNA was further 
purified using a QIAexII kit (Qiagen). Finally, 300ng of the purified PCR product 
was electroporated into EL350 cells containing targeting vectors as described in the 
previous section 2.2.2.5. The electroporated cells were plated out on SOC plates 
containing kanamycin.  
 
2.2.4 Excision of the floxed neo cassette  
EL350 cells were inoculated into 5ml of LB broth with 2% sucrose, and 
grown overnight at 32ºC. The next day, 10ml of fresh LB were inoculated with 1 ml 
of EL350 overnight culture and grown at 32ºC until the culture reached O.D.=0.5. 
100μl of L(+)-arabinose (Sigma) was added to the culture, and Cre induction from 
arabinose promoter (pBAD-cre) was allowed to proceed for 1 hour at  32ºC. The 
cells were collected at 3,000xg, and washed in ice cold water as described 
previously. Arabinose-induced EL350 cells, and un-induced controls, were 
electroporated, as before, with 10ng of the floxed neo cassette containing the 






2.3 CELL CULTURE AND MANIPULATION 
In the course of this project, four different cell lines have been used: two 
feeder-independent embryonic stem (ES) cell lines, CGR8 and E14; as well as 
immortalised cell lines COS7, and mouse C57BL/6 keratinocyte cells (Millipore/ 
Chemicon).  
Both ES cell lines were maintained in ES cell culturing medium, consisting of 
1X Glasgow Minimal Essential Medium (Gibco) supplemented with 20% fetal calf 
serum, 0.25% sodium bicarbonate (Gibco), 0.1% non-essential amino acids, 2mM L-
glutamine (Gibco), 1mM sodium pyruvate (Gibco), 0.1mM β-mercaptoethanol 
(Sigma) and 100 U/ml Leukaemia Inhibitory Factor (LIF). The working 
concentration of LIF, obtained in culture supernatant from COS7 cells transfected 
with murine LIF expression plasmid pDR10, corresponds to 100x the minimum 
concentration required to keep CP1 ES cells (Bradley et al, 1984) undifferentiated. 
COS7 cells were cultured in ES cell medium without LIF. The mouse C57BL/6 
keratinocyte cells were cultured in the culture medium provided, for this purpose, by 
Millipore. 
 To ensure adherence of cells in the tissue culture flasks, ES cells were plated 
on tissue culture plastic pre-coated with 0.1% gelatine. COS7 cells and keratinocytes 
will adhere straight to tissue culture plastic, without any other matrix.    
 All cell lines were grown at 5% CO2 in a 37ºC humidified incubator (Galaxy 
S, Wolf Laboratories). 
 
2.3.1 Thawing cells 
Cells, stored at -140ºC, were thawed rapidly in 37ºC water bath and 
transferred into a Universal tube containing pre-warmed culture medium to a final 
volume of 10ml. The cells were centrifuged at 180xg for 3 minutes, the supernatant 
removed. Then, the cell pellet was carefully resuspended in fresh culture medium 
and transferred into a 25cm
2
 culture flask with 10ml culture medium. The culture 





2.3.2 Passage and expansion of ES cells 
 Cells were generally passaged every 2 days, when they had reached around 
70% to 80% confluency. The medium was aspirated from flask, and the cells were 
washed with PBS and then incubated for 5 minutes in enough trypsin solution ( 1% 
trypsin, 1% chick serum and EDTA in PBS) to cover the bottom of the culture flask 
or plate. Once the cells had lifted off the tissue culture plastic and been agitated into 
single cell suspension, the trypsin was neutralised with at least 5X volume of culture 
medium in a Falcon tube, and cells were spun at 180xg for 5 minutes. The cell pellet 
was resuspended in 10ml fresh medium and cell number was determined using a 
haemocytometer on a Leitz Labovert microscope. 1x10
6
 cells per ml (in 10ml) were 
transferred to a new 25cm
2
 flask, or 3x10
6
 cells per ml (in 30ml) to a 75cm
2
 flask.   
 After 2 days of growth, cells from a 75cm
2
 flask can be trypsinised and 
passaged at approximately 8x10
6




2.3.3 G418 concentration kill curve 
 Wild type ES cells were plated at 4x10
3
 cells into each well of a 6-well plate, 
and left overnight to settle in 5ml of ES cell medium with LIF. On the following day, 
the medium was replaced with 5ml of fresh medium containing different 
concentrations of G418 (Geneticin, PAA). The concentrations used were 0, 100, 150, 
200, 250, 300, 350 and 400µg/ml. The medium containing G418 was replaced on a 
daily basis, and cells monitored. The optimal G418 concentration was defined as the 
minimum concentration used to kill all wild type ES cells. This was found to range 
from 260-280µg/ml.   
  
2.3.4 ES cell electroporation 
 Cells grown on a 225cm
2
 flask were trypsinised, pelleted and resuspended in 
20ml culture medium. Cells were counted; then, 3x10
7
 cells were centrifuged again 
and resuspended in 0.6ml PBS. This cells suspension was mixed with 20μg of 
linearized targeting vector DNA and then transferred into an electroporation cuvette 
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(Invitrogen, 0.4cm gap). The cells were electroporated in a GenePulser
TM
 (Biorad) 
with one pulse of 250V, set at a capacitance of 500μF.  
 After a recovery period of 5 minutes the cells were plated onto 11 pre-
gelatinised 100mm tissue culture dishes, and cultured in 10ml ES cell culture 
medium per plate. 
 On the following day, the medium on 10 of the plates was replaced with ES 
cell medium containing 280 to 320μg/ml G418 (PAA). The antibiotic selection 
continued for 6-9 days with daily washing and media changes. After this period, 
individual resistant colonies were picked into 96-well plates. Once the cells in the 
majority of the wells reached confluency, the cells were trypsinised and triplicate 
plated. After a further 2 days of growth, one of the triplicate plates was frozen for 
further expansion of correctly targeted clones. The cells in each well were trypsinised 
with 50μl of trypsin, and then agitated into single cells suspension on addition of 
50μl of 20% DMSO in fetal calf serum. The plate was sealed and stored at -80ºC. 
The two remaining plates were left for a further one to two days. DNA was extracted 
from these plates (see section - DNA extraction from cells). 
 
2.3.5 Transient Cre expression in ES cells  
 ES cells containing a loxP flanked allele were harvested from a 75cm
2
 tissue 
culture flask and counted.  5x10
6
 cells are resuspended in 0.6ml of PBS, mixed with 
25μg Cre expression plasmid (pCAGGS-Cre-IRESpuro (plasmid map in Appendix 
Figure 4), and electroporated. The electroporated cells were returned to a 75cm
2
 flask 
to recover overnight. The following day, the cells were trypsinised again, counted, 
and replated at varying cell numbers of 500; 1,000 and 2,000 cells in 10mm plates 
with ES cell medium. After 7-9 days of culture, 20- 30 distinct colonies were picked 
into a 96-well plate. These clones were subsequently processed as in section 2.3.4.  
 
2.3.6 Transfection of DNA into COS7 cells  
 COS7 cells were plated at 2x10
5
 cells per well in a 6-well plate. After 2 days, 
5μl of Lipofectamine 2000 (Invitrogen) and 250ng vector DNA was added to 50μl of 
serum-free OptiMEM (Gibco), and incubated for 20 minutes at room temperature. 
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This vector/lipofectamine mix was added to each well of the 6-well plate, in which 
the ES medium had been replaced by 1ml OptiMEM. After 4 hours of incubation 
with this transfection mix (at 37ºC in a humidified 5% CO2 incubator), the OptiMEM 
on the cells is replaced with fresh ES medium again, and cells are grown for a further 
2 days before protein was extracted.  
 
2.3.7 ES cell self renewal assay 
 1x10
3
 ES cells were plated in each well of a 6-well plate with ES cell medium 
containing LIF. The following day, the wells were washed with PBS and the medium 
replaced.  In half of the wells, LIF was added to the medium; whilst the other half did 
not receive any LIF in the medium. After a further 4 days under these culture 
conditions, the ES cell colonies were stained for alkaline phosphatase activity.  
 The cells were washed with PBS and the staining procedure was performed 
using an Alkaline Phosphatase Kit (Sigma-Aldrich). In accordance with the protocol, 
cells were first fixed (67% acetone, 25% citrate solution, 8% formaldehyde) for 30 
seconds, then rinsed in water and subsequently incubated with the colour substrate 
solution for 15 minutes in the dark. After a final rinse and drying of the plate, the 
alkaline phosphatase staining of individual colonies was analysed using an inverted 
Zeiss Axiovert25 microscope. 
 
2.3.8 Preparation of embryoid bodies (EB) and cardiomyocyte assay 
ES cells were trypsinised from a 25cm
2
 flask, resuspended and counted. 
6x10
5
 cells were added to a Universal tube in a volume of 20ml ES cell medium with 
LIF. Using a multichannel pipette, the lid of a square Petri-dish (measuring 120mm
2
) 
was covered with 10μl drops of this ES cell suspension. The lid, with these hanging 
drops attached, was then placed on the base of the square dish, filled with 10ml of 
water to maintain a humid atmosphere. The hanging drops were incubated at 37ºC in 
a humidified incubator for 2 days and then harvested by tapping the dishes on the 
bottom of the hood. The collected, 2 day old, embryoid bodies in the medium were 
spun at 800 rpm for 3 minutes, and fresh medium (without LIF, but supplemented 
with Penicillin/Streptomycin solution (Sigma) at 1:100) was added. The embryoid 
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bodies were then cultured in suspension, in a bacteriological 100mm dish, for a 
further 5 days, with medium changes every two days.  
 After 5 days, the embryoid bodies are transferred (one EB per well) into a 
pre-gelatinised 24-well plate. The embryoid bodies were analysed every 2 days, and 
the number of EBs with beating foci was counted.  
 
2.3.9 Karyotyping of ES cell clones 
 ES cells were passaged at 2x10
6
 cells into a 25cm
2
 flask. The next day, 100μl 
of KaryoMAX (Invitrogen) was added to the flask and cells were incubated at 37ºC 
in the incubator for 2 hours. After that time, the cells were trypsinised, pelleted in 
15ml Falcon tubes, and the medium removed. Under gentle vortexing, 8ml of a 
0.56% KCl solution were added drop-wise to resuspend the pellet, and this cell 
suspension was incubated in a 37ºC water bath for 12 minutes. Next, 2ml of freshly 
prepared fixative (methanol 3:1 acetic acid) was added to the tube and mixed gently. 
The cells were then spun at 1000 rpm for 5 minutes, the supernatant removed and the 
cells resuspended in 8ml of fixative. This spin and resuspension process was repeated 
3 times, and after the final spin the cells were resuspended in about 1ml of fixative. 
One drop of this final suspension was then dropped onto a slide, which had first been 
pre-cooled at 4ºC in ethanol and then dried.  
 These karyotyping spreads were stained with a 1:2,500 dilution of DAPI 
(Sigma) and a cover slide mounted. Images of 20-30 karyotyping spreads, for each 
clone, were captured under fluorescent light on a Zeiss Axioskop2 microscope using 
a 63x oil emulsion objective. The camera used was a ProgRes C14 from Jenoptik, 
and images were modified and saved using Openlab
TM
 software. The number of 
chromosomes in each of the spreads was counted manually, using Adobe Photoshop, 
by marking each counted chromosome on the image with a red dot.      
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2.4 ANTIBODY PURIFICATION AND TESTING 
2.4.1 Synthetic peptide generation and antibody production 
 Synthetic peptides corresponding to the N-terminal 15 amino acids of 
Mospd1 and Mospd3 were generated by Thistle Research, and also by Yorkshire 
Biosciences. These peptides were conjugated to a immunogenic KLH carrier protein. 
The synthetic peptides - generated by Thistle Research - were supplied to PTU/BS 
(Roslin), who raised polyclonal antibodies in two rabbits for each peptide. The 
animals were bled prior to inoculation with the peptides (pre-immune) as well as 4, 8 
and 12 weeks after subcutaneous injection of the peptide antigen. 
 The synthetic peptides - generated by Yorkshire Biosciences - were used to 
inoculate mice. Splenocytes and lymph node cells from mice showing the best 
response to the antigen, tested by ELISA screening, were then fused to 
histocompatible myeloma cells. Fusion hybridomas were selected using HAT 
medium, and subsequently screened (using ELISA) for the production of the desired 
monoclonal antibodies. Three culture supernatants containing monoclonal antibodies 
were supplied for further analysis.    
 
2.4.2 ELISA analysis of rabbit antisera 
Dynatech Immulon 96-well ELISA plates were coated overnight with 0.5µg 
of synthetic peptide per well, at room temperature, in sodium carbonate-bicarbonate 
buffer. The plates were blocked for 30 minutes, at room temperature (RT), with 
250µl/well blocking buffer (PBS with 0.05% Tween plus 2% (wt/vol) BSA), before 
being rinsed several times with distilled water. A 50 µl/well volume of rabbit antisera 
(pre-immune and week 4, 8 and 12 ); diluted in 1/20,000 increments from 1/20,000 
to 1/160,000 with ELISA blocking buffer; was added to 3 wells each of the plate and 
incubated for 2 hours at RT.  The wells of the plate were then washed 3 times with 
wash buffer (PBS with 0.05% Tween 20 and 0.25% BSA) before being incubated 
with 50 µl/well goat anti-rabbit IgG horseradish peroxidase conjugate (diluted 
1/1,000 in blocking buffer) for 2 hours at RT. After being washed 3 times with wash 
buffer, the plate was then incubated with 100 µl/well of the OPD substrate (Sigma 
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p9187), for 2 hours at RT. The reaction was left to proceed in the dark for 30 minutes 
before the absorbance was measured at 450nm on a microplate reader (Vmax 
kinetic).  
 
2.4.3 Antibody purification 
Specific antibodies were purified from 8-week rabbit antiserum using an S-
PAC column, containing the bound synthetic peptide (Thistle Research, Glasgow, 
UK), used for rabbit immunisation. The purification was performed in accordance 
with the protocol supplied by the manufacturer. The S-PAC90 column was 
equilibrated with 20ml of 2M KSCN solution, followed by 50ml of PBS, before 
being loaded with 2ml of ultra-filtered (0.45µm filter) rabbit antiserum (diluted 1/10 
in PBS). Subsequently, the column was washed with 50ml PBS before eluting the 
bound antibody with 5ml of 2M KSCN solution. The eluate was collected in 2 
fractions of 2.5ml sample each, and each fraction was immediately desalted using a 
PD10 column (Amersham). The column was pre-equilibrated with 25ml PBS prior to 
addition of the 2.5ml antibody eluate sample. The desalted antibody was 
subsequently eluted from the PD10 column using 3.5ml PBS, and 0.5ml elution 
fractions were collected. The amount of antibody in each of these fractions was 
measured using a spectrophotometer at 280nm.    
 
2.4.4 Protein extraction from cells and animal tissues 
Animal tissues were dissected and immediately placed in ice cold PBS, 
containing a 2x stock solution of Complete Protease Inhibitor Cocktail (Roche) and 
20µg/ml of pepstatin (Roche). The tissues were then homogenised on ice using a 
Polytron Homogeniser. Finally, an equal volume of 2x Laemmli sample buffer 
(62.5mM Tris-HCl pH6.8, 1% SDS, 0.1M glycerol, 0.25% β-mercaptoethanol; and 
traces of bromophenol blue) was added to the homogenate and boiled in a hot block 
for 10 minutes. 
 Protein samples were obtained from cells in monolayer culture by adding 
500µl of cold PBS/ protease inhibitor cocktail into a 6-well plate containing 90% 
confluent cell culture washed with PBS. Upon the addition of 500µl 2x Laemmli 
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sample buffer, the lysed cell were lifted of the well using a cell scraper and 
transferred to a 1.5ml Eppendorf. The cell lysate was boiled for 10 minutes at 100ºC. 
 
2.4.5 TritonX100 protein extraction from ES cell clones 
 ES cells from monolayer (25cm2 flasks) were harvested and washed in PBS. 
Cells were resuspended in 500µl TritonX100 lysis buffer (cold PBS/ protease 
inhibitor cocktail with EDTA (Roche) and 0.5% TritonX100). The cells were lysed 
at 4ºC for 30 minutes (on rolling platform), and the lysate was spun at 1,000xg for 30 
minutes. The obtained supernatant was used for antibody preclearing.   
 
2.4.6 Gel electrophoresis and Western blotting procedure 
The proteins, contained in the solubilised cells and tissues, were separated by 
SDS-PAGE gel electrophoresis. The samples were denatured for 5 minutes at 80ºC, 
loaded onto a precast 10% or 12% Tris-HCl gel (Biorad), and a current of 70V to 
80V was applied for 2 to 3 hours. The gels were then soaked in transfer buffer (Tris 
3.03g, glycine 14.4g and 20% methanol made up in 1 litre) along with Nitrocellulose 
membrane (Whatmann) and 3MM Whatmann paper. Subsequently, the gel and 
membrane were assembled in a commercial semi-dry blotting apparatus (Biorad), 
according to manufacturer‟s instructions, and the proteins transferred onto the 
membrane for 1 hour at 15V.     
Blots were blocked for non-specific binding for 1 hour at RT, or at 4ºC 
overnight, in 5% milk in TBS with 0.05% Tween20. The appropriate dilution of 
primary antibody in 5% milk/ TBS with Tween20 was added to the membrane and 
incubated for 2 hours at RT, or overnight at 4ºC, depending on the binding efficiency 
of the antibody.    
Following three 10-30 minute washes, the membrane was incubated for 1 
hour in secondary HRP-conjugated antibody, diluted in 0.5% BSA in TBS with 
0.05% Tween (according to manufacturer‟s instructions). The membrane was washed 
a further 3 times to remove any unbound antibody. All incubations and washes were 
performed on a shaking platform. 
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 After the final washes, the membrane was exposed to ECL chemi-
luminescent substrate (Amersham Pharmacia Biotech) for 1 minute and visualised on 
photographic film (Kodak). 
 
2.4.7 Antibody preclearing and peptide competition  
 Purified polyclonal antibodies were mixed with the preclearing substance 
(mouse serum (Sigma) or TritonX100 lysates of ES cells) at a ratio of 1:1. This mix 
was incubated at 4ºC overnight, on a shaking platform, before being used for primary 
antibody incubation of a western blot, at an appropriate dilution in 5% milk in TBS 
with 0.05% Tween20.  
 For peptide antigen competition, purified antibodies were mixed at a ratio of 
2:1 with a 2mg/ml solution of peptide antigen in PBS and incubated at 4ºC overnight 
(on a shaking platform), before being used for primary antibody incubation of a 
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3.1  INTRODUCTION 
Mospd3 is one of four genes, of an as yet largely undescribed gene family, in 
the mouse model. The gene was discovered through a gene trap experiment aimed at 
identifying novel developmental genes. Loss of Mospd3 in mice carrying two 
trapped alleles of the gene resulted in cardiac defects as well as neonatal death (Pall 
et al., 2004). This phenotype closely resembled other mouse model phenotypes 
caused by deletion of genes involved in intercalated disc attachments and contractile 
force transmission in the heart. This similarity indicates that Mospd3 may also 
function to provide structural integrity in the heart.  
Unfortunately, for a number of reasons, the gene trap model of Mospd3 was 
unsuitable for further analysis of the genes function. These reasons include: the 
genetic complexity of the gene trap vector integration; the finding that the expression 
of the vectors β-gal marker gene did not fully correspond to the endogenous 
expression pattern of Mospd3 in the embryo; and, most importantly, the fact that 
some aspects of the gene trap phenotype have been lost (Pall et al., 2004).  
Nevertheless, loss-of-function approaches in the mouse model represent a 
particularly powerful experimental tool for studying genes involved in development. 
We, therefore, chose to generate a conditional knockout of Mospd3. The plan for this 
conditional allele involved flanking important 5‟ exons of Mospd3 with loxP sites in 
such a way that Cre-mediated deletion results in a complete loss of the encoded 
Mospd3 protein. The combination of this loxP-flanked construct with tissue-specific 
and inducible Cre expression systems would make it possible to determine if Mospd3 
function is particularly required in the heart tissue. This system should also provide 
an answer to whether Mospd3 is required either for embryonic heart development, or 
the maintenance of cardiac structural integrity in newborn and adult mice. 
In addition to Mospd3, we also chose to generate a conditional knockout 
mouse model of Mospd1 in order to determine whether this member of the Mospd 
gene family is functionally redundant to Mospd3.  
This chapter describes the production of conditional Mospd1 and Mospd3 
targeting vectors by recombineering, and their subsequent introduction into two 
different mouse ES cell lines to produce mutant alleles for functional analysis. We 




3.2.1 Generation of Mospd1 targeting construct and targeted allele 
3.2.1.1 Design of the conditional targeting vector  
The sequence of Mospd1 to be targeted, and to be used in the targeting 
vector, was chosen to include exons 2 to 4 of the gene along with 3 to 4kb of 5‟- and 
3‟-flanking homology arms. Taking account of the genomic structure and protein 
domain information of Mospd1, we chose to place the loxP sites in the intron 
between exons 1 and 2 as well as the intron between exons 4 and 5 (Figure 3.1 A). 
Being placed in these large (7.7kb and 12.5kb) non-coding intronic regions, the loxP 
sites are not anticipated to interfere with the normal function, nor the expression of 
Mospd1.  
To ensure that the loxP sites were not positioned in possible conserved non-
coding regulatory elements within the introns between exon 1 and 2, and between 
exons 4 and 5; a genome alignment between mouse and human was performed 
(Figure 3.1 B). The genomic sequence of Mospd1 in the NCBI mouse genome build 
m33 (May 2004) was aligned with the human orthologue from the human reference 
sequences (genome build 35) published in May 2004. Intronic sequences showing a 
high level of conservation (more than 70% sequence identity), marked by pink 
coloured peaks in the alignment, were avoided when placing the loxP sites as these 
conserved sequences could potentially represent regulatory element such as 
enhancers of Mospd1 or other genes in the vicinity. The loxP integration sites, shown 
in Figure 3.1, were chosen to minimise the size of the genomic sequence being 
deleted in the conditional allele whilst including all the important exons - containing 
both the translational start site (ATG) and MSP domain.   
As the start-codon of Mospd1 is located in the second exon, the 
recombination of the two loxP sites is expected to ablate the entire 5‟-coding 
sequence region of Mospd1. The next usable in-frame start codon beyond exon 4 of 
Mospd1 is located in exon 5, in the middle of a sequence encoding the first 
transmembrane domain. Thus, even if an alternative start-codon is utilised, the 
resulting protein would only contain a short portion of the C-terminal transmembrane 
domains.   
Figure 3.1: Design of the conditional knockout allele of Mospd1 and genomic sequence alignment of the
Mospd1 gene of mouse and human using VISTA Genome Browser. (A) Schematic of the endogenous Mospd1
gene locus and proposed placement of the loxP recombination sites (one in form of a FRT-neo-FRT-loxP cassette)
for the generation of the conditional knockout allele of Mospd1. the six exons of Mospd1 are marked as black
boxes. In the targeting cassettes containing the loxP sites, loxP is marked as a red triangle and FRT sites are
represented as purple ovals. (B) The VISTA graph shows the conservation between Mospd1 in mouse (genomic
build May2004) and MOSPD1 in human (genomic build May 2004) across the entire genomic sequence of the
gene. An arrow signifying the Mospd1 gene is shown above the graph, with the arrowhead pointing in the direction
of the gene. The exons of Mospd1 are indicated as pale and medium blue blocks. In the VISTA graph, peaks
marked in pink indicate non-coding sequences (CNS) of more then 70% sequence identity between mouse and
human. More than 70% sequence identity in coding exons is marked by medium blue peaks, and with pale blue
peaks in untranslated regions (UTR). The grey bar below the plot indicates that a single human contig was used to
generate the alignment with the mouse. The bar immediately above the plot denotes regions of repetitive
sequences (listed in the legend under Repeats). The scale bar at the top of the figure shows the size and location
of Mospd1 on mouse chromosome X. Abbreviations: CNS, non-coding sequences, DNA, DNA-transposon; LINE,
Long Interspersed Nuclear Elements; LTR, Long Terminal Repeats; neo, neomycin resisance marker; RNA, RNA-










3.2.1.2 Identification of a Mospd1-BAC clone    
A BAC clone containing the entire genomic sequence of Mospd1 was chosen 
using the clone finder tool of the Mouse Genome Resource Database
5
. This BAC 
clone (GenBank Accession: AC100311), held at the BACPAC facility at the CHORI 
(Children‟s Hospital Oakland Research Institute), originated from a BAC library 
generated from female C57BL/6 DNA, from kidney and brain. 
3.2.1.3 Subcloning of Mospd1 
 Although it is possible to use the whole BAC as targeting vector, and 
engineer the loxP sites into Mospd1, working with such a large construct (usually 
around 20kb) has several drawbacks. Due to its size, a BAC has to be handled 
carefully to keep it from shearing; which, in turn, makes it difficult to examine the 
vectors integrity after every modification. Additionally, most BACs already contain 
loxP sites which have been used to generate the BAC library. These loxP sites would 
need to be removed before starting to generate the conditional knockout (cko) vector 
(Liu et al., 2003). Finally, the electroporated ES cell clones would have to be 
screened and verified for targeting vector integration by FISH (Fluorescent in situ 
Hybridisation); instead of the preferred Southern blot analysis of diagnostic 
restrictions, which allows more detailed analysis of the site of integration.   
 An 11kb DNA fragment, containing exons 2 to 4 of Mospd1 along with 
flanking homology arms, was directionally subcloned from the BAC into a pNEB-
DT vector (see Appendix figure 1 for plasmid map) using SmaI and SacI restriction 
sites (Figure 3.2 A). The targeting fragment integrated into the multiple cloning site 
of the vector, upstream of a negative selection cassette. The negative selection 
cassette, in this case, consisted of the diphtheria toxin-A gene (DT) driven by a 
modified MC1 eukaryotic-expression promoter - engineered from the promoter 
sequences of Herpes Simplex Virus thymidine kinase (Pinto et al., 2000; Thomas and 
Capecchi, 1987; Yagi et al., 1990). This cassette also contains a polyadenylation 
signal (Yanagawa et al., 1999).  
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Figure 3.2: Recombineering strategy for Mospd1 targeting vector
construction. (A) Schematic of recombineering strategy for generating a
conditional targeting vector of Mospd1 and (B) diagnostic EcoRI digests of
constructs generated in this procedure. An 11kb targeting fragment of Mospd1
was subcloned from the Mospd1-BAC into pNEB-DT using SmaI and SacI
restriction sites (construct 1 and Lane1 in EcoRI digest gel). The exons of
Mospd1 are marked by black boxes. The Mospd1 targeting vector was then
electroporated into EL350 cells for further manipulation. The first loxP site (loxP
marked as red triangle) was introduced into the vector by recombineering a PCR
amplified loxP-neo-loxP cassette into the sequence upstream of exon 2 of
Mospd1 in the vector (A, construct 2 ;B, lane 2). Recombineering-specificity to
this region was achieved through the 60bp sequence homology of the PCR with
sequences upstream of exon 2. Homologies for targeting of the selection
cassettes are marked as blue lines in the constructs. Subsequently, the neo
selection cassette was removed by inducing the EL350 cells to express Cre
recombinase by addition of 0.1% arabinose (A, construct 3; B, lane 3). The
second loxP site in the form of a FRT-neo-FRT-loxP cassette (FRT site marked
with purple oval) was introduced by recombination downstream of Mospd1 exon
4 in the same way as the first targeting cassette (A, construct 4 and B, lane 4). A
1kb plus ladder from Invitrogen was used for gel electrophoresis (B).





Diagnostic digests were used to confirm the correct subcloning of the 11kb 
targeting fragment. The presence of this additional sequence in the pNEB-DT 
parental plasmid, which itself is not cut by EcoRI (data not shown), resulted in the 
release of 3 fragments (7.4kb, 4.8kb and 2.6kb), when digested with EcoRI (Figure 
3.2 B (lane 1)). 
 In preparation for further modifications, the targeting vector Mospd1-pNEB-
DT was electroporated into recombination efficient EL350 E.coli cells, and 
maintained under ampicillin selection. 
3.2.1.4 Introduction of the first loxP site 
 The next step, towards generating the Mospd1 targeting vector, involved the 
introduction of a loxP site into the intron between exons 1 and 2 of the subcloned 
DNA (Figure 3.2 A). To this end, a floxed neomycin resistance (neo) cassette was 
integrated via homologous recombination into the vector DNA. The cassette was 
amplified from plasmid PL452 (Appendix figure 2) with 80mer primers (Appendix 
table 1). To achieve homologous recombination of the cassette into the subcloned 
plasmid DNA, the flanking 60bp of the PCR primers consisted of sequence 
homologous to the target intron of Mospd1, where the cassette was to be placed; and 
20bp of the primers was homologous to the floxed Neo cassette, to be amplified.   
 The purified PCR product was electroporated into EL350 cells containing the 
Mospd1-pNEB-DT targeting vector. The EL350 cells were grown at 42ºC for 15 
minutes, prior to electroporation, to induce the expression of the Red recombination 
genes. EL350 cells carrying the floxed cassette in the Mospd1-pNEB-DT targeting 
vector were selected with kanamycin.  
Sequencing across the site of integration, using flanking primers, as well as 
diagnostic digests confirmed the presence of the floxed neomycin resistance cassette. 
The presence of the approximately 2kb floxed neo cassette resulted in the 
introduction of an additional EcoRI site into the targeting vector. EcoRI digestion of 
this new construct produced two separate fragments of 4kb and 2.8kb (Figure 3.2 B, 
lane 2), instead of the single 4.8kb fragment seen in the previous construct (Fig. 3.2 




3.2.1.5 Removal of the neo resistance marker 
 Once the correct targeting vector construct, containing the floxed neo 
cassette, was identified using kanamycin selection, the neomycin resistance gene was 
removed to create a single loxP site. This was achieved by electroporation of the 
targeting vector, containing the floxed neo cassette, into EL350 cells which had been 
grown for 1 hour in arabinose-supplemented medium. This prior incubation led to the 
expression of Cre recombinase from an arabinose-inducible promoter. The high 
efficiency of Cre-induced recombination in these cells (Liu et al., 2003) has 
facilitated the recombination of the two loxP sites to allow excision of the resistance 
marker in all of the electroporated cells. When the electroporated cells were spread 
on antibiotic selection plates, colonies were only observed on ampicillin; but not on 
kanamycin. In addition, colonies picked from ampicillin plates were found to be 
sensitive to kanamycin due to the absence of the deleted neomycin resistance marker 
(data not shown). 
 The excision of the neo resistance marker in these clones was verified by 
sequencing across the remaining loxP site, as well as by diagnostic digestion. The 
removal of the 2kb neo sequence, within the 4kb EcoRI fragment (seen in Figure 
3.2B, lane 2), resulted in a 2kb EcoRI restriction fragment (Figure 3.2 B, lane 3).  
3.2.1.6 Introduction of the second loxP site 
 In order to introduce the second loxP site 3‟ of Mospd1 exon 4 in the 
targeting vector, a cassette containing a neo resistance gene flanked by two FRT 
sites, and followed by a single loxP site, was used.  
This cassette was used, instead of the floxed neo cassette, to ensure that the 
subsequent removal of this neo resistance marker in ES cells would not result in a 
knockout allele. As the neo resistance marker is required to select for the integration 
of the targeting vector into ES cells, it cannot be removed until the correctly targeted 
ES cell clone is confirmed.  If a floxed neo cassette was used, Cre recombination of 
this conditional allele would result in 1 of 3 different excision products due to the 
presence of 3 loxP sites in the allele (see Chapter 1 figure 1.9 C). However, using a 
cassette containing neo
R
 flanked by FRT sites - coupled with transient expression of 
flp recombinase, which acts on FRT sites, will lead to the removal of the neomycin 
resistance marker without affecting the rest of the Mospd1 targeted allele. 
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 The FRT-neo-FRT-loxP cassette was PCR amplified from plasmid PL451 
(Appendix figure 3) using 70mer primers containing: a 50bp flanking sequence 
specific to the target sequence of the cassette in intron 4-5 of Mospd1, and 20bp of 
sequence specific to the FRT-neo-FRT-loxP cassette itself (primer sequences in 
Appendix table 1). The purified PCR product was electroporated into red-
recombination induced EL350 cells containing the Mospd1 targeting vector 
(Figure.3.2A). Cells having integrated the cassette were selected with kanamycin.  
The presence of the FRT-neo-FRT-loxP cassette and the integrity of the 
targeting vector were confirmed by sequencing and diagnostic digests. With the 
introduction of the FRT-neo-FRT-loxP cassette, a new EcoRI site is added to the 
restriction pattern; thereby, decreasing the size of the 2.6kb fragment to 1.74kb, and 
generating a new fragment of 2.8kb from the remaining 0.9kb plus the 1.9kb of the 
FRT-neo-FRT-loxP cassette (Figure 3.2 B, lane 4). Once the sequence integrity of the 
loxP sites has been confirmed, the targeting vector was ready to be linearized and 
electroporated into ES cells. 
3.2.1.7 Linearization and electroporation of the targeting vector into ES cells 
and selection of neo resistant clones 
 The 17kb targeting vector, containing exons 2 to 4 of Mospd1 flanked by 
loxP sites and, both, a 4kb 5‟ homology and a 3kb 3‟ homology; was linearized using 
PmeI, a unique restriction site present in the multiple cloning site of pNEB-DT.  
Two different ES cell lines (E14 and CGR8) were electroporated with the 
linearized Mospd1 targeting vector. The electroporated cells were subsequently 
selected for their resistance to G418, conferred by the neomycin resistance marker in 
the FRT-neo-FRT-loxP cassette. In addition, non-homologous recombination events 
were selected against by the diphtheria toxin (DT) cassette present in the targeting 
construct. 
 After 6 to 8 days under selection, ES cell clones were picked into 96-well 
tissue culture plates, and subsequently split in triplicate. One master plate was frozen 




3.2.1.8 Design of the Southern blot strategy to detect Mospd1 targeted ES cell 
clones 
 In order to allow identification of ES cell clones targeted at the Mospd1 
locus, a Southern blot strategy was designed, with help of the DNA Star software,  
and tested using wild type genomic DNA from CGR8 ES cells. Both, the 5‟ and 3‟ 
probe used were designed to label genomic sequences outwith the Mospd1 sequence 
contained in the targeting vector (Figure 3.3 A).  
 The Southern blot probes were hybridised to blots of wild type CGR8 DNA 
digested with various restriction enzymes, which generated different sized restriction 
fragments in Mospd1 wild type, targeted or null allele (Figure 3.3B). Analysis of 
these test Southern blots showed that the 5‟ probe bound well to the genomic target 
sequence and exhibited a good level of radioactive signal. However, the 3‟ probe 
showed a less distinctive signal.  
ES cell clones containing the targeting vector integration at the Mospd1 locus 
could be distinguished from wild type cell by DNA digestion, with either Spe1 or 
Pst1 restriction enzyme, and labelling with the 5‟ probe (Figure 3.3 A). 5‟ probe 
labelling of Spe1 digested DNA resulted in a distinct 14.7kb signal (Figure 3.3 B), 
which shifted to 7kb in Mospd1 targeted ES cell clones due to the presence of a Spe1 
site in the loxP site proceeding exon 2 of Mospd1 in the targeting vector . The shift in 
fragment sizes using Pst1 restriction was smaller. In this case, the wild type fragment 
of about 9kb was shifted to an 8kb fragment due to the insertion of a new Pst1 site in 
the upstream loxP sequence of the targeting vector (Figure 3.3 A). As the ES cell 
lines (CGR8 and E14) used to generate the targeted allele are male, and mouse 
Mospd1 is an X-linked gene, a single band is expected in the wild type Southern blot. 
This signal should shift in size if the allele is correctly targeted. 
 Generation of a null allele of Mospd1 can be detected using 5‟ probe labelling 
of a Bcl1 restriction digest. The loss of the Bcl1 restriction site in exon 3 of Mospd1, 
through the Cre induced recombination of the conditional allele, led to a shift of the 














Figure 3.3: Design and testing of Southern blot screening strategy for
Mospd1 targeted clones. (A) Design of 5’ and 3’ probe hybridisation to different
restriction enzyme fragments of genomic DNA in order to distinguish between
wild type, targeted and null alleles in ES cells. The upper panel in (A) shows the
wild type allele of Mospd1 as well as the integration sites of the single loxP site
(marked as red triangle) and FRT-neo-loxP cassette (FRT site marked as purple
oval) to generate the targeted allele. The lower panel of (A) shows the anticipated
restriction fragments detected with 5’ probe (blue line) or 3’ probe (orange line)
labelling of different restriction digests of genomic DNA. The solid black lines
mark restriction fragments anticipated in wild type alleles (wt) whilst the grey lines
mark the restriction fragments anticipated for targeted (t) or null alleles. (B)
Southern blot verification of anticipated wild type restriction fragment sizes using
5’ and 3’ probe labelling of genomic DNA isolated from wild type (wt) CGR8 ES
cells. Abbreviations: neo, neomycin resistance marker; t, targeted allele; wt, wild
type allele or wild type ES cell genomic DNA.
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Figure 3.4: Southern blot analysis of Mospd1 targeted ES cell clones.
(A) Schematic showing a map of the Mospd1 genomic locus (wild type allele, wt),
the targeting vector and the Mospd1 targeted allele (t) as well as a targeted allele
generated from incomplete target vector integration (it). The exons of Mospd1 are
represented by black boxes. The Southern blot probes used are marked by blue
boxes for the 5’ probe and orange boxes for the 3’ probe. The targeting vector
construct includes the relative position of the loxP site (red triangles), the FRT–
neo-FRT-loxP cassette (FRT, purple ovals) and the diphtheria toxin (DT)
cassette. Whilst the black dashed lines represent the crossover event between
the wild type allele and targeting vector leading to integration of the both loxP and
FRT–neo-FRT-loxP cassette in the targeted allele (t), the red dashed line
represents the cross-over event leading to incomplete vector integration and lack
of loxP site in the targeted allele (it). (B) Southern blot analysis of ES cell
genomic DNA to screen for ES cells carrying a correctly targeted allele of
Mospd1. Abbreviations: DT, diphtheria toxin cassette; it, clone containing an
incomplete targeting vector integration into the Mospd1 locus; neo, neomycin
















3.2.1.9 Southern blot screening of Mospd1 targeted ES cell clones 
Southern blot analysis of the G418 resistant clones, using a 5‟ probe on Spe1 
digested genomic DNA, was used to identify correctly targeted clones (Figure 3.4 
A). Southern blot screening of G418 resistant ES cell clones identified 6 correctly 
targeted clones out of 351 in CGR8 cells, and 4 correctly targeted clones out of 179 
in E14 ES cells. These numbers correspond to a targeting frequency of 1.7% in 
CGR8, and 2.2% in E14 cells. Integration of the targeting vector at the Mospd1 
locus, in these clones, resulted in the expected shift in restriction fragment sizes from 
14.7kb (wild type) to 7kb (targeted allele) (Figure 3.4 B).  
Among the G418 resistant CGR8 clones, 18 showed a SpeI restriction fragment 
size of about 10kb on the Southern blot (Figure 3.4 B, lane (it)). Both, the single loxP 
site upstream of Mospd1 exon 2, and the FRT-neo-FRT-loxP cassette in the intron 
between exons 4 and 5, contain Spe1 restriction sites. Instead of cutting at the loxP 
site in the intron between exon 1 and 2 of Mospd1 resulting in a restriction fragment 
of 7kb, the next Spe1 digestion site 3kb downstream in the FRT-neo-FRT-loxP 
cassette was utilised. This suggested that the upstream loxP site of the targeting 
vector had not integrated into the endogenous Mospd1 locus. The vector integration, 
in these cases, seemed to have occurred via one homologous recombination event in 
the 3‟ homology arm, and a second recombination event downstream of the first loxP 
site instead of within the 5‟ homology arm. This type of crossover event was 
expected, as the sequences (including exons 2 to 4) between the two loxP cassettes of 
the vector were also homologous to the wild type Mospd1 allele.  
3.2.1.10  Expansion and verification of targeted clones 
 The Mospd1 targeted ES cell (CGR8 and E14) clones, identified from the 
Southern blot screen, were thawed from the master 96-well plate and expanded. 
Genomic DNA was extracted for further Southern blot verification using a 5‟ and 3‟ 
probe as well as a Neo
R
 specific sequence probe (neo probe). Both, 5‟ and 3‟ probes, 
in conjunction with SpeI restriction, confirmed that in five out of six of the CGR8 
derived clones the targeting vector had integrated at the Mospd1 locus. This analysis 
also confirmed that, both, the upstream loxP site and the FRT-neo-FRT-loxP cassette 
were present in the targeted allele (Figure. 3.4 A and B). E14 targeted clones have 
been expanded, from the master plate, for DNA extraction. Southern blot 
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confirmation of the four Mospd1 targeted clones in E14 cell is currently underway 
(performed by Madina Kara). 
 Using the neo (neomycin cassette specific) Southern blot probe, genomic ES 
cell sequences can be screened for unwanted multiple targeting vector integrations. 
In all 5 targeted clones of Mospd1, derived from CGR8 cells, a single EcoRV 
restriction fragment was labelled, indicating the presence of only one vector 
integration (data not shown). 
3.2.1.11 Generation of a Mospd1 null allele in ES cells 
 In order to analyse whether the loss of Mospd1 had any effect on the 
physiology of ES cells themselves, a knockout allele of the gene was produced. 
This null allele was generated by transient transfection of two of the targeted 
Mospd1 clones with a Cre expression vector (pCAGGS-Cre-IRESpuro) (see 
Appendix figure 4 for vector map). The Cre recombinase, expressed in these cells, 
drove the recombination of the loxP sites in the conditional allele, resulting in an 
excision of exon 2 to 4 of Mospd1 and the production of a loss-of-function knockout 
allele (Figure 3.5 A).  
 Clones containing the knockout allele were identified by Southern blot 
screening, using the Mospd1 3‟ probe to label HindIII restriction fragments in 
digested genomic DNA. A shift of fragment sizes from the 6.7kb of the targeted 
allele to a larger fragment of 8.3kb, due to the loss of a HindIII site present in 
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Figure 3.5: Southern blot analysis of Mospd1 null ES cell clones. 
(A) Schematic showing a map of the Mospd1 genomic locus (t) and the Mospd1
null allele after Cre mediated recombination of the loxP sites (marked by red
triangles), which mediates deletion of the FRT-neo-FRT-loxP cassette (FRT
marked by purple oval) as well as exons 2 to 4 of Mospd1. The exons of Mospd1
are represented by black boxes. The 3’ Southern blot probe used to distinguish
between HindIII (H) restriction fragments of the targeted and the null allele of
Mospd1 is marked by orange boxes. (B) Southern blot analysis of ES cell
genomic DNA to screen for ES cells carrying a loxP site-specific recombination
at the Mospd1 locus. Abbreviations: H, HindIII; neo, neomycin resistance marker;
null, loxP -recombined allele or ES cell clone carrying a recombined null allele; t,




3.2.2 Generation of Mospd3 targeting construct and targeted allele 
3.2.2.1 Design of the conditional targeting vector 
 In order to generate a conditional knockout allele of Mospd3, the targeting 
vector was designed to include the start-codon in exon 2 and the MSP domain 
encoded in exons 3 and 4 (Figure 3.6 A). 
 Unlike for Mospd1, it was not possible to place the 5‟ loxP site within the 
intron between exons 1 and 2 of Mospd3. Due to the short sequence length of this 
intron (198bp), the presence of a loxP site and its flanking restriction site sequences 
(100bp) might interfere with correct splicing. A genome sequence alignment between 
mouse and human also revealed that a large region of this intron contained sequences 
which appear to be conserved between the two species (Figure 3.6 B). In fact, the 
alignment indicates the presence of two peaks of sequence conservation in the 
vicinity of exon 1, which may indicate promoter or enhancer elements of Mospd3.  In 
view of these findings, we opted to place the 5‟ loxP site upstream of exon 1 (as 
shown in Figure 3.6 A).  The 3‟ loxP site was to be placed in the intron between 
exons 4 and 5, which according to the genome alignment was devoid of any regions 
of significant sequence conservation.  
Cre induced recombination of the loxP sites, in this conditional allele, is 
anticipated to lead to a complete loss of the Mospd3 transcript, as not only the start 
codon but also the putative promoter of the gene will be removed. 
3.2.2.2 Identification of a Mospd3- BAC clone 
 Using the aforementioned Mouse Genome Resource
6
, a BAC clone 
(GenBank Accession: BH063983), containing the entire genomic sequence of 
Mospd3, was chosen to subclone the targeting sequence. This BAC clone was part of 
a male C57BL/6 library, generated from spleen and brain DNA. 
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Figure 3.6: Design of the conditional knockout allele of Mospd3 and genomic sequence alignment of the
Mospd3 gene of mouse and human using VISTA Genome Browser. (A) Schematic of the endogenous Mospd3
gene locus and proposed placement of the loxP recombination sites (one in form of a FRT-neo-FRT-loxP cassette) for
the generation of the conditional knockout allele of Mospd3. The six exons of Mospd3 are marked as black boxes. In
the targeting cassettes containing the loxP sites, loxP is marked as a red triangle and FRT sites are represented as
purple ovals. (B)The VISTA graph shows the conservation between Mospd3 in mouse (genomic build May2004) and
MOSPD3 in human (genomic build May 2004) across the entire genomic sequence of the gene. The VISTA graph also
contains alignments of approximately 700bp upstream of exon 1 of Mospd3. An arrow signifying the Mospd3 gene is
shown above the graph, with the arrowhead pointing in the direction of the gene. The exons of Mospd3 are indicated as
pale and medium blue blocks. In the VISTA graph, peaks marked in pink indicate non-coding sequences (CNS) of more
then 70% sequence identity between mouse and human. More than 70% sequence identity in coding exons is marked
by medium blue peaks, and with pale blue peaks in untranslated regions (UTR). The grey bar below the plot indicates
that a single human contig was used to generate the alignment with the mouse. The bar immediately above the plot
denotes regions of repetitive sequences (listed in the legend under Repeats). The scale bar at the top of the figure
shows the size and location of Mospd3 on mouse chromosome 5. Abbreviations: CNS, non-coding sequences, DNA,
DNA-transposon; LINE, Long Interspersed Nuclear Elements; LTR, Long Terminal Repeats; neo, neomycin resistance
marker; RNA, RNA-retrotransposon; SINE, Short Interspersed Nuclear Elements; UTR, untranslated region.
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3.2.2.3 Subcloning of Mospd3 by Gap repair 
 The initial strategy for subcloning a sufficiently long Mospd3 sequence, 
containing the exons to be flanked by loxP sites as well as a minimum of 3kb 
homology arms, involved the use of XbaI restriction and ligation into the pNEB-DT 
plasmid. The chosen Xba1 fragment contained the entire genomic sequence of 
Mospd3. However, this subcloning method proved unsuccessful as the pNEB-DT 
plasmid appeared to contain an additional XbaI site. A digest with this enzyme 
revealed two restriction sites: one, in the multiple cloning site of the vector; and the 
other, in the diphtheria toxin (DT) cassette. Digestion of the DT cassette, a negative 
selection cassette for targeting vector integration into ES cells, would have caused 
problems at a later stage when selecting for homologous vector integrations into ES 
cells.  
As an alternative to using specific restriction sites for the subcloning step, a 
gap repair approach in E.coli cells was utilised (Liu et al., 2003).  This homologous 
recombination approach is based on the repair of a double strand gap in the 
linearized pNEB-DT plasmid by DNA synthesis with a homologous DNA as a 
template.  
Sequences homologous to regions flanking the 10.6kb Mospd3 targeting 
DNA, in the BAC, were PCR amplified (Figure 3.7 A). These, approximately 200bp, 
sequences were directionally subcloned into pNEB-DT using restriction sites 
engineered into the PCR primers. The resulting retrieval vector, linearized with 
BamH1, was electroporated into recombination efficient EL350 cells containing the 
Mospd3 BAC. The double-strand break of the linearized vector was repaired by 
homologous recombination with Mospd3 sequences in the BAC. This process 
allowed the genomic sequences of Mospd3 to be integrated into the multi-copy 
pNEB-DT plasmid.  
The electroporated clones were selected using ampicillin. Most of the clones 
obtained and analysed, by sequencing and diagnostic digests, contained the 10.6kb 
Mospd3 targeting sequence within the pNEB-DT vector backbone (Figure 3.7 A, 
construct 1). The EcoR1 digest in (Figure 3.7 B) confirmed the presence of the 
correct fragment, as the pNEB-DT vector, which had no EcoRI site, could now be cut 
by the enzyme; and the restriction fragments of 9kb, 3.8kb 1.7kb and 0.46kb were 
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those expected from the presence of the 11.5kb Mospd3 fragment (Figure 3.7 B, lane 
1).      
3.2.2.4 Introduction of the first loxP site 
The floxed neo cassette containing the upstream loxP site was PCR amplified 
from plasmid PL452 (Appendix figure 2) in a similar way to that described for 
Mospd1. The primers, which were used, contained 60bp of sequence homologous to 
the genomic region preceding exon 1 of Mospd3 and 20bp of sequence homologous 
to the neo targeting cassette. The PCR amplified cassette was electroporated into 
recombination efficient EL350 cell containing the Mospd3-pNEB-DT targeting 
vector.  
Kanamycin resistant clones, having integrated the cassette, were analysed by 
diagnostic restriction digestion and sequencing across the integration site. From the 
EcoRI restriction digest, it was observed that not all the multi-copy Mospd3-pNEB-
DT plasmids, which have integrated into a single EL350 cell, contained the floxed 
neo cassette (data not shown). This can sometimes occurs because one single plasmid 
containing the neo resistance marker is sufficient in an electroporated EL350 cell to 
confer resistance to kanamycin. Re-electroporation of 1ng of the vector DNA, 
isolated from the original electroporated clones, allowed the retrieval of colonies in 
which all plasmids contained the floxed neo cassette. 
3.2.2.5 Removal of the neo resistance marker 
The neo resistance marker was removed by electroporation of the Mospd3 
targeting clone into arabinose-induced Cre expressing EL350 cells. Through the 
action of Cre, the two loxP sites recombine, and the neo resistance marker was 
excised in the process; rendering the resulting bacterial colonies kanamycin sensitive 
(Figure 3.7 A, construct 3).  
 The presence of the single 100bp loxP site, which does not change the EcoRI 
digestion pattern of the Mospd3 targeting vector significantly (Figure 3.7 B, lane 3), 
was confirmed by sequencing. 
  
A





Figure 3.7: Recombineering strategy for Mospd3 targeting vector
construction. (A) Schematic of the recombineering strategy used to generate a
conditional Mospd3 targeting vector and (B) EcoRI diagnostic digest of successive
constructs generated in the procedure. The 10.6kb targeting fragment containing
Mospd3 exons 1 to 6 (exons marked by black boxes) was subcloned into the
pNEB-DT vector (A, construct 1 and B, lane 1) using gap repair between two
approximately 200bp homology regions (yellow and orange box) flanking the
10.6kb fragment. These homologous regions were PCR amplified from the
Mospd3-BAC and subcloned into pNEB-DT using the HindIII, BamHI and AvaI
restriction sites engineered into the PCR primers (yellow and orange arrows). The
BamHI linearised pNEB-DT retrieval vector was electroporated into EL350 cells,
which already contained the Mospd3-BAC, leading to subcloning of the 10.6kb
fragment into the pNEB-DT vector. The PCR amplified loxP-neo-loxP targeting
cassette (loxP sites marked as red triangles) containing 60bp flanking sequence
homologous to sequences upstream of Mospd3 exon1 (homologies marked as
blue lines) has integrated into the targeting construct (A, construct 2).
Subsequently, the neo casstte was removed by arabinose-induced Cre expression
(A, construct 3 and B, lane 3) leaving a single loxP site upstream of exon 1. The
second loxP site downstream of Mospd3 exon 4 was integrated in the form of a
PCR amplified FRT-neo-FRT-loxP cassette (FRT site maked with purple oval) (A,
construct 4 and B, lane 4) in the same way as the previous loxP-neo-loxP
cassette. A 1kb plus ladder from Invitrogen was used for gel electrophoresis (B).




3.2.2.6 Introduction of the second loxP site 
 The FRT-neo-FRT-loxP cassette, containing the second loxP site, was PCR 
amplified from vector PL451 (Appendix figure 3). The 70mer primers, used for this 
amplification, included a 50bp homology to the sequence downstream of Mospd3 
exon 4 into which the loxP site was to be integrated, as well as a 20bp sequence 
homologous to the FRT-neo-FRT-loxP cassette (primer sequence in Appendix table 
1). The recombineering procedure used was similar to that described for the Mospd1 
targeting vector. Once again, the targeting vector had to be re-electroporated into 
EL350 cells to obtain pure colonies, which contained only targeting vectors with the 
FRT-neo-FRT-loxP cassette (Figure 3.7 A, construct 4). 
 The addition of this new cassette resulted in the introduction of a new EcoRI 
site into the targeting vector; thereby, shortening the 3.70kb fragment to 3.54kb, and 
adding a new fragment of 1.96kb (Figure 3.7 B, lane 4). 
3.2.2.7 Linearization and electroporation of the targeting vector into ES cells 
and selection of neo resistant clones 
 When the 200bp homologies for gap retrieval subcloning of the Mospd3 
targeting vector sequence were designed, the rare restriction site PmeI was lost from 
the pNEB-DT plasmid. This meant that, in order to linearize the targeting construct, 
a unique restriction site (AflII) present in the 5‟ homology arm of Mospd3 had to be 
utilised. Unfortunately, this approach resulted in the loss of about 2kb of upstream 
homology of the vector.  
 CGR8 and E14 ES cells were electroporated with the linearized DNA of the 
truncated Mospd3 targeting vector. The electroporated ES cells were selected using 
G418.  After 6-8 days, clones were picked and further processed in the same way as 
previously described for Mospd1. 
3.2.2.8 Design of the Southern blot strategy to detect Mospd3 targeted ES cell 
clones 
 A Southern blot strategy to distinguish Mospd3 targeted and null allele from 
the wild type, by using diagnostic restriction digests, was designed using DNA star 
software.  In order to identify these different alleles, 5‟ and 3‟ probes were designed 
to sequences flanking the site of the targeting vector integration, and tested on 
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restriction digests of wild type CGR8 genomic DNA (Figure 3.8 A). Both probes 
were found to label the hybridised DNA well, resulting in a distinct band of the 
expected size on the Southern blot of SpeI and KpnI digests (Figure 3.8 B). XhoI 
restriction digestion, chosen specifically to identify the Mospd3-null allele, appears 
to be unsuitable for Southern blot identification of targeted ES cell clones  as the 3‟ 
probe was found to label two different wild type fragments (Figure 3.8). The 
presence of two restriction fragments is likely due to incomplete DNA digestion with 
XhoI as this enzyme can be affected by CpG base pair methylation in the restriction 
site sequence.   
3.2.2.9 Southern blot screening of Mospd3 targeted ES cell clones 
 The 3‟ probe was used to screen for SpeI restriction products in the genomic 
DNA of G418 resistant clones. The presence of a targeting vector integration at the 
Mospd3 locus led to a shift in the restriction fragment size of one of the wild type 
Mospd3 alleles. The Spe1 fragment in the targeted allele was 7.8kb in size, compared 
to 12.7kb in the wild type allele (Figure 3.9 A and B). Out of 320 screened clones for 
CGR8 ES cells, 5 were found to contain, both, a wild type as well as the targeted 
restriction fragment. This corresponds to a targeting frequency of 1.5% in CGR8 
cells. Amongst the G418 resistant E14 ES cell clones, 5 (out of 451) appear to carry 
a correctly targeted allele of Mospd3, corresponding to a targeting frequency of 
1.1%.   
3.2.2.10  Expansion and verification of targeted clones 
 Correctly targeted clones, of both CGR8 and E14 ES cells, were thawed from 
the frozen master plate and expanded under continuing G418 selection. The integrity 
of the gene targeting integration was examined in these clones using, both, the 3‟ 
probe to label the SpeI digests, and the 5‟ probe to detect KpnI restriction fragments, 
in order to analyse the upstream integration site (Figure 3.9 A and B). Only two of 
the CGR8 targeted clones exhibited the anticipated Southern blot pattern. E14 





To establish the absence of any unwanted targeting vector integrations in the 
genome of these targeted clones, the ES cells were also probed using a neomycin 
specific probe - in conjunction with an NdeI diagnostic digest of the integration site. 
Only a single fragment at the expected size of 17kb was found in both the clones 













Figure 3.8: Design and testing of Southern blot screening strategy for
Mospd3 targeted clones. (A) Design of 5’ and 3’ probe hybridisation to
different restriction enzyme fragments of genomic DNA in order to distinguish
between wild type, targeted and null alleles in ES cells. The upper panel in (A)
shows the wild type allele of Mospd3 as well as the integration sites of the
single loxP site (marked as red triangle) upstream of Mospd3 exon1 and FRT-
neo-loxP cassette (FRT site marked as purple oval) downstream of Mospd3
exon 4 to generate the targeted allele. The lower panel of (A) shows the
anticipated restriction fragments detected with 5’ probe (green line) or 3’ probe
(red line) labelling of different restriction digests of genomic DNA. The solid
black lines mark restriction fragments anticipated in wild type alleles (and the
null/ loxP recombined allele in XhoI digests) whilst the grey lines mark the
restriction fragments anticipated for correctly targeted alleles (t) of Mospd3. (B)
Southern blot verification of anticipated wild type restriction fragment sizes
using 5’ and 3’ probe labelling of wild type CGR8 genomic DNA. Abbreviations:
neo, neomycin resistance marker; wt, wild type allele or wild type ES cell











Figure 3.9: Southern blot analysis of Mospd3 targeted ES cell clones.
(A) Schematic showing a map of the Mospd3 genomic locus (wild type allele, wt),
the targeting vector and the Mospd3 targeted allele (t). The exons of Mospd3 are
represented by black boxes. The Southern blot probes used are marked by green
boxes for the 5’ probe and red boxes for the 3’ probe. The targeting vector
construct includes the relative position of the loxP site (red triangles), the FRT–
neo-FRT-loxP cassette (FRT, purple ovals) and the diphtheria toxin (DT)
cassette. (B) Southern blot analysis of ES cell genomic DNA to screen for ES
cells carrying a correctly targeted allele of Mospd3. Abbreviations: DT, diphtheria
toxin cassette; t, targeted allele or ES cell clone containing a correctly targeted







  We have demonstrated the successful creation of a floxed allele of, both, 
Mospd1 and Mospd3 in ES cells, as well as the subsequent generation of a Mospd1 
null allele. The construction of the conditional targeting vectors, for both genes, has 
been almost entirely performed by using a recombineering approach (Lee et al., 
2001; Liu et al., 2003). Recombineering facilitates the fast and efficient construction 
of even complex targeting constructs. It has been estimated that the use of this 
approach can, on average, reduce the construction time of targeting constructs from 
several months, when using traditional restriction and ligation subcloning methods, 
to just a few weeks, when using a recombineering approach (Lee et al., 2001). 
 In agreement with these estimates, we found that the generation of the 
conditional targeting construct of Mospd1 was quick and effortless, using a 
recombineering approach. We only used conventional restriction and ligation 
methods to subclone the Mospd1 targeting construct, with sufficiently long 
homology arms, from a BAC into a high-copy plasmid backbone. All subsequent 
steps, leading to the generation of the floxed Mospd1 targeting construct, were 
performed using recombineering methods. Using recombineering, it was possible to 
integrate both loxP sites into the targeting vector in exactly the positions chosen in 
the initial conditional allele design (Figure 3.1).     
 In contrast to Mospd1, the generation of the conditional targeting vector of 
Mospd3 proved to be more time consuming. As indicated in section 3.2.2.3, it was 
not possible to subclone a suitably sized genomic fragment of Mospd3, including 
homology arms, by Xba1 restriction and ligation. We struggled to find alternative 
restriction sites which would allow a conventional subcloning approach for the 
Mospd3 targeting sequence. 
 We, therefore, chose to subclone the Mospd3 targeting fragment from the 
BAC by gap repair (Lee et al., 2001; Liu et al., 2003). For this subcloning approach, 
homology sequences flanking the desired genomic fragment of Mospd3 were PCR 
amplified and subcloned into the pNEB-DT target plasmid. Electroporation of 
recombination efficient EL350 cells (containing the Mospd3-BAC) with the 
linearized plasmid should lead to the retrieval of the Mospd3 targeting sequence by 
homologous recombination.  
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This method, in particular the design of the homology regions, is highly 
dependent on knowing the correct genomic sequence of Mospd3 in the BAC. Our 
initial attempts, at subcloning Mospd3 by gap repair, failed. It later emerged that 
parts of the genomic sequence downstream of exon 6 of Mospd3 (the last exon of 
Mospd3), which we had originally used to generate the initial 3‟ homology for gap 
repair, had been mis-annotated in the mouse genome build (NCBI m33).  
Both publicly available mouse genome resources (NCBI and Celera) are 
created by a tiling approach of sequenced contigs, to stretch across whole Mus 
musculus genome. The genome sequence published by NCBI is updated yearly. 
Analysis of the mouse genome build, NCBIm34, published in May 2005 
revealed, that the initially designed 3‟ gap repair homology had been re-annotated to 
a location approximately 45kb away from the expected site: in the intergenic 
sequences immediately downstream of Mospd3 exon 6. A subsequently designed 
homology arm resulted in the successful subcloning of the Mospd3 target sequence.    
  The only way this problem might have been foreseen would have been by 
sequencing the entire sequence intended for subcloning. This would have been a time 
consuming and complicated endeavour as the intergenic sequences flanking Mospd3 
are quite large, and may be hard to sequence due to the abundance of repetitive 
elements in non-coding sequences. The design of homology sequences to target the 
loxP sites has the potential to be affected by similar problems. Interestingly, a recent 
high-throughput recombineering study, which generated more than 100 BAC 
targeting vectors, reported that in about 10% of the cases the generation of the vector 
failed due to BAC clones being wrongly mapped in the mouse genome, or 
chimaerisms and rearrangements occurring in the BAC clones (Poser et al., 2008). 
 Even though this sequence problem held up the construction of the Mospd3 
targeting vector, traditional vector construction methods would most likely have also 
been affected by the same sequence mis-annotation.  In fact, one of the XbaI 
restriction sites initially chosen for Mospd3 subcloning had been located in the same 
mis-annotated genomic sequence. Just like the 3‟ homology sequence designed for 




Table 3.1: Targeting frequencies of Mospd1 and Mospd3 conditional targeting 
vector in two different ES cell lines. 
 
 
Cell line Mospd1 Mospd3 
CGR8 1.7% 1.5% 
E14 2.2% 1.1% 
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 Another hurdle, for the use of conventional cloning methods for constructing 
a conditional Mospd3 targeting vector, was the absence of suitable restriction sites to 
allow such an approach. Analysis of the restriction enzyme pattern in the genomic 
sequence of Mospd3 revealed a lack of suitable unique sites to allow the introduction 
of loxP sites into regions flanking exons 1 to 4 of Mospd3. 
 Once construction of the conditional targeting vectors of Mospd1 and 
Mospd3 had been concluded, they were electroporated into ES cells. The frequencies 
of homologous vector integrations in G418 resistant clones, from two different ES 
cell lines, ranged from 1.7% to 2.2% for the Mospd1 targeting vector, and from 1.1% 
to 1.5% for the Mospd3 targeting vector (Table 3.1).  
 The process of homologous recombination into ES cells is not very efficient, 
with targeting frequencies often less than 0.1 - 1% (Joyner, 1999). The targeting 
frequencies obtained for Mospd1 and Mospd3 are better than these average values. 
Several factors are known to enhance the rate of homologous recombination of a 
targeting vector in ES cells. These factors include the use of longer homology arms 
in the targeting vector as well as ensuring isogenicity between the targeting vector 
and the ES cell DNA (Deng and Capecchi, 1992; Hasty et al., 1991b; te Riele et al., 
1992).  
 There are several ways in which the targeting frequencies of the constructs 
generated in this study could have been improved. One possible way would have 
been to increase the length of the homology arms. This could be achieved by using 
the whole BAC as the targeting construct (Valenzuela et al., 2003; Yang and Seed, 
2003). Vector targeting frequencies of up to 8.3% (and 3.8% average) have been 
reported when using a BAC targeting vector (Valenzuela et al., 2003). The targeting 
frequency of such large vector constructs does not appear to be adversely affected by 
using non-isogenic vector DNA.  The drawback of such an approach, however, is 
that screening for integrations at the correct locus cannot be performed by 
conventional Southern blotting methods. 
Another way to improve the targeting frequency of the conditional knockout 
vectors of Mospd1 and Mopd3 would have been to use isogenic vector sequences. At 
the time, when the Mospd1 and Mospd3 targeting vectors were generated, the only 
BAC clones publicly available were generated from C57BL/6 mouse DNA, whilst 
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the ES cells used in this study were obtained from a 129/Ola mouse strain (Hooper et 
al., 1987; Nichols et al., 1990). As both, C57BL/6 and 129/Ola, mouse strains are 
only distantly related, there is likely to be differences in the genomic sequence 
between the Mospd1 and Mospd3 genes in the BAC targeting vectors, and the 
Mospd1 and Mospd3 alleles in the ES cells.  
The reason for this mouse strain discrepancy was that, at the time, BAC 
clones from a 129 mouse strain were not publicly available. The first resource of 
BAC clones from a 129 mouse strain (129Sv) was reported in 2005 (Adams et al., 
2005). Although 129Sv is a different substrain of 129 from the 129/Ola strain (used 
to derive E14 and CGR8 ES cells), the targeting frequency obtained using vectors 
generated from these BAC clones should be better. A Japanese research group has 
since reported the generation of BAC clones from 129/Ola cells (Ohtsuka et al., 
2006). These clones are now available through the Japanese Collection of Research 
Bioresources (JCRB) Gene Bank. 
Another approach, to ensure isogenicity between the targeting construct and 
the endogenous gene sequence, would have been to use C57BL/6-derived ES cells 
for gene targeting. C57BL/6-derived ES cells have not been widely used for gene 
targeting experiments. Compared to 129-derived ES cell strains, these ES cells were 
previously found to be more difficult to propagate in vitro as well as being less 
efficient at generating chimaeras and contributing to the germ line (Auerbach et al., 
2000; Brook and Gardner, 1997).  A report in 2003, comparing the efficiency of a 
C57BL/6 ES cell line versus 129 ES cell lines at generating targeted mutation in 
mice, found that their C57BL/6-derived ES cells performed only marginally less well 
in the generation of germ line transmitting chimaeras (Ware et al., 2003).  The use of 
C57BL/6-derived ES cells, for the generation of transgenic mouse lines, has the 
added advantage of circumventing the need for laborious breeding to establish the 
targeted mutation on a homogeneous (≥ 99%) inbred C57BL/6 background.     
 Another aspect in the generation of the Mospd1 and Mospd3 targeted allele 
which would benefit from improvement is the screening process for correct 
integrations of the conditional targeting vector. Southern blot screening of neomycin 
resistant clones can be time consuming, especially if the targeting frequency of the 
vector only ranges from 1.1% to 2.2%.  The approach would benefit from a high-
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throughput method of determining ES clones which carry an integration of the 
targeting vector at the desired locus. Two methods applicable for such a screen 
would be long range PCR, or the more recently developed loss-of-native-allele assay 
(Valenzuela et al., 2003). Although these methods enable a quick screen for targeted 
alleles, detailed analysis of the integration site by Southern blot is still necessary. 
During the integration of the conditional targeting vector of Mospd1, we found that 
in some of the neomycin resistant clones only part of the conditional targeting vector 
had integrated into the endogenous Mospd1 locus. Southern blot analysis of these 
clones indicated that the loxP site in the intron between exons 1 and 2 of the Mospd1 
targeting vector had failed to integrate into the ES cell DNA. There is a chance that, 
due to its small size of only 100bp, the lack of this loxP site  might not have been 
picked up by long range PCR. Similarly, unless the PCR primers used for the loss-of-
native-allele assay were designed to the single loxP target site, and not the more 
likely target site of the FRT-neo-FRT-loxP cassette, the lack of the loxP sequences 













4 CHAPTER 4:  FUNCTIONAL STUDY OF 















 ES cells are pluripotent cells capable of populating all germ layers of a host 
blastocyst in vivo, including the germline. This ability to generate germline 
transmitting ES cell/blastocyst chimaeras facilitates the introduction of genetic 
modifications into the mouse model.  
In this chapter, we describe our attempts to generate transgenic mice from ES 
cells carrying the conditional targeted alleles of Mospd3 and Mospd1 (which have 
been described in their creation in Chapter 3). In both conditional alleles, the 
upstream exons of the two Mospd genes are flanked by loxP sites so that Cre-
mediated recombination results in the loss of the entire coding sequence of these 
genes. Tissue-specific and induced Cre-expression in mice carrying the conditional 
allele would allow us to study the effect of loss of function of both Mospd genes in a 
particular tissue or at a defined time point of development. In addition, the question 
of a possible genetic redundancy between the two Mospd genes could be answered 
by generating double knockout animals.  
A complimentary approach, to studying the role of genes in cell lineage 
development in the knockout mouse model, is to employ in vitro differentiation of 
ES cells carrying the targeted mutation. Through culture in 3 dimensional aggregate 
structures, called embryoid bodies, ES cells can be induced to differentiate into cells 
of all three germ layers of the embryo. This process recapitulates early embryonic 
development. Specialized cell lineages, such as cardiomyocytes, can be rapidly 
derived through this in vitro system, facilitating initial studies of loss-of-function 
mutations on the differentiation and function of specific cell lineages, prior to 
generating a knockout mouse model. Both, Mospd3 and Mospd1 are expressed in the 
adult mouse heart. In order to determine whether Mospd1 might be involved in heart 
development, and thus share functional redundancy with Mospd3, we chose to use 
the hemizygous Mospd1 knockout ES cell lines, generated in Chapter 3, to study the 
effect of loss of Mospd1 expression on the potential of ES cells to differentiate into 
cells of the cardiac lineage in vitro.   
Unless specifically mentioned, all ES cell clones (carrying either a cko allele 
of Mospd1 or Mospd3, or a Mospd1 null allele) described in this chapter have been 




4.2.1 Generation of chimaeras 
 All five conditionally targeted clones of Mospd1, generated from a CGR8 
parental ES cell line, were analysed for their growth in culture before using them for 
blastocyst injections. The two clones most closely resembling the growth pattern of 
wild type CGR8 ES cells were used to generate chimaeras. Blastocyst injections 
were kindly performed by Gail M
c
Walter at the Genetic Intervention and Screening 
Technologies Service, as well as Jan Ure at the Institute of Stem Cell Research (both 
University of Edinburgh). Unfortunately, neither of these 2 conditionally targeted 
clones resulted in the generation of germline competent chimaeras. Clone 1 produced 
only 1 female and 1 male chimaera from 98 injected blastocysts and 30 pups born, 
whilst the second clone resulted in 4 male and 2 female chimaeras out of 33 injected 
blastocysts and 14 pups born. However, none of these 5 chimaeras showed a 
significant level of chimaerism - as observed by the agouti coat colour striping on the 
black (C57BL/6) host blastocyst-derived animals. The male chimaera generated from 
conditionally targeted Mospd1 clone 1 was allowed to breed with two C57BL/6 
females, but produced no transgenic offspring.  
 In the case of Mospd3, the two CGR8 ES cell clones carrying the correctly 
targeted allele of Mospd3 were used for chimaera generation. From a total of 162 
injected blastocysts and 19 pups born none yielded any chimaeric offspring. 
 
4.2.2 Karyotyping 
 Due to the problems observed with the generation of chimaeras from 
blastocyst injection, karyotype analysis was performed on all ES cell clones carrying 
a conditional allele of either Mospd1 or Mospd3. ES cell clones carrying the 
hemizygous null allele of Mospd1 were also analysed for their karyotype stability.  
The karyotypes of the targeted clones were compared to their parental wild type ES 
cell lines (CGR8 and E14). Euploid murine somatic cells contain 40 chromosomes 
(2n=40) (Figure 4.1 A (left panel)). 
A count of the number of chromosomes present in 20 to 30 chromosome 
spreads per cell line revealed that CGR8 wild type ES cells and almost all the 
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targeted lines generated from this line had an abnormal karyotype (Figure 4.1 A and 
B). In 30% of CGR8 cells at passage 23, the presence of an extra chromosome 
(2n=41) was observed (see Figure 4.1 A (right-most panel), B). Among four of the 
Mospd1 targeted ES cell clones generated from vector electroporation into these 
CGR8 cell at passage 17-19, we found that two exhibited a similar aneuploid pattern 
in the majority of the karyotyping spreads (Mospd1
0/cko 
clones (3) and (4) in Figure 
4.1 B). Both clones appear to have been generated from an integration of the 
targeting vector into CGR8 ES cells containing 41 chromosomes, as almost all the 
spreads counted had accumulated an extra chromosome. The same karyotype defect 
was also observed in the two CGR8 ES cell lines carrying the conditional allele of 
Mospd3 (Figure 4.1 B, Mospd3
+/cko 
clones (1) and (2)). Similar to Mospd1, it is likely 
that the Mospd3 allele in these clones was targeted in CGR8 cells already carrying a 
trisomy, which was then clonally expanded. As G-banding analysis has not been 
performed, it is not known which chromosome has been duplicated, or if indeed the 
extra chromosome in the aneuploid targeted clones is the same as the one found in 
some of the CGR8 chromosome spreads. 
In a small percentage (7%) of CGR8 cells at passage 21, one of the 40 murine 
acrocentric chromosomes has acquired two additional chromosome arms, making it 
appear metacentric (Figure 4.1 A (middle panel), B Mospd1
0/cko 
clone (1)). The same 
type of chromosomal defect was also found in one of the Mospd1 targeted clones, 
generated from the CGR8 parental cell line. Of all targeted CGR8 cell lines, only one 
(carrying a Mospd1 conditional allele - Figure 4.1 A (left panel), B Mospd1
0/cko 
clone 
(2)) appeared to have a normal karyotype. 
 The Mospd1 null lines generated by Cre recombinase exposure of ES cell 
clones carrying a conditional allele of Mospd1 (previously described in section 
3.2.1.11) were also analysed for their karyotype. The Mospd1 null ES cell lines 
exhibited the same karyotype pattern as the targeted cell line used to create them 
(Figure 4.1 B). Whilst the Mospd1 null clones generated from the euploid 
Mospd1
0/cko
 (clone 2) cell line also showed a normal karyotype, the second group of 
Mospd1 null clones (generated from Mospd1
0/cko 
clone 1) contained the same 
metacentric chromosome as its parental targeted cell line.  
  






null clones 40 X 41 other
CGR8 60 30 7 3
Mospd10/cko 
clone     (1)
24 64 4 8
Mospd10/-
two clones 
26 61 4 9
(2) 84 0 11 5
Mospd10/-
two clones 
80 0 5 15
(3) 35 0 55 10
(4) 43 0 48 9
Mospd3+/cko
clone      (1)
39 0 53 8
(2) 48 0 42 10
B
Figure 4.1: Karyotype abnormalities in targeted ES cell clones derived from
CGR8 cells. (A) This panel shows three predominant karyotypes observed in
CGR8 and clones derived from this ES cell line. From left to right these panels
show an euploid karyotype spread containing 40 chromosomes, a euploid
karyotype featuring an abnormal metacentric chromosome (highlighted by the
red arrow) and an aneuploid karyotype of 41 chromosomes (trisomy). The table
in B) shows the karyotyping results obtained from each of the targeted Mospd1
and Mospd3 ES cell clones, generated from CGR8 wild type ES cells. The clone
identity numbers are shown in brackets. Karyotyping results are also shown for
Mospd1 null (Mospd10/-) clones generated by Cre-mediated recombination in
Mospd10/cko clones (1) and (2). The results obtained from the Mospd1 null clones
correspond to the average distribution of karyotypes observed in two Mospd10/-
clones. The values listed correspond to percentages of cell with a particular
karyotype in all the karyotype spreads of a particular ES cell clone. The
karyotype categories in the table correspond to the karyotypes panels pictured in
(A). (X) denotes spreads containing a metacentric chromosome. (Other) denotes
karyotypes not within these categories including chromosome counts of less than




In contrast to the chromosome abnormalities observed in CGR8 cells, the 
other ES cell line (E14), routinely used in this laboratory, was found to contain a 
normal number of chromosomes in 97% of all the chromosome spreads analysed. All 
targeted ES cell lines, carrying a conditional allele of either Mospd1 or Mospd3, 
derived from E14 cells were found to be euploid (data not shown). The karyotype 
analysis of targeted E14 cell lines was performed with the help of Madina Kara.  
 
4.2.3 Self renewal and differentiation potential of Mospd1 null ES 
cells 
Prior to studying the effect of loss of expression of Mospd1 on cardiomyocyte 
differentiation, we confirmed that the loss of function of this gene did not interfere 
with the potential of ES cells to self renew or initiate differentiation. For this 
purpose, a standard self renewal and differentiation assays was performed by plating 
1,000 cells (either wild type ES or Mospd1 null) into each well of a 6-well culture 
dish, in ES cell medium. After 24 hours, the culture medium in half the wells was 
replaced with ES cell medium lacking LIF (Leukaemia Inhibitory Factor). LIF is 
used as a growth supplement in murine ES cell culture to keep cells in an 
undifferentiated, self-renewing state. Removal of LIF drives the cells towards 
differentiation. Cells were maintained in these conditions for 3 days to form colonies, 
which were then stained for alkaline phosphatase activity. Undifferentiated ES cells 
exhibit high levels of alkaline phosphatase activity, which diminishes as cells start to 
differentiate. 
The stained colonies were subsequently scored for their level of 
differentiation. Tight red staining colonies were scored as undifferentiated stem cell 
colonies, whilst colonies with a fainter more pink stain or colonies with a red centre 
and unstained differentiated periphery were counted as mixed colonies. If there was 
no red staining detected in a colony, it was scored as differentiated.  
Under self renewing conditions in the presence of LIF, the contribution of 
stem cell, mixed and differentiated colonies appeared to be similar between the two 
wild type ES cell lines (CGR8 and E14) and the two karyotypically normal Mospd1 
null ES cells clones used in this assay, as indicated by chi-squared analysis (Figure 
4.2 B). This result suggests that the loss of Mospd1 in the null cells does not have an  
Figure 4.2: Self-renewal and early differentiation of Mospd1 null ES cells
compared to wild type ES cell lines (E14 and CGR8). (A) Graph shows the
number of colonies of either undifferentiated (stem cell), mixed and differentiated
phenotype formed by wild type or Mospd1 null ES cells in culturing conditions
promoting stem cell self renewal (+LIF) whilst graph (B) represents the distribution of
the three different colony type in the total number of colonies as a percentage. (C)
This graph shows the numbers of stem cell, mixed and differentiated colonies in both
wild type and Mospd1 null ES cells in conditions, which promote ES cell
differentiation (-LIF), whilst graph (D) shows the contribution of the three different
colony types in the total number of colonies formed under these differentiating
conditions. Chi-squared analysis of the colony type contribution (B and C) in +LIF
and –LIF conditions indicates that the contribution of stem cell, mixed and
differentiated colonies does not differ significantly between Mospd1 null ES cells





















































































effect on the ability of these ES cells to self-renew in the same way as wild type 
cells. However, we did detect lower overall colony numbers in the Mospd1 null 
clones compared to the two wild type ES cell lines (Figure 4.2 A). A similar picture 
was seen under differentiating conditions, where the ratio of the three colony types 
appeared to be distributed comparable to wild type clones (Figure 4.2 D), but overall 
fewer colonies were seen in the wells (Figure 4.2 C). As under self renewing 
conditions, the comparable contribution of stem cell, mixed and differentiated 
colonies, between wild type and Mospd1 null cells, in the absence of LIF indicates 
that the loss of Mospd1 does not have an effect on the potential of ES cells to 
commence differentiation.  
It is difficult to account for the lower total colony number observed in the 
Mospd1 null colonies compared to the two wild type ES cell clones. As only three 
different Mospd1 null clones have been used for this comparison, and all these clones 
have originated from the same conditionally targeted CGR8-derived ES cell clone, it 
is likely that this is a clonal effect. Due to the limited availability of karyotypically 
normal Mospd1 null clones, the sample number in this experiment was very low. 
This cardiomyocyte differentiation experiment would, no doubt, benefit from being 
repeated once Mospd1 null clones have been generated from karyotypically stabile 
E14 ES cells, to confirm the results gained in this study.  
As the loss of Mospd1 did not appear to affect the early differentiation 
potential of ES cells, the Mospd1 null clones were analysed for their potential to 
differentiate into functional cardiomyocytes. In this experiment, Mospd1 null ES 
cells were allowed to form embryoid body aggregates in hanging drops. These 3-
dimensional structures have been found to mimic in vivo embryo development, 
enabling the ES cells in the EB to initiate differentiation in vitro into all three germ 
layers. After harvesting, the embryoid bodies (EBs) were cultured for a further 5 
days in ES cell medium lacking LIF before each EB is added to one well of a pre-
gelatinised 24-well plate. Under these conditions, the embryoid bodies attach to the 
gelatine surface and flatten. Over the course of 9 days in culture, the formation of 
beating cardiomyocytes was observed. The cardiomyocyte differentiation was 
represented in this experiment as a percentage of the number of EBs exhibiting 
beating cardiomyocyte activity, over the number of embryoid bodies present in a 24-  
Figure 4.3: Comparison of the in vitro cardiomyocyte differentiation
potential of wild type and Mospd1 null ES cells. The graph shows the
percentage embryoid bodies forming beating cardiomyocytes with respect to
the number of embryoid bodies (EBs) plated out on gelatine. Data represents
results from two wild type ES cell lines (E14 and CGR8) and three Mospd1 null
clones. All plated EBs were monitored throughout the nine day differentiation















































well culture dish (Figure 4.3). This was done because some wells contained two EBs, 
or not enough EBs were obtained from the 5 day EB suspension culture to fill all 24 
wells of the plate. 
Although this experiment has only been performed once, using two wild type 
ES cell lines (CGR8 and E14) and three Mospd1 null clones, the result strongly 
indicates that the lack of Mospd1 does not have any effect on the ability of the cells 
to differentiate into cardiomyocytes. 89% of the embryoid bodies derived from wild 
type ES cells, and 79% from Mospd1 null clones formed beating cardiomyocytes. 
Thus, the cardiac-specific differentiation potentials of these cells appear to be 
comparable.  
We also tried to discern whether the loss of Mospd1 may affect the function 
of the cardiomyocytes, rather than their formation. As a measure of their function, 
we chose to analyse the contraction frequency of myocardial foci in the embryoid 
bodies on day nine of cardiomyocyte differentiation. The number of contractions per 
minute, of 5 randomly chosen beating EBs per wild type and Mospd1 null ES cell 
clones, was counted under the microscope. We found that the rate of contraction 
varied greatly even amongst beating EBs of the same cell line, leading us to conclude 
that contraction frequencies would not be a suitable measure to determine functional 





As Mospd1 is expressed in the mouse heart, and is suspected to be a possible 
genetic modifier affecting the phenotype in the Mospd3
Gt1lmf/Gt1lmf 
animals, a Mospd1 
null ES cell line was generated to assess the effect of lack of this gene on the in vitro 
cardiac differentiation potential of these cells. We found that ES cells lacking 
Mospd1 expression were still able to self renew and differentiate into cells of the 
cardiac lineage. Because the cardiac defect in Mospd3
Gt1lmf/Gt1lmf 
animals was only 
observed in d19 embryos, it is still possible that Mospd1 may only compensate for 
loss of Mospd3 at later stages of cardiac development, rather than the early cardiac 
differentiation mimicked by embryoid bodies in in vitro culture. In order to 
determine whether the function of these in vitro derived cardiomyocytes might be 
affected by the loss of Mospd1, we looked for changes in the rate of contraction in 
the beating EBs.  
In a study on the effect of loss of β1-integrin on cardiomyocyte formation, it 
was found that the absence of this extracellular matrix interactor protein led to an 
increase in the beating frequency of cardiomyocytes in EBs (Fassler et al., 1996). 
However, the rate of contraction of beating cardiomyocyte is very heterogeneous, in 
correspondence with the heterogeneity of different myocardial cell types present in 
these beating EB cultures (Boheler et al., 2002). The frequency of contractions in 
wild type cardiomyocyte cultures also changes with progressive differentiation of 
cardiomyocytes, from slow contractions of early pacemaker cells to the faster 
contractions of intermediate differentiated myocardial cells. Upon terminal 
cardiomyocyte differentiation, contractions become slower or even stop. 
 Additional experiments to study the cardiomyocyte differentiation potential 
of Mospd1 null ES cells could include testing the beating embryoid body cultures for 
cardiac muscle specific proteins, such as cardiac myosin heavy chain (MHC), to 
determine the percentage of cells which have developed into cardiac muscle.  
It is also possible to isolated single cardiomyocyte cells from beating 
embryoid body cultures. These ES cell derived cardiomyocytes can be analysed for 
their electrophysiological properties, as well as the expression of cardiac gene 
products by RT-PCR and immunohistochemical analysis. To determine if Mospd 
proteins are involved with cell adhesion or tethering of the contractile apparatus, the 
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localisation of components of the sarcomeric cytoskeleton as well as desmosomal 
and adherens junction proteins could be examined in isolated cardiomyocytes. 
 In this study, ES cells containing a targeted allele of Mospd1 and Mospd3 
were used to generate chimaeric animals by blastocyst injection, in order to produce 
a transgenic conditional mouse line of either gene. The generation of chimaeras 
failed in the case of Mospd3, and even if chimaeras were produced, as for two of the 
Mospd1 clones, the level of ES cell contribution to the animals was very low. In 
addition, one male chimaera bred with two C57BL/6 females did not produce any 
transgenic offspring. 
 An explanation for these low numbers of chimaeras produced, was gained 
from subsequent karyotyping analysis of the targeted ES cell clones generated from 
the CGR8 parental ES cell line. Almost all the clones had acquired a trisomy of one 
of the chromosomes, which was also found in a proportion of the wild type CGR8 
cells.  
It has been shown, in a number of reports, that mouse ES cells are prone to 
accumulation of chromosome abnormalities in long term in vitro culture (Liu et al., 
1997; Longo et al., 1997; Robertson, 1987). Of 540 mouse ES cell lines analysed in a 
Japanese study, only 60% exhibited a normal karyotype (Sugawara et al., 2006). 
Karyotype abnormalities in mouse ES cells include monosomy, trisomy, polyploidy, 
as well as translocation and duplication of chromosomal regions (Rebuzzini et al., 
2008). The most commonly observed karyotype abnormality, in mouse ES cells, is 
trisomy of chromosome 8 (Liu et al., 1997). Trisomy of chromosome 11 is also quite 
common (Sugawara et al., 2006). It is believed that the presence of an extra 
chromosome 8 or 11 gives these cells a growth advantage, which leads to a rapid 
replacement of a euploid ES cell, in culture, with aneuploid cells (Liu et al., 1997; 
Sugawara et al., 2006). This thinking corresponds with findings that euploidy in an 
ES cell culture can deteriorate from 100% to 16% in only 5 passages (Nichols et al., 
1990).  
 The CGR8 cells used to generate the Mospd1 and Mospd3 conditional allele 
were electroporated with the targeting vector at passage 17 to 19, and then clonally 
expanded. This expansion holds the risk of selecting a particular cell, which may 
have already acquired a karyotype defect. In fact, CGR8 cells at passage number 19 
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were found to already contain as many as 30% aneuploid cells. Karyotype instability 
is a common problem with all of the established and widely distributed mouse ES 
cell lines; as, by their nature, they have been in culture for a long time. Some cell 
lines have been shown to be more stable over long periods of culture, even past 
passage number 33, whilst others can accumulate aneuploid cells at very early 
passages (Longo et al., 1997; Nichols et al., 1990).  
Several studies have found that an abnormal karyotype is the main cause for 
failure of ES cells to generate germline-transmitting chimaeras (Liu et al., 1997; 
Longo et al., 1997; Nagy et al., 1993). The higher the number of aneuploid cells in an 
ES cell culture, the fewer blastocyst injections of these cells resulted in chimaeras 
being generated. Also, the level of ES cell contribution to the chimaera was reduced. 
If the contribution of euploid cells in a given ES cell culture dropped below 50%, no 
chimaeras could be generated at all. 
 Interestingly, the reason for using CGR8 ES cells for the generation of the 
conditional knockout allele of Mospd3 and Mospd1 was the finding that this cell line 
performed particularly well when used for blastocyst injection, resulting in a high 
number of germline transmitting chimaeras (Nichols et al., 1990) (personal 
communication Jan Ure, Edinburgh).  However, over the years of continuous culture 
the CGR8 line appears to have lost this potential, along with an increase of karyotype 
instability in these cells.  
Only one of the conditional targeted clones generated in the CGR8 parental 
cell line resulted in the production of a suitable number of chimaeras. Similar to one 
of the ES cell clones studied by (Longo et al., 1997), this clone shows no obvious 
karyotype defects with nearly all of the cells being euploid (Mospd1
0/cko 
(2), Figure 
4.1B). But despite their normal chromosome contribution, the cells appear to have 
lost their totipotency as they show only a very low level of ES cell contribution, and 
the male ES cells were not able to lead to a sex distortion in the chimaeras towards 
male animals. Both, sex distortion and the level of ES cell contribution have been 
shown to influence the ability of a clone to contribute to the germline. These findings 
indicate that this clone may have lost the potential to be transmitted in the germline, 
either due to a subtle genetic defect not detected by karyotyping, or a due to partial 
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commitment of the cell, precluding them from contribution to all germ layers of the 
embryo. 
 Karyotype analysis of E14 cells at passage 22 and 23, alongside the CGR8 
cells and targeted clones, revealed that about 97% of the E14 ES cells were euploid. 
In addition, a recent gene trap mutagenesis project in our laboratory, using the E14 
wild type line, found that these cells were capable of generating a good level of 
germline transmitting chimaeras. It was therefore decided to use E14 cells in the 
attempt to retarget the Mospd1 and Mospd3 allele (Chapter 3). To date, 5 clones 
containing the Mospd3 conditional allele, and 4 clones targeted at the Mospd1 locus 
have been identified. All 9 clones display a more than 95% euploid karyotype, and 
are anticipated to result in the successful generation of a transgenic mouse line of 










5 CHAPTER 5:  GENERATION AND TESTING OF 





 Mospd3 is part of a novel gene family in vertebrates. To date, the only 
evidence for a function of Mospd genes has come from the analysis of a gene trap 
integration into the mouse Mospd3 gene. Loss of function of this mammalian specific 
Mospd gene resulted in a cardiac defect, and in severe cases death, in neonatal mice. 
The severity of this phenotype appeared to be affected by a genetic modifier, 
possibly another member of the Mospd gene family such as Mospd1. Little else is 
known about the function of this gene family, although the Mospd3 gene trap 
phenotype and the protein domain similarities of Mospd3 to an ancestral protein 
(Major Sperm Protein) in C. elegans, indicate that Mospd3 protein may be involved 
in the development or structural integrity of the right ventricular chamber of the 
heart.  
 To test this hypothesis as well as learn more about this family of genes, it is 
important to study the function of the proteins encoded by members of the Mospd 
gene family. An important tool for the functional study of novel proteins is the use of 
antibodies. Antibodies could be used to study the tissue-specific distribution as well 
as the subcellular localisation of both Mospd3 and Mospd1. This would help to 
confirm whether Mospd proteins form part of the desmosome or adherence junction 
complexes, which provide structural integrity in the heart. In addition, specific 
αMospd antibodies can be used to identify novel protein interactors of Mospd3 or 
Mospd1.  
 Various strategies were available to generate the antigens required for raising 
specific antibodies against Mospd3 and Mospd1. One option would have been to 
clone the appropriate cDNA into an expression vector in-frame with a tag, such as 
His6 or GST. Overexpression of the fusion construct in protease deficient E.coli cells 
would allow the production of a tagged Mospd protein, which could be purified by 
immuno-chromatography using sephadex or charged nickel columns. However, due 
to the high levels of protein conservation between the MSP and transmembrane 
domains of Mospd3 and Mospd1, some of the antibodies raised against the whole 
proteins would most likely display antibody cross-reactivity.    
 To overcome this problem, we used an alternative approach for generating 
immunogenic antigens. Instead of using the whole protein to raise antibodies, we 
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chose to design a small peptide antigen. Small peptide antigens have become the 
preferred immunogen class used today, as they can be quickly and easily synthesised. 
Publicly available computational sequence analysis programs
7
 can be used for the 
identification of suitable peptide epitopes.  
Peptide immunogens, which typically consist of 12 to 20 amino acid residues, 
can be designed to reduce unwanted cross-reactivity with related proteins. When 
designing a suitable peptide immunogen for Mospd1 and Mospd3, we chose to avoid 
peptide sequences within the MSP and transmembrane domains of either protein as 
these regions exhibit the highest degree of sequence conservation (see Chapter 1 
figure 1.2). The most N-terminal protein sequences of Mospd1 and Mospd3, on the 
other hand, show no significant sequence similarities making potential cross-
reactivity between antibodies, raised against either protein, unlikely. An added 
advantage of peptides designed to either the N- or C-terminal protein sequences is 
that these regions often exhibit low structural complexity and are less likely to be 
buried in the tertiary structure of the native protein. Peptide antibodies may not 
recognise epitope sequences buried within the tertiary structure of a protein.  Also, 
antibodies raised against surface exposed peptide sequences are likely to detect both 
the native and the denatured form of a protein.  
 In this study, peptide antigens were designed to the most N-terminal 20 
amino acid sequences of Mospd1 and Mospd3 (Figure 5.1). The antibodies raised 
against these peptide sequences were anticipated to bind specifically to either 
Mospd1 or Mospd3, and to not exhibit any cross-reactivity between these two 
proteins. 
    
  






5.2.1 Generation of peptide antigens and raising of polyclonal 
αMospd1 and αMospd3 antibodies 
 Specific peptides were designed and synthesised by Thistle Research. The 
sequence of these peptides corresponded to the most N-terminal 20 amino acids of 
either Mospd1 or Mospd3, as these sequences showed minimal sequence identity 
between the two proteins (Figure 5.1). 
 Both peptides, conjugated to KLH carrier proteins, were subsequently used 
for the inoculation of two rabbits per peptide (performed by PTU/BS (Roslin)). 
Preimmune sera, as well as first, second and third bleeds (taken at weeks 4, 8 and 12, 
respectively) were collected. 
 
5.2.2 Testing of antiserum by ELISA and western blotting 
 ELISA (Enzyme-Linked ImmunoSorbent Assay) was performed using 
preimmune and week 4 to 12 sera, in order to determine whether antibodies detecting 
Mospd1 or Mospd3 were present in the antisera, and to find a good antiserum sample 
for further purification and immunoblot analysis. 
The ELISA involved the immobilisation of the peptide antigen onto a solid 
support and subsequent detection of this peptide by antibodies present in the antisera. 
As pre-immune serum was taken from the rabbits prior to inoculation with the 
peptide antigen, it should not contain those antibodies which would specifically 
detect the immobilised peptide. The absorbance reading (as a measure of antibody 
binding) of pre-immune serum could therefore serve a baseline of non-specific 
antibody binding (Figure 5.2). An increase in the absorbance reading in subsequent 
bleeds indicated a specific immune response to the peptide antigen in the rabbits. 
With further booster injections, the amount of specific antibody present in the 
antisera should further increase between week 4 and 12, resulting in an increase of 
absorbance readings. This increase in the levels of specific antibody binding was 
observed in the antisera samples of one rabbit inoculated with the Mospd3 peptide 
(Figure 5.2 A) and one rabbit inoculated with the Mospd1 peptide (Figure 5.2 D). 
  
Mospd1 (24kDa)                Peptide: MHQQKRQPELVEGNLPVFVF
Mospd3 (25kDa)                Peptide: MRRGAPQDQELVGPGAPGRG
MSP TM TM
40                                        100                                                                       176      198  213        233
Figure 5.1: Location of protein sequences used to generate synthetic peptide
antigens. The sequence ( ) used for generation of the synthetic peptide and
subsequent raising of Mospd1 and Mospd3 specific antibodies is located at the N-
terminus of both Mospd proteins. The N-terminal protein sequences preceding the
MSP domain correspond to non-conserved sequences between the Mospd1 and
Mospd3 protein (also see Figure 1.2. for protein sequence alignment of both Mospd
proteins).
MSP TM TM
24                                        80                                                                   158        180 190         212
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Figure 5.2: ELISA of αMospd1 and αMospd3 rabbit antisera. αMospd1
rabbit antisera from two rabbits (A, B) as well as αMospd3 antisera from two
rabbits (C, D) were analysed for antibody binding to the relevant peptide
antigen using ELISA . The assay measured the amount of specific antibody
binding of preimmune serum and antisera obtained at week 4, 8 and 12 at
various antisera dilutions. The level of antibody binding to the immobilised
peptide antigen is expressed as a measure of the absorbance at λ450nm. An
increase in the slope of the curve at week 4, 8 or 12 compared to the







The ELISA results from rabbit 1 injected with Mospd3 peptide show barely 
any increase in the antibody binding activity between pre-immune and any of the 
later bleeds (Figure 5.2 C). This could indicate either an insufficient immune 
response in this rabbit or, possibly, the production of specific antibodies with weak 
affinity to Mospd3.  
 In the second rabbit immunised with Mospd1 peptide, on the other hand, the 
concentration of specific antibody rises in the sera from week 4 and 8, but drops 
drastically in the last bleed (Figure 5.2 B). Peptide antigen booster injection are 
performed, not only to increase the amount of specific antibody produced, but also to 
promote immunoglobulin shift from IgM to IgG antibodies, which usually display 
stronger epitope binding affinity. In some cases, however, the resulting antibodies 
can show reduced binding affinity or specificity (Roitt and Delves, 2001). This might 
have been the case in the second rabbit immunised with the Mospd1 peptide. 
Another explanation could be an infection in this rabbit after the second bleed. Based 
on the ELISA results, we chose to use week 8 antiserum for further immunoblotting 
analysis of the antibodies, as this bleed, from all four rabbits, appeared to give 
consistently good results. 
 In order to analyse the specificity of the antibodies, western blot analysis was 
performed on COS7 cells transiently transfected with either a Mospd1-cDNA, or a 
cDNA encoding an eGFP-Mospd3 fusion protein, in a mammalian expression vector. 
The Mospd1 expression construct (Appendix figure 6) was obtained as an I.M.A.G.E 
clone from the I.M.A.G.E Consortium
8
, whilst the eGFP-Mospd3 fusion vector was 
produced by EcoRI digestion and ligation of the Mospd3-cDNA into a pC2-EGFP 
vector by Dr. Richard Axton, Edinburgh (both pEGFP vector maps in Appendix 
figure 5). Western blot membranes of protein lysates from these transfected COS7 
cells were probed with αMospd1 and αMospd3 preimmune and week 8 sera. Whilst 
the pre-immune serum did not show any signal on the western blot (Figure 5.3), the 
week 8 αMospd1 antiserum (used at a dilution of 1/1,000) detected a protein band at 
approximately 24kDa corresponding to the predicted molecular weight of the 
Mospd1 protein.  































































































































































































































Figure 5.3: Assessment of polyclonal αMospd1 antibody purification
from rabbit antiserum. Preimmune serum, αMospd1 antiserum and
immunoaffinity purified polyclonal αMospd1 antibody were used for western
blot analysis of cell lysates from COS7 cells transfected with either no DNA or
a Mospd1 expression construct . The purple arrow marks the 24kDa Mospd1






































































Figure 5.4: Assessment of polyclonal αMospd3 antibody purification
from rabbit antiserum. Preimmune serum, αMospd3 antiserum, immuno-
purified polyclonal αMospd3 antibody and αGFP were used for western blot
analysis of cell lysates from COS7 cells transfected with either no DNA, an
eGFP expression vector or an eGFP-Mospd3 fusion construct. The red arrow
indicates the 52kDa eGFP fusion protein and the green arrow marks the




The αMospd3 antiserum also detected a specific band (Figure 5.4) in the 
lysate of transfected COS7 cells. This band, at 52kDa, corresponded to the eGFP-
Mospd3 fusion protein. The identity of the fusion protein was confirmed using a 
commercially available monoclonal anti-eGFP antibody (Figure 5.4).         
 Although using crude week 8 antisera for western blot analysis enabled the 
detection of both Mospd1 and Mospd3 in COS7 cell lysates, a high level of non-
specific background signal was detected, despite increasing the timing of washing 
steps significantly compared to standard western blotting protocols. Neither 
reduction of the amount of COS7 protein sample or antisera concentration (1/2,500, 
minimum concentration able to generate signal) nor the use of different blocking 
agents resulted in clearing the non-specific background signal (data not shown). 
     
5.2.3 Purification of αMospd1 and αMospd3 antibodies from week 8 
antiserum 
 Immunoaffinity purification of the polyclonal αMospd antibodies from week 
8 antiserum was performed in an attempt to increase specificity. 
 Initial purification attempts involving the use of a Protein „A‟ column, which 
binds immunoglobulins via interactions with their heavy chain, were unsuccessful 
(data not shown).  
 A second approach, to purify the antibodies from the serum, involved the use 
of immunoaffinity columns containing the immobilised Mospd1 or Mospd3 peptide 
antigen which was used to inoculate the rabbits for antiserum production. These 
columns were supplied by Thistle Research. The αMospd1 and αMospd3 antibodies 
purified by this method were tested on western blots of protein lysates from 
transiently transfected COS7 cells, and from mouse tissues. 
 
5.2.4 Testing of immunoaffinity purified polyclonal αMospd1 and 
αMospd3 antibodies on transfected COS7 cell lysates 
 Probing western blot membranes of transfected COS7 cell lysates with the 
immunoaffinity purified antibodies showed that the non-specific background has 
been significantly reduced. Used at a dilution of 1 in 200, the purified αMospd3 
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antibody detected the 52kDa protein band corresponding to the eGFP-Mospd3 fusion 
protein (Figure 5.4). The identity of this fusion protein was again confirmed using an 
anti-eGFP antibody. 
 At the same 1 in 200 dilution, the immunoaffinity purified αMospd1 antibody 
detected a distinct protein band at 24kDa, the predicted molecular weight of Mospd1 
protein (Figure 5.3). The identity of this protein has not been confirmed as we have 
not been able, to date, to clone an eGFP-Mospd1 fusion construct. 
 We assessed whether the antibodies we had raised were specific to either one 
of the Mospd proteins. We detected no protein bands when αMospd1 antibodies were 
incubated with western blots of eGFP-Mospd3 transfected COS7 cells, nor when 
αMospd3 antibodies were incubated with blots of Mospd1 transfected COS7 cells 
(Figure 5.5).   
These experiments confirmed that we have successfully raised polyclonal 
antibodies, which were able to detect Mospd1 and Mospd3. We have also shown 
that, using specific peptide antigens corresponding to non-conserved regions of 
Mospd1 and Mospd3, we were able to raise antibodies which can distinguish 
between these two closely related Mospd proteins. 
 
5.2.5 Testing of polyclonal αMospd1 and αMospd3 antibodies on 
mouse tissue lysates 
 In order to establish whether the purified antibodies were able to detect 
endogenous mouse Mospd1 and Mospd3, they were used to probe western blots of 
mouse tissue lysates of various organs, including heart and kidney (αMospd1, Figure 
5.6).  
 Even at very short exposure times a multitude of protein bands were detected 
throughout the lanes of the western blot. The amount of non-specific signal was too 
high to determine specific protein bands at 24kDa or 25kDa, corresponding to 
endogenous mouse Mospd1 and Mospd3, respectively (Figures 5.6, data for 
αMospd3 not shown). Reducing the amount of protein sample or antibody 




















































Figure 5.5: Western blot analysis to assess cross-reactivity between
immunoaffinity purified polyclonal αMospd1 and αMospd3 antibody.
Antibody cross-reactivity was assess by antibody labelling of protein lysates of
COS7 cells transfected with either an eGFP-Mospd3 fusion construct or a
Mospd1 expression construct. The red arrow indicates the eGFP-fusion





In order to identify the Mospd3 specific protein band in mouse tissue lysates, 
heart and kidney protein extracts of wild type animals were compared to those from 
homozygous Mospd3
Gt1lmf/Gt1lmf 
gene trap animals which do not express Mospd3. 
However, the non-specific background signal made it impossible to distinguish a 
particular protein band present in wild type lysates but absent in Mospd3
Gt1lmf/Gt1lmf
 
samples (data not shown). 
 
5.2.6 Reduction of background signals from mouse tissue western 
blots 
In order to reduce the background signals observed on mouse tissue western 
blots, the purified antibodies were incubated with mouse serum prior to being used 
on wild type mouse tissue lysates. This pre-incubation might have reduced the 
background signals if they had been due to non-specific antibody binding to 
circulating murine proteins. However, in this case, no reduction of the background 
signals was observed.  
 An alternative approach to eliminate the background signals involved pre-
incubation of the purified antibodies with ES cell lysates which did not express the 
Mospd protein of interest. Using TritonX100 protein lysates of Mospd1 null ES cells 
(described in section 3.2.1.11), the purified αMospd1 antibody was pre-incubated 
and subsequently used to probe western blot of mouse heart and kidney protein 
lysates. This approach resulted in a reduction of the non-specific background signal. 
The same result was achieved by pre-incubation of the αMospd1 antibody with wild 
type CGR8 ES cell lysates.     
 In fact, after pre-incubation with either cell lysate, a protein signal more 
distinct than most of the surrounding background bands was detected in heart and 
kidney sample. This protein band, with an approximate molecular weight of 24kDa, 
appeared to correspond with endogenous murine Mospd1. If this signal indeed 
corresponds to endogenous Mospd1, it would also indicate that this protein is not 
expressed in undifferentiated ES cells (as both Mospd1 null and CGR8 wild type 
lysates appeared to reduce western blot background signals but not the 24kDa band).  
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Further confirmation of the identity of this signal would be required. This could be 
done by out-competing the αMospd1 antibody with its peptide antigen prior to 
probing western blots of mouse tissue lysates.  
 It was not possible to perform similar pre-incubation experiments with the 
purified αMospd3 antibody as, at the time, neither Mospd3 null ES cell lines nor 
Mospd3
Gt1lmf/Gt1lmf
 animals were available for tritonX100 extraction of proteins.  
 These preclearing (pre-incubation with ES cell lysates) experiments show that 
it was possible to reduce the non-specific binding of the αMospd1 antibody. 
However, the presence of persistent non-specific background indicated that, even 
after preclearing with Mospd1 null ES cell lysates or Mospd3
Gt1lmf/Gt1lmf 
mouse tissue 
lysates, the antibodies were unlikely to be suitable for use in immunohistochemical 
procedures. Due to the remaining non-specific binding activity of the αMospd1 
antibody, it would not be possible to correlate a positive immunohistochemical 
staining pattern with specific detection of Mospd1 alone. 
 
5.2.7 Generation of monoclonal αMospd1 and αMospd3 antibodies 
 As the polyclonal antibodies appeared to be unsuitable for functional analysis 
of Mospd proteins, monoclonal antibodies specific to Mospd1 and Mospd3 were 
generated. These monoclonal antibodies were raised against the same N-terminal 20 
amino acid peptide antigen of Mospd1 and Mospd3 as the polyclonal antibodies. The 
peptides, synthesised and conjugated to KLH by Yorkshire Biosciences, were 
injected into mice. Splenocytes and lymph node cells of these inoculated mice were 
subsequently fused to myeloma cells to generate hybridomas expressing monoclonal 
αMospd1 or αMospd3 antibodies. The conditioned medium from positive hybridoma 
lines was then collected (Nelson et al., 2000; Shepherd and Dean, 2000). 
 
  
Figure 5.6: Western blot analysis of CGR8 ES cells and heart and kidney tissue
lysates from mouse using polyclonal αMospd1 antibody. The immunoaffinity
purified polyclonal was precleared by prior incubation with TritonX100 lysates of
either Mospd1 null ES cells or CGR8 cells. Red asterisk indicate the proposed
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5.2.8 Testing of monoclonal antibodies on recombinant and 
endogenous Mospd proteins    
 Initial analysis and testing has to date only been performed on αMospd3 
monoclonal antibodies with the help of Madina Kara. Conditioned medium 
containing αMospd3 monoclonal antibodies was used to probe western blots of 
COS7 cells expressing the eGFP-Mospd3 fusion protein (Figure 5.7). The 
monoclonal antibody detected a protein band of approximately 52kDa (eGFP-
Mospd3), indicating that this antibody is able to detect the Mospd3 protein. 
 In subsequent western blot analysis of mouse tissue lysates of heart and 
kidney, the antibody detected a specific protein band at about 25kDa which could 
correspond with endogenous murine Mospd3 (Figure 5.7). In addition to this signal, 
two further protein bands were labelled (at approximately 15kDa and 50kDa). 
 Further comparison of the protein bands labelled in wild type and 
Mospd3
Gt1lmf/Gt1lmf
 mouse tissue lysates, as well as outcompeting αMospd3 
monoclonal antibody with the peptide antigen prior to western blot hybridisation, 




Figure 5.7: A monoclonal αMospd3 antibody detects protein in lysates from
mouse heart and kidney tissues, and transiently transfected COS7 cells.
Monoclonal αMospd3 and αGFP antibody were used to label lysates of COS7
cells transfected with eGFP alone or eGFP-Mospd3 fusion construct. Red
asterisks indicate the proposed endogenous mouse Mospd3. The white and green













































Antibodies represent a very powerful tool for the functional analysis of a 
gene. Not only can they provide detailed information about the cell and tissue 
specific localisation of the protein encoded by a gene of interest, but co-
immunoprecipitation using antibodies can also facilitate the discovery of interacting 
proteins. 
 This thesis describes the generation, testing and purification of both 
polyclonal and monoclonal antibodies raised against N-terminal peptide antigens of 
Mospd1 and Mospd3. These antibodies were found to detect both recombinant and 
endogenous Mospd1 and Mospd3, as well as being able to successfully distinguish 
between these two closely related proteins.  
 Immunoblotting analysis of purified and precleared αMospd3 polyclonal 
antibodies, and αMospd1 monoclonal antibodies, detected expression of both 
Mospd3 and Mospd1 in adult mouse heart and kidney tissues. This is the first time 
the expression of Mospd proteins has been shown. The presence of both Mospd1 and 
Mospd3 in the same adult mouse tissues appears to be evidence for the hypothesis 
that both proteins perform a similar function and may be able to compensate for each 
other. This finding could also explain the phenotype variability in Mospd3
Gt1lmf/Gt1lmf 
animals (Chapter 1, section 1.1.3), as well as the gradual loss of the neonatal death 
phenotype in homozygote gene trap animals noted in offspring after about generation 
12. It is possible that, through successive breeding, animals with improved survival 
and compensation by Mospd1 have been selected.   
 In addition to potential Mospd1 expression in adult heart and kidney, 
immunoblotting using αMospd1 indicated that Mospd1 may not be expressed in 
undifferentiated ES cells (Figure 5.6). Therefore, any differences observed in the 
physiology of undifferentiated Mospd1 null ES cells (described in Chapter 4) might 
not have resulted from the loss of Mospd1, but might be more likely to be caused by 
clonal differences or an experimental effect due to the low numbers of clones 
analysed.  
 We have shown by immunoblotting that Mospd1 is expressed in mature heart 
cells but (most likely) not in ES cells. This indicates that at some point during 
cardiac development the expression of Mospd1 is initiated. To study the importance 
144 
 
of the Mospd1 gene during cardiac development, we have used an in vitro 
cardiomyocyte assay (Chapter 4, section 4.2.3) which mimics the in vivo model. In 
light of the protein expression pattern of Mospd1 shown in this chapter, there appear 
to be two different explanations for the lack of phenotype observed in Mospd1 null 
cardiomyocyte cultures. Either Mospd1 is not expressed and required in the earlier 
stages of cardiomyocyte differentiation analysed in this assay, or alternatively 
Mospd3 can compensate for the loss of Mospd1 in these cells. From results in this 
chapter, both appear to be valid conclusions. The answer to this question will require 
further immunohistochemical analysis of Mospd proteins during myocardial 
development both in vitro and in vivo.            
 Even though the polyclonal αMospd1 and αMospd3 antibodies were shown 
to be able to detect recombinant Mospd proteins in COS7 cell lysates and potentially 
endogenous Mospd in mouse tissue lysates, these antibodies could not be sufficiently 
purified. This may be due to the intrinsic nature of the polyclonal antibodies which 
contain multiple different antigen recognition sites. Up to 90% to 99% of antiserum 
could potentially contain antibodies which are not specific to the antigen of interest 
and can cause non-specific background cross-reactivity (Harlow and Lane, 1988). 
Even after purification using a specific peptide antigen affinity column, the 
polyclonal antibodies may still bind to other murine proteins, through antigen 
recognition sites not specific to Mospd1 or Mospd3. Nevertheless, the background of 
non-specific proteins detected, in our experiments, was unexpectedly high. These 
background problems are not uncommon due to the complexity of the immune 
reaction generated in animals inoculated to raise the antibodies.  
 Unlike polyclonal antibodies, monoclonal antibodies represent a more 
homogenous population of immunoglobulins which are derived from one clonal 
hybridoma line and thus contain the same antigen recognition site (Nelson et al., 
2000). This feature makes these antibodies more specific and, therefore, preferred 
primary antibody reagents. Our initial western blotting analysis indicated that the 
monoclonal αMospd3 antibody strongly detects not only recombinant but also 




 Pending further analysis to verify that the proteins detected by these 
monoclonal antibodies are indeed Mospd3 or Mospd1, and additional purification of 
the monoclonal antibodies from the hybridoma supernatant, these antibodies can be 
used to determine whether Mospd proteins form part of the cell adhesion complexes 



















Mospd3 has previously been identified in a gene trap experiment. The 
resulting loss of function in Mospd3
Gt1lmf/Gt1lmf 
animals led to neonatal death of some 
animals, whilst the survivors exhibited cardiac abnormalities. This is the only 
published study relating to the function of the mammalian Mospd gene family. 
Genetic background variability in the observed phenotype suggested the existence of 
a genetic modifier locus. Whilst there are likely to be a whole host of possible 
genetic modifiers which could be the reason for the compensation of the Mospd3 
gene trap phenotype, we chose to analyse the closely related Mospd1 gene. The 
proteins encoded by Mospd1 and Mospd3 are very similar in the identity and 
arrangement and of their functional domains, which show a high degree of 
conservation between both proteins.  
The proteins encoded by the Mospd family of genes contain an N-terminal 
MSP domain as well as one or two C-terminal transmembrane domains. Whilst the 
presence of the transmembrane domain suggests a membrane-bound protein, the only 
indication concerning the function of the MSP domain comes from the nematode 
major sperm protein (MSP).  Similarity with this protein, which appears to be an 
ancestral form of the MSP domain (Tarr and Scott, 2005) suggests that Mospd 
proteins may function as mediators of protein-protein interactions. 
In fact, in C. elegans, MSP was found to be essential for actin-like cell 
motility of nematode sperm.  Further analysis of this nematode system indicated that 
the sperm cells do not only highly express MSP protein but also LIM and PDZ 
domain proteins, which are known to associate with actin-filaments to mediate cross-
linking and tethering of the actin cytoskeleton. 
This information along with the cardiac phenotype of Mospd3
Gt1lmf/Gt1lmf 
animals, which display a thinning of the right ventricular myocardium and a possible 
defect in the structural integrity and function of the heart muscle, led us to speculate 
that Mospd proteins may be involved in the cell adhesion between the 
cardiomyocytes of the right ventricular heart wall. Such speculations have been 
substantiated by similar defects in animal models and humans, involving a loss of 
function of known cell-adhesion components such as proteins associated with 
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desmosomes and adherens junctions (Awad et al., 2008; Kostetskii et al., 2005; 
Perriard et al., 2003). 
Alternatively, it is possible that Mospd proteins are involved in vesicle 
trafficking as they are similar in structure to VAP proteins. The VAP protein class 
also evolved from the nematode MSP protein and consists of an N-terminal MSP 
domain and a C-terminal transmembrane domain protein (Tarr and Scott, 2005). A 
preliminary study of the subcellular localisation of the eGFP-Mospd3 fusion 
construct in COS7 cells, showed a punctate fluorescence signal akin to vesicle- 
specific labelling, which would support this possibility (Forrester, unpublished data). 
Vesicle trafficking is a process which ensures correct distribution of molecules not 
only within the cell, but also between neighbouring cells. The central nervous system 
was found to be particularly sensitive to disturbances in this process, and almost all 
human syndromes caused by vesicle trafficking defects appear to display a 
neurological component (Olkkonen and Ikonen, 2006). One of these human 
syndromes, called Danon disease caused by a mutation in lysosomal-associated 
membrane protein 2 (Lamp2), is characterized clinically by hypertrophic 
cardiomyopathy, skeletal myopathy and variable degrees of mental retardation (Yang 
and Vatta, 2007). Danon disease is, as yet, the only described vesicle trafficking 
related defect which also display cardiac abnormalities. However, this disease affects 
multiple organs and we have not observed any obvious muscle wasting or 
behavioural defects in Mospd3
Gt1lmf/Gt1lmf
 animals.  
An alternative explanation for the punctuate fluorescence of eGFP-Mospd3 in 
transfected COS7 kidney cells could be that the protein localises to focal adhesion 
sites of the cells with the matrix or gelatine culture surface. Interestingly, a recent 
review on the function of α-actinin reports that this evolutionary conserved actin-
crosslinking protein localises to stress fibres and lamellopodia; as well as cell-cell 
and cell-matrix adhesion sites in non-muscle cells, such as kidney cells (Otey and 
Carpen, 2004). A punctuate localisation pattern has also been reported for the α-
actinin-associated LIM domain protein (ALP) in spherical chick cardiomyocytes in 
primary culture (Henderson et al., 2003). ALP was found to co-localise with α-
actinin at focal matrix adhesion sites prior to the formation of the sarcomeric 
cytoskeleton (myofibrillogenesis) in these myocardial cells. Once myofibrillogenesis 
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has occurred in these cardiac cells, both ALP and α-actinin localise to the sarcomeric 
Z-disc. The similarity in the localisation patterns of Alp, α-actinin and eGFP-Mospd3 
in non-muscle and pre-sarcomeric cardiomyocytes indicates that Mospd3 may be 
able to interact with α-actinin, and maybe Alp.   
The third possible reason for the punctate fluorescent signal could be that the 
transfected COS7 cells (derived from monkey kidneys) are sequestering the 
overexpressed foreign eGFP-Mospd3 fusion protein in lysosomal vesicles for 
degradation. An answer to whether Mospd3 is involved in cell-cell and cell-matrix 
adhesion, or vesicle trafficking will, no doubt, be reached through future subcellular 
immunohistochemical analysis of this protein.   
To date, other than the conclusions drawn from the similarity of the gene trap 
phenotype of Mospd3 to other loss of function mutations in adherens junction and 
desmosomal proteins, there is little functional information about this gene. In 
addition, the expression pattern of Mospd3 is not very informative in determining 
gene function. Unlike the initial β-gal reporter gene expression of the trapped 
Mospd3 locus, which seemed to indicate specific expression of Mospd3 in the heart 
of developing mouse embryos, subsequent RT-PCR and in situ hybridisation analysis 
suggested that the gene might be expressed much more widely in the developing and 
adult mouse (McClive et al., 1998; Pall et al., 2004). Mospd3 expression has been 
detected in in vitro differentiated EBs, hematopoietic tissues of the mouse embryo; as 
well as a range of tissues - including the heart - in the neonatal animal. This 
widespread expression pattern is corroborated by data from the Gene Expression 
Omnibus website.   
A similar widespread pattern of expression has also been found for Mospd1. 
Like Mospd3, this gene is expressed in in vitro differentiated embryos at day 3 and 5; 
as well as in a range of embryonal hematopoietic tissues and in the adult mouse heart 
(data not shown). This overlapping expression pattern of Mospd3 and Mospd1, 
particularly in the mouse heart, suggests that it could be possible for Mospd1 to 
compensate for the loss of Mospd3. In order to answer the question of a possible 
genetic redundancy between these two genes, and to analyse our hypothesis that 
Mospd3 and possibly also Mospd1 could be involved in providing structural integrity 
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in the heart, we have in this project generated the tools to facilitate a detailed 
functional study of both Mospd genes and their protein products. 
Firstly, by employing a recombineering approach, conditional knockout 
constructs were generated for Mospd3 and Mospd1. Both constructs, containing loxP 
sites which flank the MSP domain encoding exons of either Mospd gene, were 
successfully used to generate targeted alleles in ES cells. Recombineering proved to 
be an efficient technique for the generation of targeting vectors for both Mospd1 and 
Mospd3. The generation of these targeting vectors by conventional restriction and 
ligation methods would most likely have proven more difficult. This would have 
been the case especially for Mospd3, as the genomic sequence of this gene was found 
to contain very few suitable restriction sites for this task. As recombineering does not 
require the use of restriction sites, it was possible to place the required loxP sites and 
targeting cassettes into the genomic sequences of our choosing. The only hurdle, we 
encountered using this approach, involved the mis-annotation of genomic sequences 
in the Mospd3-containing bacterial artificial chromosome (BAC). As mouse genome 
sequences are reviewed on a yearly basis, this issue is almost negligible for most 
current recombineering projects. 
One of the most time consuming factors in the generation of the conditional 
knockout alleles of Mospd1 and Mospd3 was the targeting into ES cells and 
subsequent verification of correctly targeted clones.  The use of whole BAC targeting 
vectors and novel innovative ES cell screening approaches (Valenzuela et al., 2003) 
has helped to make high-throughput targeting in ES cells feasible. The development 
of these high-throughput methods (recombineering and loss-of native-allele ES cell 
screening) led to the establishment of three major initiatives with the goal of large 
scale mutagenesis of all annotated genes in the mouse genome. The aim of the 
Knock-Out Mouse Project (KOMP), European Conditional Mouse Mutagenesis 
project (EUCOMM) and the North American Conditional Mouse Mutagenesis 
project (NorCOMM) is to saturate the mouse genome with targeted gene mutations. 
A recent search of the publicly available repository of targeted clones, held at the 
Sanger Centre
9
, revealed the availability of an ES cell line carrying a conditional 
frame shift allele of Mospd1. The conditional allele generated by KOMP features an 





FRT-flanked promoterless targeting cassette containing a splice acceptor, β-gal 
reporter gene, neomycin resistance marker and polyadenylation site in the intron 
between exons 3 and 4 of Mospd1; as well as two loxP sites flanking exon 4 of the 
gene. The design of this allele allows the expression of gene sequences downstream 
of exon 3 of Mospd1 to be disrupted due to a frame shift in the targeting cassette. As 
exon 4 contains a large part of the MSP domain encoded by Mospd1, the resulting 
protein will be, most likely, inactive. Subsequent use of flp recombinase allows the 
gene to be reactivated by deleting the promoterless cassette, whilst the use of Cre 
recombinase allows gene inactivation to be re-established. The use of this 
reactivatable allele of Mospd1 may be useful, in combination with our own 
conditional allele, for future functional analysis of the Mospd1 gene. There is no 
conditional allele available for Mospd3 through KOMP, as the generation of a 
conditional targeting vector for this gene has been annotated as failed.  
 We generated E14 ES cells carrying targeted alleles of Mospd1 and Mospd3. 
These cells were confirmed to be karyotypically normal and can now be used to 
generate chimaeric animals and establish transgenic mouse lines.       
We have shown that the loss of Mospd1 expression in ES cells had no effect 
on the ability of these cells to self-renew, nor did it interfere with their ability to 
differentiate into cells of the cardiomyocyte lineage. This finding suggests that 
Mospd1 is not required for early cardiac development. 
 Specific polyclonal and monoclonal antibodies have been generated, which 
can detect, as well as distinguish between, Mospd1 and Mospd3 proteins. These 
antibodies have been used to show that, both, Mospd1 and Mospd3 are expressed in 
adult mouse heart and kidney. We have also shown that the Mospd1 protein is not 
expressed in undifferentiated ES cells, a finding that would account for the normal 
self-renewal and early differentiation potential in Mospd1 null ES cells.  
Unfortunately, the polyclonal antibodies could not be sufficiently purified to be 
used for further immunohistochemical analysis of Mospd1 and Mospd3, but initial 
results for the monoclonal antibodies are very promising. The use of these antibodies 
should facilitate detailed analysis of Mospd protein expression in the embryo and 





6.2.1 Protein analysis 
 Pending further validation and purification, the monoclonal antibodies can be 
used for detailed functional analysis of Mospd1 and Mospd3 proteins. These studies 
would include immunohistochemical studies, of whole-embryo and adult tissue 
sections, to determine where in the animal each Mospd protein is expressed. It would 
also be of interest to perform a detailed study of the localisation of Mospd3 in the 
heart. This would help to establish if the cardiac defect observed in particular in the 
right ventricle of Mospd3
Gt1lmf/Gt1lmf 
animals stems from a loss of the protein 
specifically in the wall of this heart chamber.  
To test our hypothesis that Mospd3, and possibly also Mospd1, might be 
involved in cell-cell adhesion at the intercalated disc of cardiomyocytes, subcellular 
localisation studies will be performed; and the distribution of either Mospd protein 
will be compared to the subcellular localisation of known desmosome and adherens 
junction (AJ) components such as desmoplakin, plakophilin-2, N-cadherin and ALP 
in cardiac muscle sections. Furthermore, multi-coloured immunohistochemical 
analysis will be performed to directly co-localise proteins that are predicted to 
interact. These co-localisation experiments could be conducted on heart muscle 
sections as well as in vitro differentiated cardiomyocyte cultures (derived from ES 
cells); along with cultured primary mouse cardiomyocyte and keratinocyte cells. 
Both isolated cardiomyocytes and cultured keratinocytes express high levels of 
desmosome and adherens junction proteins (Buxton and Magee, 1992; Westfall et 
al., 1997). Aside from their use in co-immunohistochemical analysis, these cells can 
also be used in co-immunoprecipitation experiments to determine whether Mospd 
proteins can interact with cell adhesion complex proteins, and to identify novel 
interacting proteins. If Mospd1 or Mospd3 do indeed interact with desmosomes or 
adherens junctions, it should be possible, using αMospd1 and αMospd3 antibodies, 
to co-immunoprecipitate components of such these adhesion complexes if bound by 
Mospd proteins, from cardiomyocyte or keratinocyte lysates. If the co-precipitated 
proteins correspond to known cell adhesion complex components, they can be 
identified by western blot analysis using antibodies against desmosomal or AJ 
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proteins, whilst mass spectrometry of the interacting proteins could be used to 
establish the identity of any novel co-precipitated proteins. 
An alternative method to establish whether Mospd1 or Mospd3 form part of 
the desmosomal complex, in particular, entails western blot analysis of tritonX100 
lysates of either keratinocytes or in vitro derived cardiomyocytes. It has been 
previously reported that desmosome complexes cannot be disassociated in 
tritonX100 cell lysis buffer (Cheng et al., 2004). Thus monoclonal antibody detection 
of Mospd1 or Mospd3 in the insoluble fraction of such lysates would indicate that 
either of these proteins are part of the desmosome complex.   
Cardiomyocyte cells derived from Mospd1 and Mospd3 null ES cells as well 
as tissue sections and primary keratinocyte cell lines derived from Mospd1 and 
Mospd3 null transgenic animals (generated from the conditional knockout ES cell 
lines described in Chapter 3), will serve as valuable controls in all proposed protein 
function experiments. In addition, western blot analysis of these Mospd null animal 
tissues and cell lines could reveal whether there is any functional compensation for 
the loss of one Mospd protein by increased expression of the other. 
 If the monoclonal antibodies should at any stage prove to be unsuitable for 
any of the previously described protein localisation and immunoprecipitation studies, 
a recently developed alternative method to study the function of proteins without the 
need for specific antibodies can be employed. This novel method is based on the 
introduction of a fluorescent reporter tag into a gene of interest using a high-
throughput BAC recombineering approach (Poser et al., 2008). The advantage of a 
BAC, compared to traditional gene targeting vectors or cDNA-based transgenes, is 
that due to its large size of 100 to 200kb the BAC targeting construct will almost 
always contain not only the entire sequence of the gene to be tagged but also 
endogenous regulatory sequences. This allows the BAC transgene, once integrated 
by homologous recombination, to be expressed at near-physiological levels.  
The reporter gene tag used in this approach corresponds to a modified LAP 
tag (Cheeseman and Desai, 2005). This modular protein tag consists of enhanced 
GFP, an S-peptide sequence as well as a protease cleavage site, and can be used for 
tagging either the N- or C-terminus of a protein. The expression of this LAP tag in 
mammalian cells allows not only in vivo localisation analysis of a protein of interest; 
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but, using Protein „A‟ immunochromatography, the protein can be isolated from cell 
lysates along with other proteins or DNA molecules it directly interacts with.  
A particularly interesting aspect of this approach is that it can be used in ES 
cells. These ES cells containing the tagged construct of either Mospd1 or Mospd3 
could in the first instance be differentiated into cardiomyocytes. This way, the 
subcellular localisation of Mospd proteins can be studied in these in vitro cardiac 
muscle cells and compared to the localisation pattern of desmosomal and AJ 
complex proteins. Moreover, the ES cells expressing tagged Mospd1 or Mospd3 
could be used to generate transgenic mouse lines, thus allowing detailed protein 
functional analysis throughout the murine development and in the adult animal. 
Additionally, primary cell lines, which express the tagged Mospd protein of interest 
at high levels, could be isolated from mouse tissues and then used for live imaging of 
endogenous Mospd protein. These primary cell lines would also be ideal for co-
localisation studies as well as co-precipitation of tagged Mospd1 and Mospd3, and 
their protein interactors.  
 
6.2.2 In vitro studies in isolated cardiomyocytes  
As previously mentioned (in section 6.1), in a transient transfection 
experiment in COS7 kidney cells, the eGFP-labelled Mospd3 protein displayed a 
punctuate signal (Forrester, unpublished). This pattern could potentially correspond 
to a co-localisation of Mospd3 with α-actinin protein at cell-matrix adhesion sites. In 
order to confirm whether Mospd3 can indeed interact with α-actinin, or as 
hypothesised with other desmosomal and adherens junction proteins, the eGFP-
Mospd3 plasmid could be transiently transfected into cardiomyocyte cells isolated 
from in vitro ES differentiation cultures or mouse hearts. If Mospd3 is involved in 
cell-cell adhesion, or structural integrity of the sarcomeric cytoskeleton with the cell 
membrane, we would expect the fluorescently labelled protein to localise to the 
intercalated discs of these myocardial cells. If (like Alp) Mospd3 can interact with α-
actinin, a fluorescent GFP signal might also be expected at the Z-discs of the cultured 
cardiomyocytes. This type of in vitro experiments can also be performed with a 
fluorescently labelled expression construct of Mospd1, to see if this Mospd family 
member shares functional similarities with Mospd3. 
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In their study, showing that Alp protein can interact with α-actinin to 
facilitate actin-bundling, Pashmforoush and colleagues found that overexpression of 
Alp in cultured cardiomyocytes resulted in a marked enhancement of cell 
cytoarchitecture and sarcomeric organization (Pashmforoush et al., 2001). By 
studying the subcellular localisation of cytoskeletal proteins, such as actin or α-
actinin, in cultured cardiomyocytes which have been transiently transfected with 
eGFP-Mospd3 compared to untransfected cells, it should be possible to see if 
Mospd3 is involved in the structural organisation and integration of myofibrils.  
A further avenue for studying the function of Mospd proteins in vitro is by 
silencing the expression of Mospd3 or Mospd1 through RNAi (RNA interference) in 
cultured cardiomyocytes (Kasahara and Aoki, 2005) and study the resulting effect on 
the physiology of the cells. This RNAi-mediated gene expression knockdown has 
been successfully used in cultured rat cardiomyocytes to study the importance of the 
desmosomal protein plakophilin-2 in maintaining cell-cell adhesion at the 
intercalated discs of adjoining cardiomyocytes (Pieperhoff et al., 2008).  
In the study of Mospd protein function, RNAi of select desmosomal and 
adherens junction proteins could be used in conjunction with transient transfection of 
eGFP-Mospd3 in cultured cardiomyocytes. This would allow us to determine if and 
how the loss of these desmosomal and AJ proteins in these cells affects the 
localisation of the fluorescently labelled Mospd3 protein.  
 
6.2.3 In vivo mouse studies 
Whilst in vitro studies are a key tool to understanding the function of a 
particular gene, the results gained from these studies generally require verification in 
the in vivo animal model. Gene knockin and knockout techniques provide an 
invaluable tool to gain insight into the in vivo function of a gene. Analysis of the 
expression pattern of Mospd3 or Mospd1 in vivo in the developing and adult mouse 
model could be facilitated by a targeted knockin of a reporter gene, such as eGFP or 
β-gal, and a positive selection marker downstream of the endogenous Mospd3 or 
Mospd1 promoter sequence. The expression pattern of the reporter gene should 
mirror that of the endogenous gene. As gene targeting allows precise modification of 
a target locus, problems like the complex reporter gene integration observed in the 
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gene trapping experiment of Mospd3 can be circumvented with this method. Also, 
depending on the placement of the reporter gene cassette and its composition, the 
expression of the endogenous gene at the targeted locus can either be conserved or 
disrupted. The second scenario would lead to the constitutive ablation of gene 
expression from the targeted allele, therefore allowing parallel in vivo analysis of a 
loss-of-function phenotype of the Mospd gene of interest in the animal model.       
However, for the purpose of gaining more detailed insight into the tissue and 
developmental stage specific effects of Mospd3 or Mospd1 inactivation, we have 
chosen to generate conditional knockout alleles of these two genes. Once transgenic 
mouse lines carrying the conditional alleles have been successfully generated, either 
gene can be inactivated in a tissue and time-dependent manner.   
Initial crossing of mice carrying the conditional knockout allele to a 
ubiquitous Cre deleter mouse strain will allow the assessment of complete loss of 
Mospd gene expression on mouse development and phenotype. This study would 
involve detailed histological analysis to determine which tissues, if any, are affected; 
as well as close monitoring of the Mendelian ratio of mice born to determine whether 
loss of expression of either gene results in embryonic or neonatal death. If either 
gene is, as speculated, involved in cell-cell adhesion complexes, one might expect to 
see defects in heart structure and possibly even skin blistering. If the loss of Mospd1 
or Mospd3 expression causes embryonic lethality, or a complex phenotype involving 
multiple organs or different stages of embryonic development, it may be necessary to 
delete Mospd1 or Mospd3 in a specific tissue or at a defined time point during 
development. (A schematic showing the conditional knockout mouse lines of 
Mospd1 and Mospd3 –detailed in the remainder of this section - and their breeding, 
dependent on the observed knockout phenotype, is shown in figure 6.1.)  
The requirement of Mospd genes specifically in the heart could thus be 
assessed by mating the conditional knockout (cko) mouse line of Mospd1 or Mospd3 
to an effecter strain expressing Cre from a cardiac specific promoter, such as MHC-
Cre or Nkx2.5-Cre. Similarly, if evidence from the Mospd1 and Mospd3 null animals 
indicates that either gene is involved in the structural integrity of the heart instead of 






























Figure 6.1: Breeding scheme for transgenic mouse lines carrying the conditional knockout allele of Mospd1 or Mospd3.
This figure shows mating of the transgenic Mospd mouse lines to different Cre expressing strains and to each other. Also






inducible Cre can be used to assess this possibility. Inducible deletion can be 
achieved by mating transgenic animals carrying the conditional knockout allele of 
Mospd1 or Mospd3 to a transgenic mouse line carrying a Cre recombinase transgene 
which can be induced by either a doxycycline through the tet-“on” system or via a 
tamoxifen or RU486-inducible mutant ligand binding domain system.  
Using either of these two systems, Mospd1 and Mospd3can be inactivated in 
adult animals by administration of either doxycycline or synthetic steroid by 
injection or through their food (Lewandoski, 2001; Zhang et al., 1996).     
It is possible that the deletion of neither gene results in a detectable 
phenotype or only a mild defect due to genetic redundancy. If this is the case, the 
generation of a Mospd1/Mospd3 double mutant should result in a more severe 
phenotype for further study. If the resulting double mutant animals display a complex 
phenotype or embryonic lethality, it may be necessary to generate a double mutant 
carrying a null allele of one of the two Mospd genes and a conditional allele of the 
other, like Mospd3 null/Mospd1
cko/cko
. Using a tissue-specific or inducible Cre 
expressing mouse strain, the conditional allele can then be inactivated to generate a 
double null allele in a desired tissue or at a specific time point.  
The proposed studies of the loss of function of Mospd1 and Mospd3 in the 
animal and in vitro model, in addition to the Mospd protein analysis, will help assign 
a function to the currently uncharacterised Mospd gene family. 
 
6.2.4 The zebrafish as a model system for cardiac development and 
structural integrity of the heart muscle 
Evolutionary analysis of Mospd1 and Mospd3, two members of the Mospd 
gene family in mouse, has shown that Mospd3 is a mammalian specific gene, whilst 
orthologs of Mospd1 were found in a wide range of vertebrate species including 
chicken, Xenopus, Fugu and zebrafish (Pall et al., 2004). The presence of Mospd1 
but not Mospd3 makes the zebrafish a promising complementary model organism for 
studying the function of Mospd genes in the cardiac system without the complexity 
of genetic redundancy.  
Several aspects of mammalian cardiac development, such as early 
cardiogenic specification and heart tube formation, appear to be mirrored in the 
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zebrafish. Genetic determinants of heart tube formation and cardiac looping have 
also been shown to be largely conserved between zebrafish and mammals (Stainier, 
2001). Hence, despite the obvious anatomical differences between the four-
chambered mammalian heart and the two-chambered heart of the fish, zebrafish have 
been successfully used to model aspects of human cardiomyopathies (Gerull et al., 
2002; Heuser et al., 2006; Xu et al., 2002).  
The zebrafish might prove to be a very useful tool for studying the effect of 
Mospd genes on cardiac development and the structural integrity of the heart as: 1) 
zebrafish only posses Mospd1 and not Mospd3, avoiding the issue of genetic 
redundancy; 2) the large number of embryos produced, as well as the use of gene 
expression knockdown by morpholino injection, enables high throughput gene 
function study in this model system; and 3) the zebrafish is transparent allowing all 
organs to be visualised during development, and heart contractility to be measured 
non-invasively by electrocardiogram methods described by (Milan et al., 2006). 
Work on studying the importance of mospd1 in zebrafish is currently 
underway in the laboratory. Initial zebrafish mospd1 morpholino knockdown 
experiments (carried out with the help of, and now continued by Madina Kara) 
indicate that expressional down-regulation of this gene in zebrafish embryos leads to 
cardiac oedema and blood pooling at day 2 to 3 of development. This phenotype may 
be caused by defects in the structural integrity of the heart and aberrant contractility 
caused by the loss of desmosomal structures similar to that found in desmocollin-2 
ablation in zebrafish (Heuser et al., 2006). As in the mouse model, it will be 
important to correlate the localisation of the mospd1 protein with desmosomal and 
adherens junction components to verify our hypothesis of involvement of this protein 
in cell-cell adhesion at the intercalated disc of cardiomyocytes. 





















Appendix Table 1: Primer sequences used for Mospd1 and Mospd3 targeting 
vector generation by recombineering. 
 
Mospd1 
Mospd1-loxpneo-1_for 5‟- ATGATCCTGATTCAATTCCCAGCACCCATGGCAGCA 
CACAGCTATGTAGAACTATGTAGCTCGACCTGCAGCCA
AGCTATCG -3‟ 
Mospd1-loxpneo-2_rev 5‟- GCACATGACTTTAATCCAACACTCAGAAGGATTCAG 
GTACATCTCTTGTGAGTTCCATGACGGCCGCTCTAGAAC
TAGTG -3‟ 







Mospd-3B‟-BamHI 5‟- GGTGTGGATCCAGGTTGGGATTTAGGTTTAGTG -3‟ 
Mospd-3Y3-BamHI 5‟ - GTACGGATCCCTGTTTGTCAGCTGCATC -3‟ 














Appendix Table 2: Primer sequences used for Southern blot screening of 




Mospd1-up1_for 5‟- CAGAAGGCAGGAGCAGGAAGAC-3‟ 




Mospd3-up1_for 5‟- GGCCCCAAACAACCCTGAC-3‟ 
Mospd3-up1_rev 5‟- GATCGCTTCCCCTTTTATTTTTGA-3‟ 
Mospd3-down2_for 5‟-TCTGGCTCGGGTGAATGTCTGCT -3‟ 












































Appendix Figure 5: Plasmid map of the empty pEGFP-C2 vector (upper; 






Appendix Figure 6: Plasmid map of the I.M.A.G.E clone (ID 3962906) 
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